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MicroRNAs (miRNAs) are a recently identified class of short regulatory RNAs 
involved in a diverse array of cellular processes in mammals. Aberrant expression of 
miRNAs can lead to the development of several diseases including cancers. Mammalian 
miRNAs regulate the expression of target genes by binding to partially complementary 
sites usually located in the 3’UTR of target mRNAs (Bartel, 2009). With rare exceptions, 
this leads to a decrease in translation followed by destabilization and degradation of the 
mRNA (Fabian et al., 2010). As a result of this targeted degradation, development of 
miRNAs as targets for gene therapy has garnered increasing interest. Because 
transfection with a single miRNA can lead to global changes in gene expression (Baek et 
al., 2008; Lim et al., 2005; Selbach et al., 2008), identifying the mechanisms and also the 
broad implications of such large scale perturbations must be addressed before miRNAs 
can make the transition into the clinical setting. 
To address these issues, we assessed miRNAs and mRNAs in epithelial ovarian 
cancer using high throughput microarray and computational analysis, pathway 
enrichment, network building, statistical analysis, and experimental evidence. The results 
of our study indicate that in vitro based models of miRNA function are inadequate to 
explain the effects of changes in expression of miRNAs in vivo. Specifically, we found 
that the direct regulatory action of miRNAs on target mRNAs can induce a series of 
indirect effects including regulation of trans-regulatory genes and other miRNAs. These 
indirect effects can initiate a cascade of down-stream effects resulting in feed-back loops 
that can mask direct effects of miRNA regulation. Interestingly, the indirect effects 
 
 xxi
appear not to be random but functionally coordinated suggesting that miRNAs may have 
particular value in the treatment of cancer from the systems perspective. 
 Research Advance 1. Using a combination of genome-wide miRNA and mRNA 
profiles in ovarian cancer samples collected from patients and cell lines, we studied the 
nature of miRNA-mRNA interactions at the molecular level. Microarray analysis 
demonstrated that nine miRNAs are significantly up-regulated and three miRNAs are 
significantly down-regulated between patients' samples from ovarian cancer epithelial 
cells (CEPI) and normal ovarian surface epithelial (OSE) cells. While current models of 
miRNA regulation suggest a pattern of inverse correlation between miRNAs and their 
cognate targets, our analysis of mRNA profiles from the same cancer samples showed 
that only ~11 % of predicted targets of each miRNA are inversely correlated. This 
finding was reaffirmed by using predictions from multiple computational algorithms as 
well as experimentally validated targets from miRNA transfection experiments. These 
data suggest the current model of miRNA regulation may be inadequate to address the 
complex nature of these interactions in vivo. 
Research Advance 2. To begin to systemically dissect the mechanisms of 
genome-wide consequences of miRNA over-expression, parallel transfection experiments 
using different miRNAs were carried out in the ovarian cancer cell line, HEY. The off-
target effects of the miRNAs were studied in a therapeutic framework by targeting the 
EGFR oncogene. Transfection of each miRNA affects hundreds of genes in addition to 
EGFR, but less than 20 % of these genes are predicted targets of the miRNAs. Network 
analysis of the differentially expressed genes suggests miRNAs may target hub genes that 
in turn modulate the expression of multiple downstream transcripts. Enrichment analysis 
 
 xxii
of target and off-target genes demonstrates significant over-representation of genes 
belonging to pathways specific for cancer and development, which is consistent with 
functional specialization of miRNAs. In addition, miRNAs were found to modulate the 
levels of other miRNAs suggesting a new layer of regulation for these small RNAs. 
Computational and experimental evidence is presented in support of mechanisms that 









Epithelial ovarian cancer is the leading cause of gynecologic cancer-related 
mortality and the 5
th
 most deadly cancer in women in the United States (Jemal et al., 
2008). Because most cases of ovarian cancer are diagnosed at an advanced stage (stage 
III or IV) where long-term treatment responses are low, the 5-year survival rate stands at 
less than 30% (www.seer.cancer.gov, SEER, 2009). Thus, understanding the biology of 
ovarian cancer development and progression is critical to improving the outcome of 
ovarian cancer patients.  
MicroRNAs (miRNAs) are a class of short (~22 nucleotides) regulatory RNA 
molecules that modulate gene expression and translation in unicellular and multicellular 
organisms. In recent years miRNAs have emerged as regulators of several critical 
processes and are often expressed at altered levels in many cancers including ovarian 
cancer (Li et al., 2010; van Jaarsveld et al., 2010). While they may have initially evolved 
as a mechanism of cellular defense against viruses (Shabalina and Koonin, 2008), 
mammalian miRNAs are now known to be involved in such diverse processes as the 
regulation of development, differentiation, inflammation, apoptosis, and cell proliferation 
(Bartel, 2004; Chang and Mendell, 2007). In cancer, up-regulation or down-regulation of 
miRNAs has been shown to be causally linked with oncogenesis, progression, metastasis, 
and can be potentially used in diagnosis, prognosis and therapy (Garofalo and Croce, 
2011; Lee and Dutta, 2009). 
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MiRNAs were identified within a few years of the discovery of RNA silencing 
(Napoli et al., 1990). While studying the temporal regulation of C. elegans development a 
small RNA from the locus ‘lin-4’ was found to block the translation of lin-14 mRNA in a 
developmentally specific pattern by binding to complementary sites on the 3’ 
untranslated region (3’ UTR) of the mRNA (Lee et al., 1993; Wightman et al., 1993). 
While initially thought to be limited to C. elegans, it was later realized that these small 
RNAs belong to a novel class of regulatory RNAs conserved in vertebrates, invertebrates 
and plants (Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and Ambros, 2001; 
Pasquinelli et al., 2000; Reinhart et al., 2002). Aberrant miRNA expression was first 
linked to human disease when researchers demonstrated that a frequently deleted 
chromosomal locus in patients with a type of B-cell leukemia harbors genes encoding the 
miRNAs miR-15 and miR-16 (Calin et al., 2002). These small RNAs have since been 
implicated in the development of many other types of cancers (Lee and Dutta, 2009) as 
well as different types of neurological and cardiovascular diseases (Bushati and Cohen, 
2007; Chang and Mendell, 2007; Couzin, 2008). Recent studies also suggest that 
miRNAs are critically intertwined with ovarian tumorigenesis, progression and therapy 
resistance (Li et al., 2010; van Jaarsveld et al., 2010). This chapter gives a brief 
introduction to miRNAs by describing what is known about their synthesis and 
maturation, their mechanism of target recognition and regulation, their involvement with 
ovarian cancer, and finally the potential for their clinical applications. 
 
Biogenesis of miRNAs 
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The synthesis of miRNA is a multistep process that begins inside the nucleus. It is 
estimated that about 50 % of miRNAs are located within introns and occasionally exons 
of coding or non-coding genes, while the rest are located in intergenic regions (Rearick et 
al., 2010). Synthesis is usually carried out by RNA Pol II (Lee et al., 2004) and 
occasionally Pol III (Borchert et al., 2006) from both autonomous promoters and 
promoters of other genes (Fujita and Iba, 2008; Ozsolak et al., 2008; Zhou et al., 2007). 
The transcript synthesized at the first step can be anywhere from hundreds of bases to 
many kilobases (kb) in length (Saini et al., 2007). This primary miRNA (pri-miRNA) 
transcript is usually polyadenylated, 5’ capped, and can undergo splicing like messenger 
RNA (Bracht et al., 2004; Cai et al., 2004; Cullen, 2004). The pri-miRNA is subsequently 
cleaved into a shorter stem loop structure called the pre-miRNA by the RNAse III 
enzyme Drosha (RNASEN) with the help of its dsRNA binding partner called DGCR8 in 
humans or Pasha in Drosophila (Denli et al., 2004; Gregory et al., 2004). While 
additional cofactors may be involved, DGCR8/Pasha is a minimal requirement for 
Drosha activity. One exceptional group of miRNAs encoded from introns of genes, called 
“mirtrons,” can be processed by the splicing machinery directly into pre-miRNA 
independently of Drosha (Berezikov et al., 2007). The pre-miRNA is typically 70-90 
nucleotides (nts) in length and forms a hairpin like loop, which is then exported out of the 
nucleus by the nuclear export protein Exportin-5 and its cofactor Ran GTPase (Yi et al., 
2003). Once in the cytoplasm, the pre-miRNA is subject to further processing where the 
loop region is cleaved off by another RNAse III enzyme Dicer (Bernstein et al., 2001), 
and its RNA binding partner TAR RNA binding protein (TRBP) and/or PRKRA (Haase 
et al., 2005). At the end of this step, a ~22 base pair duplex is formed containing the 
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mature miRNA and its partner strand designated miRNA*, which exists at lower steady 
state levels. More often the more stable miRNA strand is incorporated into the miRNA 
induced silencing complex (RISC/miRISC), which also includes other proteins essential 
for complex formation (e.g., TRBP). This incorporated strand is believed to be 
thermodynamically favored due to less hydrogen bonding at the 5’end and/or other 
sequence features (Hu et al., 2009). However, in some cases both strands can participate 
in the process of regulation (Yang et al., 2011).  
 
Regulation of miRNA levels 
Transcriptional regulation of miRNA synthesis shares common themes with 
mRNA transcriptional regulation. Like oncogenes and tumor suppressor genes, miRNA 
expression in cancer can often be deregulated by translocation as miRNA genes are 
frequently located in cancer associated genomic regions (CAGR; Calin and Croce, 
2006b). MiRNA promoters can also be under the regulation of transcription factors like 
p53 (Feng et al., 2011), NF-κB (Mott et al., 2010; Pacifico et al., 2010; Wang et al., 2010; 
Zhou et al., 2009), as well as cell type specific factors like PU.1, REST or MEF2 (Davis-
Dusenbery and Hata, 2010). These transcription factors have all been implicated in 
cancer development and progression (Goh et al., 2011; He and Karin, 2011; Majumder, 
2006; Marks et al., 2001; Somervaille and Cleary, 2006) and are often aberrantly 
expressed in cancers. Epigenetic mechanisms including DNA methylation and histone 
modifications also reconfigure miRNA promoter regions and can lead to altered miRNA 
profiles in cancer. Zhang et al. (2008) reported that up to ~36 % of miRNAs down-
regulated in late-stage epithelial ovarian cancer were under epigenetic regulation. 
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Another mechanism of regulation of miRNA transcription involves feedback loops. 
MiRNAs can regulate their own transcription through single negative or double negative 
feedback loops with transcription factors (Krol et al., 2010).  
As miRNA synthesis is a multistep complex process, regulation can occur at 
every step of biogenesis (Pawlicki and Steitz, 2010). In addition to the battery of proteins 
that are required for miRNA maturation, recent work has shown that a multitude of 
accessory proteins also facilitate the process. This is exemplified by the involvement of 
the LIN-28 protein in the maturation of let-7 family miRNAs. LIN-28 can bind to the 
terminal loop of pri-let-7 molecules and block Drosha activity (Newman et al., 2008) or 
to pre-let-7 and block its maturation by interfering with Dicer (Lehrbach et al., 2009). 
This regulatory system is highly conserved across evolution and may play an essential 
role in let-7 mediated self-renewal of stem cells, development, and cancer (Viswanathan 
et al., 2008). Other examples of auxiliary factors include DEAD-box RNA helicase 
interacting proteins, hnRNPs, splicing regulators SF2/ASF, KSRP, etc. that can also 
modulate miRNA processing by interacting with Dicer and Drosha (Table 1.1; Davis-
Dusenbery and Hata, 2010; Krol et al., 2010).  
Recent studies (Bail et al., 2010; Katoh et al., 2009) have shown that the stability 
of miRNAs can be differentially regulated. Bail and colleagues showed that some 
miRNAs decay faster than others in HEK293 cells when transcription is blocked. They 
further demonstrated that the stability of one of these miRNAs, miR-382, was dependent 
on seven nucleotides at its 3’ terminal end. Therefore, in addition to the transcriptional 
regulation of miRNA synthesis and post-transcriptional regulation of miRNA processing, 
there is also differential regulation of mature miRNA stability. 
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Table 1.1. Proteins that affect miRNA processing/transcription. A partial list of 
proteins that act as co-factors or transcription factors and take part in miRNA synthesis or 
maturation. 
 
Protein ID Regulatory 
step 




Stabilizes and helps 
delivery of capped pri-
miR-21, pri-miR-155, 
pri-let-7 to the miRNA 
processing complex 
(Drosha) 
(Gruber et al., 2009; 
Sabin et al., 2009) 
p68/p72 helicases Drosha 
processing 
Components of 
microprocessor that act 
to stimulate pri-miRNA 
processing  
(Fukuda et al., 
2007) 





(Davis et al., 2008) 
SNIP1 Drosha 
processing 
Increases association of 
Drosha with pri-
miRNAs 












18a by interacting with 
its loop region 
(Michlewski et al., 
2008) 
KSRP Dicer and 
Drosha 
processing 
Binds to primary and 
pre-miRNAs and 
optimizes positioning 
and/or recruitment of 
microRNA processing 
complexes 





processing of miRNAs 




Binds to stem loop of 
primary miRNAs and 
prevents DGCR8 
binding 




Negative feedback by 
regulating DGCR8 
levels 
(Han et al., 2009) 
Table 1.1 (continued) 
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Protein ID Regulatory 
step 
Regulatory role Reference 
LIN-28/LIN-28B Drosha and 
Dicer 
processing 
Binds to terminal loop 
of primary transcript of 
let-7 family miRNAs 
and blocks Drosha. Also 
inhibits Dicer 
processing by inducing 
uridylation of pre-let-7. 
(Heo et al., 2008; 
Viswanathan et al., 
2008) 
ADAR1/ADAR2 Pri-miRNA or 
Pre-miRNA  
Adenosine deaminases 
edit pri-miRNA or pre-
miRNA and affect the 
accumulation of mature 




(Heale et al., 2009; 
Kawahara et al., 




Demonstrated to induce 
(miR-17~92 cluster) or 
inhibit (let-7, miR-15-
16, miR-34a etc.) 
miRNA transcription 
(Chang et al., 2008; 
O'Donnell et al., 
2005) 




34a and miR-34b/c 
(He et al., 2007a; 
Raver-Shapira et 
al., 2007) 
DNMT1, DNMT3b Pri-miRNA 
transcription 
Epigenetically modify 
miRNA loci to modify 
transcription 






GLD-2 miRNA stability Adds Adenosine to 3’ 
end of miR-122 to 
increase stability in 
liver 
(Katoh et al., 2009) 
 
 
Principles of target recognition by miRNAs 
The principles of miRNA target recognition are complex and a matter of intense 
research. One early observation from experimental and computational analysis lead to the 
conclusion that Watson-Crick complementarity between the binding region on the mRNA 
(e.g., 3’UTR in mammals) and a consecutive stretch of 6-8 nucleotides, called the “seed,” 
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near the 5’ terminal end of the miRNA, is the most important requirement (Bartel, 2009). 
Complementarity at the 3’ end of the molecule is much less stringent, but it may 
contribute to the overall stability and specificity of the miRNA:mRNA interaction 
(Brennecke et al., 2005). The central region of the miRNA:mRNA pair usually contains a 
bulge, the size and location of which may contribute to the efficiency of target repression 
(Kiriakidou et al., 2004; Ye et al., 2008). Sequence composition flanking the seed (e.g., 
an A across position 1, A or C across position 9) may also influence the efficacy of the 
miRNA (Bartel, 2009). Additional factors such as local sequence context (e.g. presence 
of AU rich elements in the UTR), RNA folding and accessibility of the site may also 
contribute to effective repression (Bartel, 2009; Didiano and Hobert, 2008). Finally, 
interaction of multiple miRNAs with the same transcript, distance between binding sites 
and length of the 3’UTR have also been shown to be important factors for miRNA 
repression (Doench and Sharp, 2004; Hon and Zhang, 2007; Wu et al., 2010b). 
Several target prediction programs have been developed to help identify miRNA 
targets based on some of the observations from experimental systems already mentioned. 
Different programs score their putative targets differently, and often there is little overlap 
between the targets predicted by the programs. Despite this inconsistency, three of the 
prediction programs using three different approaches (miRanda, TargetScanS and PicTar) 
have been shown to have the highest sensitivity of identifying experimentally validated 
targets (Birney et al., 2007). TargetScanS (Friedman et al., 2009; Grimson et al., 2007; 
Lewis et al., 2005) considers factors including seed region complementarity, local 
sequence context, 3’ compensatory pairing, and conservation of target sites for predicting 
miRNA targets. PicTar (Chen and Rajewsky, 2006; Grun et al., 2005; Krek et al., 2005; 
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Lall et al., 2006) uses conservation, seed complementarity, folding energy, presence of 
multiple sites, and a hidden Markov model (HMM) likelihood score to identify miRNA 
targets. Predictions from PicTar and TargetScanS usually overlap better with one another 
than predictions from other algorithms (Rajewsky, 2006). MiRanda (Betel et al., 2010; 
Betel et al., 2008; Enright et al., 2003; John et al., 2004) scores target sites mainly 
through consideration of alignment score, RNA folding energy, and sequence 
conservation. Recently, the predictions of miRanda were improved significantly by 
adding a support vector regression analysis (mirSVR) to remove false positive 
predictions for each miRNA-mRNA pair (Betel et al., 2010; based on the version of 
miRanda at the Memorial Sloan-Kettering cancer center). This change may result in 
better overlap between the miRanda predictions and predictions from TargetScanS and 
PicTar, although this is yet to be demonstrated. MiRanda-mirSVR and PicTar also take 
into account the possibility of multiple miRNAs interacting with the 3’ UTR (Betel et al., 
2010; Krek et al., 2005), which most other target prediction programs still ignore. While 
some recent studies suggest that animal miRNA sites may occasionally be located in the 
5’UTR or even the ORF (Duursma et al., 2008; Elcheva et al., 2009; Forman et al., 2008; 
Henke et al., 2008; Jopling et al., 2005; Lal et al., 2008; Moretti et al., 2010; Orom et al., 
2008; Tay et al., 2008; Tsai et al., 2009) the vast majority of target sites are typically 
located in the 3’UTR, most likely due to steric hindrance from the translational 
machinery (Gu et al., 2009). Because of this, most prediction algorithms do not include 
the 5’ UTR and ORF regions in their analysis, although a few in silico approaches have 
considered these non-canonical sites (e.g., Stark et al., 2007). Because the early versions 
of miRanda, TargetScanS and PicTar prediction programs suffered from high false 
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positive prediction rates (Table 1.2; Min and Yoon, 2010) a combination of two or more 
prediction programs was recommended for predictions (Sethupathy et al., 2006). 
However, with the expanding knowledge of miRNA biology, the latest versions of these 
prediction programs have incorporated new features, which have significantly improved 
their predictive power. The new generation target prediction methods using support 
vector machines (SVM; e.g., mirSVR for miRanda) or similar machine learning 
approaches may be better able to take into account the multitude of factors contributing to 
targeting efficacy and produce better target predictions as we learn more about the 




Table 1.2. False positive rates of first generation target prediction methods. 
Estimated false positive rates of early versions of the three major miRNA target 
prediction algorithms miRanda, TargetScan and PicTar.  
 




*Source: (Martin et al., 2007); these estimates are based on early versions of these 
prediction algorithms and these numbers may have changed since recent updates. 
 
 
Cellular components and mechanisms of miRNA regulation 
In mammals, miRNA interaction with the 3’UTR usually causes repression of 
translation and/or mRNA destabilization. This process is thought to be initiated when the 
miRNA associated RISC binds to the target mRNA and subsequently leads to 
translational inhibition and shuttling of the target to cytoplasmic foci called ‘P-bodies’ or 
processing bodies (also called GW bodies; Fabian et al., 2010). P-bodies contain proteins 
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like GW182, CCR4-NOT1 deadenylase complex, decapping enzyme complex DCP1-
DCP2, and 5’-3’ exonuclease XRN1, that help in degrading the mRNA and further 
inhibit translation (Parker and Sheth, 2007).While there are examples of translational 
inhibition without detectable changes in mRNA levels (Olsen and Ambros, 1999; 
Wightman et al., 1993), recent studies indicate a high correlation between changes in 
levels of mRNA and protein from miRNA repression (Baek et al., 2008). MiRNA 
mediated mRNA destabilization may even be the predominant mechanism in mammals 
(Guo et al., 2010). As a result, these recent results suggest that measuring global mRNA 
changes is useful and informative for studying miRNA effects.  
MiRNA mediated translational inhibition can occur pre- or post-initiation. In one 
model of pre-initiation translational repression, the miRNA-RISC complex interferes 
with the eIF4F-5’cap recognition and recruitment of the 40S ribosomal subunit (Fabian et 
al., 2010) which are both required steps for translation initiation. Alternatively, miRNAs 
may prevent recruitment of the 60S subunit (Chendrimada et al., 2007; Wang et al., 
2008). Recognition of the 5’cap might involve the Argonaute (AGO) proteins (Kiriakidou 
et al., 2007), which are essential components of the RISC. Some reports suggest 
translational inhibition may also depend on the poly(A) tail (Wakiyama et al., 2007), 
possibly because the poly(A) binding protein (PABP) helps in translation initiation by 
interacting with components of the eIF4F complex. This may also explain why 
translational inhibition is thought to occur coupled with mRNA deadenylation. The post-
initiation model of translational inhibition proposes regulation occurs by ribosome drop-
off at the elongation step of translation (Maroney et al., 2006; Nottrott et al., 2006; 
Petersen et al., 2006). However there is still no consistent model of how this might take 
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place (Fabian et al., 2010). Most existing evidence supports the model of translational 
inhibition at the pre-initiation step. 
MRNA destabilization by miRNA usually begins by removal of the poly(A) tail. 
This is followed by either degradation from the 3’ end by a 3’-5’ exonuclease or by 
removal of the 5’ cap and degradation by a 5’-3’ exonuclease (Xrn1; Eulalio et al., 2008; 
Fabian et al., 2009; Fabian et al., 2010). Repression by transcript destabilization requires 
recruitment of the GW182, PABP and the Argonaute (AGO) proteins (Tritschler et al., 
2010). Deadenylation is initiated when GW182 recruits the CCR4-NOT1 deadenylase 
complex (Behm-Ansmant et al., 2006). This may involve GW182 C-terminus interacting 
with PABP. Deadenylation of the mRNA may occur independently of translational 
repression (Fabian et al., 2009; Wakiyama et al., 2007). Decapping at the 5’ end involves 
the decapping complex DCP1-DCP2 and other proteins that act as decapping enhancers. 
Many of these proteins are enriched in P-bodies suggesting the involvement of these 
cytoplasmic bodies in repression (Fillman and Lykke-Andersen, 2005). However, 
whether P-bodies are causes or consequences of miRNA repression is still unresolved.  
Whether mRNA destabilization or translational repression occurs first is currently 
debated. Recently Djuranovic et al. (2011) argued that translation inhibition coupled with 
deadenylation precedes mRNA decay. Degradation of the transcript leads to a 
consolidation of the initial transient repression of translation. However, the authors 
acknowledge that without more experimental and kinetic studies it is impossible to know 
with conviction which is the triggering event in miRNA mediated repression. 
In rare instances, miRNAs can also induce translation and even transcription. 
Translational activation was demonstrated in quiescent cells under serum starvation 
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conditions (Vasudevan et al., 2007). In one case, translation was activated from a 
previously repressed mRNA by releasing it from P-body and recruitment of ribosome 
(Bhattacharyya et al., 2006). In another case, translation was activated when the miRNA 
targeted the 5’UTR region of ribosomal protein encoding mRNAs (Orom et al., 2008). 
Another miRNA, miR-373, was shown to bind to promoter regions of cold-shock 
domain-containing protein 2 (CSDC2) and E-cadherin to induce transcription of mRNA 
for these genes (Place et al., 2008). These studies suggest regulation by miRNAs is 
complex and may depend on the cellular state, location of target sites on the specific 
gene, the specific miRNA, or other unknown factors. 
 
MiRNAs in ovarian cancer 
As miRNAs can regulate the expression of oncogenes and tumor suppressor 
genes, disruption of miRNA expression can potentially lead to cancers. MiRNA genes 
have also been mapped to chromosomal regions frequently amplified, deleted or 
translocated in tumors (Calin et al., 2004). Many miRNA promoters have been postulated 
to be under transcriptional regulation through genetic or epigenetic mechanisms, which 
often go awry in cancer. Consequently, aberrant miRNA expression has been associated 
with various types of cancers (Calin and Croce, 2006b; Farazi et al., 2011; Garofalo and 
Croce, 2011).  
In ovarian cancer, multiple studies have reported that miRNAs show altered 
expression patterns in cancer cells compared to normal cells of the ovary (Table 1.3; 
Dahiya et al., 2008; Iorio et al., 2007; Nam et al., 2008; Wyman et al., 2009; Yang et al., 
2008; Zhang et al., 2008) [for a recent list of miRNAs associated with ovarian cancer see 
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(van Jaarsveld et al., 2010)]. However, there is little overlap between the results of these 
studies, which may be partly explained by the source of the samples used (Li et al., 2010; 
Zorn et al., 2003). In some cases, human immortalized ovarian surface epithelial 
(HIOSE) cells were used as controls while in others, cultured cancer cell lines or whole 
ovaries were used for sampling. Despite these discrepancies, aberrant expressions of 
some miRNAs have been found repeatedly across multiple studies. These included down-
regulation of members of the let-7 family (let-7a-g/i, miR-98 and miR-202) and up-
regulation of members of the miR-200 family (miR-141, miR-200a/b/c and miR-429; Li 
et al., 2010; van Jaarsveld et al., 2010). The let-7 family of miRNAs has been implicated 
in regulating development, self-renewal, and cancer (Peter, 2009) and the miR-200 
family has been shown to be involved in regulating epithelial-to-mesenchymal transition 
(EMT), a process central to metastasis of cancer cells. The involvement of these two 
miRNA families in ovarian cancer may suggest that these miRNAs are regulating key 
processes that are important in ovarian cancer development and progression. Unlike other 
cancers, epithelial ovarian cancer (EOC) is believed to progress from a less differentiated 
state to a well-differentiated state in that EOC cells resemble committed epithelial cells 
more than uncommitted surface epithelial (OSE) cells (Auersperg et al., 2001; Naora, 
2007). This is consistent with the finding that miR-200 family members are often up-
regulated in EOC cells and expressed in low levels in the OSE cells. It is possible that 
crosstalk exists between the miR-200 and let-7 families (Peter, 2009) and this interplay 
may regulate the progression of EOC from the normal to malignant and from the 
malignant to the metastatic states. Other miRNAs shown to play important roles in EOC 
include miR-9 and miR-199a, which participate in regulating the NF-κB pathway, miR-
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214, which has been shown to regulate PTEN/PI3K pathway, the miR-34 family miRNAs 
regulated by p53, and the hypoxia responsive miRNA, miR-210 (Mezzanzanica et al., 
2010; van Jaarsveld et al., 2010). Thus, the altered expression of these miRNAs may help 
push the ovarian epithelial cells into malignancy, contribute to metastatic progression, 
and even lead to the development of resistance to current cytotoxic therapies. 
 
 
Table 1.3. Comparison of previous studies for miRNA expression profiling in 
ovarian cancer. Comparison of a number of previous studies for miRNA expression 
profiling in ovarian cancer in terms of their selection of tissue/cell samples and the 
profiling method used.  
 
Reference Control group Sample Group Profiling method 
Dahiya et al., 2008  Surface epithelial 
cells (HOSE-B) 
immortalized with 
E6 and E7 
papillomavirus 
Ovarian cancer cell 




Eitan et al., 2009 Formalin fixed 
paraffin embedded 
(FFPE) tumor 
sample from patient 




sample from patient 
with stage III EOC 
Custom miRNA 
microarray 









Iorio et al., 2007 Normal ovarian 
tissue specimens 
Epithelial Ovarian 




Laios et al., 2008 Primary ovarian 
tissue specimens 
Recurrent ovarian 
tissue specimens  
TaqMan miRNA 
assay (qPCR) 
Lee et al., 2009 Normal fallopian 
tube samples 





Table 1.3 (continued) 
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Reference Control group Sample Group Profiling method 
Nam et al., 2008 Normal ovarian 
tissue specimens 

























cancer cell lines; 
also high-grade 






Clinical uses of miRNAs 
MiRNAs are capable of interacting with multiple target genes (Borgdorff et al., 
2010). In cancer and other diseases, miRNA levels are often altered and many have been 
implicated in the regulation of critical pathways involved in cell cycle, EMT, and self 
renewal. Inhibiting or over-expressing miRNAs (Garofalo and Croce, 2011) can therefore 
potentially serve to restore the pre-disease states. This has prompted intense research in 
academia and industry to explore avenues of developing miRNA-based treatments. 
Several clinical trials are currently underway to investigate this potential (Wahid et al., 
2010). While delivery is still the biggest challenge of RNA based therapeutics, additional 
challenges of miRNA therapy include identifying all the targets of a miRNA while 
avoiding false positives and understanding/predicting the unintended phenotypic 
consequences of affecting off-target genes.  
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Despite these challenges, some recent studies have achieved exciting results that 
demonstrate the potential for therapeutic use of miRNAs in cancers (Furuta et al., 2010; 
Kota et al., 2009; Trang et al., 2011; Tsuda et al., 2006). In these studies, miRNA mimics 
or miRNA expression vectors were used to reduce cancer cell growth ex vivo and in some 
cases in vivo (Kota et al., 2009; Trang et al., 2011). Several strategies have been devised 
to decrease the amounts of oncogenic miRNAs. These include using antisense 
oligonucleotides called “anti-miRNA oligonucleotides (AMOs)” or “Antagomirs” that 
bind to the miRNA and prevent it from interacting with target mRNA (Krutzfeldt et al., 
2005). A similar oligonucleotide based approach called “miR-mask” or “target protector” 
interferes with the miRNA by pairing with the target site, thus making the site 
inaccessible to the miRNA (Choi et al., 2007; Xiao et al., 2007). Another strategy 
employs aptly named “miRNA sponges,” synthetic mRNA constructs with multiple 
miRNA binding sites that isolate miRNAs from their endogenous binding sites (Ebert et 
al., 2007). Small molecule inhibitors that decrease the biogenesis of miRNAs are also 
being developed (Gumireddy et al., 2008). These and other similar approaches may bring 
the promise of miRNA therapy to the clinic in the near future.  
MiRNAs can also serve as diagnostic and prognostic markers in several cancers. 
Since miRNAs are differentially expressed in many cancers, it is possible to use miRNA 
expression signatures for diagnostic purposes (Lu et al., 2005). In particular, miRNAs can 
be reliably detected in serum even in some early stage cancers (Hausler et al., 2010; 
Zhang et al., 2010; Zhao et al., 2010). Recent studies have also demonstrated that miRNA 
profiles have the ability to help discern prognostic indicators such as higher grade versus 
lower grade tumor subtypes (Brase et al., 2011; Catto et al., 2009) and also distinguish 
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between tumor stages (Eitan et al., 2009). As miRNAs are shorter than typical mRNAs, 
they are significantly more stable to RNA degrading insults (Jung et al., 2010) and 
consequently provide more reliable and consistent signature profiles than mRNA. There 
are also reports suggesting high miRNA stability in plasma samples (Mitchell et al., 
2008). Thus, in addition to being a promising mode of therapeutic intervention, there is 
significant potential for miRNA based signatures for disease diagnosis and prognosis. 
 
Mechanisms of miRNA-mRNA interactions in ovarian tumors 
As discussed above, previous studies have established that miRNA levels often 
correlate with ovarian cancer development and progression (Dahiya et al., 2008; Eitan et 
al., 2009; Iorio et al., 2007; Laios et al., 2008; Nam et al., 2008; Yang et al., 2008; Zhang 
et al., 2008). However, the effects of miRNA expression profile changes on global 
mRNA expression have not been studied in detail in ovarian cells. We will address some 
of the limitations of the current model of miRNA-target interactions in vivo and discuss 
the different mechanisms used by miRNAs to regulate mRNA levels in ovarian cancer 
cells. Both ovarian tumor patient samples and established cell culture models were used 
to investigate the complex nature of these interactions. The direct and indirect effects of 
miRNAs on mRNA expression were investigated using a combination of target 
prediction algorithms, pathway and network analysis. In addition we describe a novel 
regulatory mechanism used by miRNAs that may help explain the downstream effects of 
miRNA over-expression. 
In CHAPTER 2 we discuss the relationship between changes in global miRNA 
and mRNA levels in ovarian tumor cells compared to normal surface epithelial cells. As 
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there is little overlap between the miRNA profiles in ovarian cancer identified in previous 
analyses (see “MiRNAs in ovarian cancer”), in this study we used epithelial cells 
collected by brushing the surface of the ovary as controls and cancer cells isolated using 
laser capture micro-dissection on tumor specimens to obtain the most appropriate control 
and sample population of cells. The miRNA and mRNA expression profiles from these 
samples were then used to test the expected model of inverse correlation between 
miRNAs and target mRNAs predicted using three different currently available in silico 
target prediction tools. This analysis revealed that only ~11 % of predicted targets were 
inversely correlated with their regulating miRNAs as expected, while the majority of 
targets demonstrated non-significant changes in expression. To ensure that the 
conclusions drawn from predictions made in silico were consistent with data from 
experimental observations, miRNA transfection experiments were carried out in ovarian 
tumor cell lines and a set of experimentally verified targets of these transfected miRNAs 
were identified. Using these verified targets, the analysis was repeated and again a low 
fraction of these targets were inversely correlated in vivo. Together these results suggest 
that current models of miRNA regulation are inadequate to explain the nature of miRNA-
mRNA interactions in vivo.  
In CHAPTER 3 we investigated the nature of miRNA-mRNA interactions further 
in a transfection model using an established ovarian cancer cell line. We studied the 
effect of miRNAs on genome-wide mRNA expression in detail by analyzing the global 
mRNA expression profile following the transfection of miRNAs. To study these genome-
wide effects in a therapeutic context, we considered the off-target effects after miRNA 
targeted knock-down of an ovarian cancer oncogene, EGFR. The analysis demonstrated 
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that the miRNAs altered the expression of hundreds of genes in addition to down-
regulating EGFR. Less than 20 % of these off-target genes could be attributed to 
predicted direct miRNA targets, while the rest were indirect downstream effects. 
Network analysis demonstrated that many of these downstream genes may be regulated 
by ‘hub genes’ which were directly or indirectly regulated by the miRNAs. Pathway 
enrichment analysis of differentially expressed genes suggested a pattern of functional 
specialization for each miRNA which supports the hypothesis that the downstream off-
target effects were not random. These results suggest that while direct targets and indirect 
downstream effects result in hundreds of altered genes following miRNA transfection, 
these may ultimately alter signature pathways associated with each miRNA.  
In the fourth chapter we discuss a hitherto overlooked effect of miRNA over-
expression which ultimately leads to the global disruption of hundreds of transcripts. 
Using microarray analysis of miRNAs, we demonstrated that a miRNA may regulate the 
expression of other miRNAs. We present evidence in support of putative mechanisms for 
this regulation, which may occur by miRNAs targeting transcripts that harbor other 
miRNAs, or through indirectly regulating transcription factors and/or other regulatory 
proteins. Specifically, in this study we propose a mechanism by which miR-7 regulates 
miRNAs through the NF-κB transcription factor. We computationally identified 
significant number of the differentially expressed miRNAs with proximity to NF-κB 
binding sites (Birney et al., 2007) and demonstrated that experimental siRNA knock-
down of the RELA component of NF-κB resulted in altered miRNA expression. We 
identified a second mechanism which could lead to miR-7 affecting miRNA levels by 
regulating the levels of the splicing factor SF2, which, in turn, may regulate miRNAs 
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(Wu et al., 2010a). We also found additional evidence supporting this hypothesis by 
mapping binding sites for SF2 (Sanford et al., 2009) on the primary transcripts of several 
of the differentially expressed miRNAs. These data are consistent with miRNAs 
regulating the levels of other miRNAs by a multitude of mechanisms which may 




EVIDENCE FOR THE COMPLEXITY OF MICRORNA-MEDIATED 
REGULATION IN OVARIAN CANCER: A SYSTEMS APPROACH 
 
Abstract 
 MicroRNAs (miRNAs) are short (~22 nucleotides) regulatory RNAs that can 
modulate gene expression and are aberrantly expressed in many diseases including 
cancer. Previous studies have shown that miRNAs inhibit the translation and facilitate the 
degradation of their targeted messenger RNAs (mRNAs) making them attractive 
candidates for use in cancer therapy. However, the potential clinical utility of miRNAs in 
cancer therapy rests heavily upon our ability to understand and accurately predict the 
consequences of fluctuations in levels of miRNAs within the context of complex tumor 
cells. To evaluate the predictive power of current models, levels of miRNAs and their 
targeted mRNAs were measured in laser captured micro-dissected (LCM) ovarian cancer 
epithelial cells (CEPI) and compared with levels present in ovarian surface epithelial cells 
(OSE). We found that the predicted inverse correlation between changes in levels of 
miRNAs and levels of their mRNA targets held for only ~11 % of predicted target 
mRNAs. We demonstrate that this low inverse correlation between changes in levels of 
miRNAs and their target mRNAs in vivo is not merely an artifact of inaccurate miRNA 
target predictions. Our findings underscore the complexities of miRNA-mediated 
regulation in vivo and the inadequacy of current models to accurately predict the 
molecular consequences of fluctuations in levels of miRNAs within the complex context 




MicroRNAs (miRNAs) are members of an abundant class of small (~22 nts) 
regulatory RNAs believed to play significant roles in a variety of biological processes 
and diseases in both plants and animals (Bartel, 2004). Of recent interest, is the possible 
contribution of aberrantly expressed miRNAs to cancer initiation and development (Calin 
and Croce, 2006a; Esquela-Kerscher and Slack, 2006). Numerous in vitro studies have 
demonstrated that miRNAs are capable of inhibiting the translation and/or facilitating the 
degradation (Bartel, 2009; Pillai et al., 2007; Tang et al., 2008b; Valencia-Sanchez et al., 
2006) of their targeted mRNAs making them attractive candidates for potential use in 
cancer therapy (Hammond, 2006; Tong and Nemunaitis, 2008). However, the potential 
clinical utility of miRNAs in cancer therapy rests heavily upon our ability to understand 
and accurately predict the consequences of fluctuations in levels of miRNAs within the 
context of tumor cells in vivo. The general expectation that changes in levels of miRNAs 
will be inversely correlated (IC) with changes in levels of their mRNA targets (Nam et 
al., 2009; Ruike et al., 2008; Sood et al., 2006; Wang and Li, 2009; Xin et al., 2009) has 
yet to be conclusively tested within the context of tumor cells in vivo. For example, 
previous independent estimates of relative miRNA levels in ovarian cancers vs. controls 
often have been inconsistent, possibly due to differences in sample type (e.g., bulk tissue 
samples vs. micro-dissected cells, etc.), biological variability among different cancer sub-
types and individual patient samples (e.g., Dahiya et al., 2008; Iorio et al., 2007; Nam et 
al., 2008; Wyman et al., 2009; Yang et al., 2008; Zhang et al., 2006) or due to 
inaccuracies in the prediction of the mRNA targets (Min and Yoon, 2010; Saito and 
Saetrom, 2010).  
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In an effort to reduce variation that may obscure biologically significant trends, 
we have conducted microarray (Affymetrix) analyses of miRNAs and mRNAs from the 
same ovarian cancer epithelial (CEPI) cells isolated from patient samples by laser capture 
micro-dissection (LCM). We monitored differences in levels of miRNA expression 
between CEPI and ovarian surface epithelial (OSE) cells (collected from ovaries of 
normal patients) with expression levels of their putative mRNA targets as determined by 
various prediction algorithms and by experimental validation. While ovarian cancers may 
arise from either the fimbrial epithelium of the oviduct or OSE, it has recently been 
shown that both classes of cells are part of a transitional epithelium of common origin 
and thus either may serve as a precursor to CEPI (Auersperg, 2011). Since OSE can be 
harvested from the surface of ovaries with minimal contamination, they were selected as 
appropriate controls in our study.  
We found that only ∼11 % of mRNA targets displaying significant (p <0.005) 
changes in levels of expression in CEPI relative to normal were IC with changes in levels 
of their regulating miRNAs (p <0.01). The levels of the majority (∼79 %) of target 
mRNAs were unchanged in CEPI while the rest (∼10 %) of the mRNA targets displayed 
changes in levels positively correlated (PC) with their respective regulating miRNAs. We 
conclude that the low predictability of miRNA regulatory effects in CEPI isolated from 
patient samples is attributable to the complexity of miRNA function in vivo.  
 
Results 




Hierarchical clustering of the expression profiles of miRNAs detected on the 
miRChip (Asuragen Inc, Austin, TX) was performed on three CEPI and three OSE 
patient samples. The miRChip contains a total of 13,349 probes including 467 annotated 
human miRNAs (Sanger miRBase V9.2; Griffiths-Jones, 2004; Griffiths-Jones et al., 
2006; Griffiths-Jones et al., 2008), 455 miRNAs annotated in various other species and 
12,894 (exploratory) probes of predicted, but as yet not validated/annotated miRNAs. 
Using a threshold of 2-fold or greater change, 42 miRNA probes were found to be 
differentially expressed (p <0.01) between our cancer and control samples. Of these, 33 
were up-regulated and 9 down-regulated in the CEPI relative to OSE, including 12 
previously annotated human miRNAs (9 up-regulated and 3 down-regulated). A heat map 
of the 42 differentially expressed miRNA probes is presented in Figure 2.1A (the miRNA 
sequences of these 42 probes, log2 difference between CEPI and OSE, and p-values from 
t-test are provided in Table A.1). To independently test the validity of the differential 
miRNA expression patterns determined by microarray, we conducted measurements of 
miRNA levels using quantitative real-time polymerase chain reaction (qPCR). Five (miR-
141, miR-429, miR-205, miR-383 and miR-320) of the 12 previously annotated human 
miRNAs shown to be differentially expressed by microarray were selected for qPCR 
analysis in three cancer and three control samples. The qPCR results confirmed the 







Figure 2.1. Differentially expressed miRNAs in CEPI relative to OSE. (A) 
Hierarchical clustering of normal and cancer patient samples (p <0.01, fold change ≥2). 
The dendogram on the left shows that the probes cluster into 2 groups corresponding to 
the up-regulated and down-regulated miRNAs differentially expressed between normal 
and cancer. The cancer stage/grade of each of the CEPI samples is also provided. IDs of 
selected probes are given on the right (including the annotated human miRNAs, see Table 
A.1 for a complete list). Key: hsa-miR-x: annotated human miRNAs; hsa-asg/cand-x: 
predicted candidate human miRNAs; ppy-: Pongo pygmaeus miRNA; cel-: C. elegans 
miRNA. (B) Confirmation of expression patterns for selected miRNAs by qPCR. The 
relative expression of each miRNA in logarithmic units in cells from three cancer patients 
is shown compared to cells from three normal ovaries after normalization to RNU6B 
(∆∆Ct method). These were found to be statistically significant by Relative Expression 
Software Tool (REST®) by a randomization method. Randomization was performed 
5000 times. Consistent with the microarray results, miR-141, miR-205 and miR-429 were 
confirmed to be significantly up-regulated in cancer, while miR-320 and miR-383 were 
found to be significantly down-regulated. Error bars represent standard error of the mean. 
** p <0.01; * p <0.05  
 
 
In contrast to some earlier studies (Dahiya et al., 2008; Iorio et al., 2007; Nam et 
al., 2008; Yang et al., 2008; Zhang et al., 2006), our results indicate that the majority of 
miRNAs displaying significant differences in levels of expression between CEPI and 
OSE are up-regulated in ovarian cancer. The basis of this discrepancy is unknown but 
may be due to differences in sample type (e.g., bulk tissue samples vs. micro-dissected 
cells, etc.) and/or biological variability among individual patient samples. Our finding 
that the majority of miRNAs are up-regulated in ovarian cancer is consistent with the fact 
that miRNA targets are significantly enriched (hypergeometric distribution, p <0.05) 
among mRNAs down-regulated in our cancer samples, while up-regulated genes have 
relatively few miRNA targets (Figures 2.2 and 2.3; see also Table A.2). A possible 
biological explanation of why miRNAs are up-regulated in EOC may lie in the fact that 
in contrast to other cancers (da Costa, 2001; Diaz-Cano, 2008), the transition from OSE 
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to CEPI is postulated to involve changes from a less differentiated to a more 




Figure 2.2: Differentially expressed mRNAs between CEPI and OSE. Hierarchical 
clustering of CEPI samples and OSE samples based on the differentially expressed genes. 
The ~3650 probesets correspond to ~2700 unique gene symbols and were selected based 
on p-value <0.005, fold change ≥2, and Affymetrix “Present” call in at least 1 sample. 
The dendogram on the left clusters the up-regulated genes and down-regulated genes into 
2 groups and the number of genes in each of these classes are approximately equal. Gene 
symbols corresponding to representative differentially expressed probesets are shown on 






Figure 2.3: Overlap between differentially expressed genes in ovarian cancer and 
miRNA target genes. Genomica was used to calculate significant (false discovery rate 
corrected p <0.05) gene set overlaps between genes differentially expressed in the 
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ovarian cancer data set and gene sets containing targets of individual miRNAs. This is 
analogous to a “GO” (gene ontology) enrichment analysis (the miRNA identities are the 
“ontologies” in this case). The coloring represents the percentage (%) of genes within the 
cancer data set that overlap with the individual miRNA target gene set listed on the right. 
The miRNAs listed here include differentially expressed miRNAs found in our 
microarray experiment as well as additional miRNAs predicted using Genomica. 
 
 
Among the 12 previously annotated miRNAs displaying a significant change in 
levels in the CEPI samples, miR-205, miR-141, and miR-429 are all significantly up-
regulated consistent with previous studies linking these miRNAs with the maintenance of 
cells in the differentiated epithelial state (Gregory et al., 2008). Of the miRNAs that are 
down-regulated in CEPI relative to OSE, miR-320 and miR-383 are located in regions 
associated with frequent DNA copy number losses in ovarian cancer (Zhang et al., 2006). 
miR-320 previously has been identified as an inhibitor of lung carcinoma proliferation 
(Schaar et al., 2009). Its down-regulation in CEPI suggests that it may act as a tumor 
suppressor in ovarian cancers as well. 
 
Only ~11 % of the predicted mRNA targets of miRNAs differentially expressed 
between the CEPI and OSE display the expected inverse pattern of change in gene 
expression.  
 Previous studies have established that human miRNAs repress gene expression by 
pairing with complementary sequences located within the 3’ untranslated regions (3’ 
UTR) of targeted mRNAs resulting in translational repression and mRNA degradation 
(Tang et al., 2008b; Valencia-Sanchez et al., 2006). Based on these findings, changes in 
the expression levels of miRNAs are generally predicted to be inversely correlated with 
 
 31
changes in the expression levels of their targeted mRNAs (Nam et al., 2009; Ruike et al., 
2008; Sood et al., 2006; Wang and Li, 2009; Xin et al., 2009). To test this hypothesis in 
the context of cells isolated from patient samples, we compared changes in the levels of 
the previously annotated human miRNAs with levels of their predicted target mRNAs in 
our CEPI samples relative to the OSE controls. The putative mRNA targets of these 
previously annotated human miRNAs were initially identified using the miRanda 
algorithm (Betel et al., 2008; Enright et al., 2003; John et al., 2004). The results indicate 
that only ∼11 % of the changes in mRNA expression between CEPI and OSE were 
inversely correlated (IC) with the observed changes in miRNA levels (Tables 2.1 and 
A.3). Earlier studies of levels of miRNAs and their targeted mRNAs in a series of cell 
lines reported similar findings (Blower et al., 2007; Guimbellot et al., 2009; Wang and 
Li, 2009). The expression of the majority (No Change, NC: ~79 %) of the predicted 
mRNA targets was not significantly different (p >0.005 and/or fold change <2) between 
the CEPI and OSE samples, while ∼10 % of the targeted mRNAs displayed changes 
positively correlated (PC) with their putatively regulating miRNAs.  
 
 
Table 2.1. Summary values of IC, PC and NC targets in CEPI vs. OSE using 
miRanda. MiRNA targets that were differentially expressed between CEPI and OSE 
based on t-test p <0.005 and fold change of at least 2 were classified as being IC or PC 
with their regulating miRNAs (while target genes that do not meet the above criteria are 
classified as NC). Total number of targets from miRanda algorithm present after 
removing probesets with “Absent” calls in all samples is shown along with fraction of IC, 
PC and NC targets for each miRNA. On average, 78.6 % of the target mRNAs are “No 
Change”, or do not change significantly with miRNAs, 11.2 % are “inversely correlated” 

















miR-7 2363 10.62 79.94 9.44 
miR-18a 1738 11.10 79.86 9.03 
miR-18b 1710 11.40 79.24 9.36 
miR-126 84 14.29 75.00 10.71 
miR-128 2691 11.82 79.23 8.96 
miR-141 3074 13.53 77.91 8.56 
miR-205 2268 13.49 78.31 8.20 
miR-429 3316 13.48 78.62 7.90 
miR-93* 2252.00 13.14 77.00 9.86 
Average (for up-
regulated 
miRNAs) 2166.22 12.54 78.34 9.11 
miR-383 2118 9.02 78.80 12.18 
miR-320a 3073 8.30 79.08 12.63 
miR-193a-5p 1216 12.01 78.45 9.54 
Average (for 
down-regulated 
miRNAs) 2135.67 9.77 78.78 11.45 
Average (for Up 
and Down) 2150.94 11.16 78.56 10.28 
 
 
Table 2.2. Summary values of IC, PC and NC targets using TargetScan. MiRNA 
targets that were differentially expressed between CEPI and OSE based on t-test p <0.005 
and fold change of at least 2 were classified as being IC or PC with their regulating 
miRNAs (while target genes that do not meet the above criteria are classified as NC). 
Total number of targets from TargetScan algorithm present after removing probesets with 
“Absent” calls in all samples is shown along with fraction of IC, PC and NC targets for 
each of the 12 annotated miRNAs. On average, 79.3 % of the target mRNAs are NC, 10.4 













miR-7 272 13.24 78.68 8.09 
miR-18a 177 15.82 79.66 4.52 
miR-18b 177 15.82 79.66 4.52 
miR-126 15 0 80 20 













miR-128 671 12.97 77.94 9.09 
miR-141 471 14.65 76.01 9.34 
miR-205 262 16.03 74.81 9.16 
miR-429 736 14.13 78.4 7.47 
miR-93* 
(Custom) 248.00 13.71 77.02 9.27 
Average (for 
up-regulated 
miRNAs) 336.56 12.93 78.02 9.05 
miR-383 95 3.16 84.21 12.63 
miR-320a 468 7.26 79.49 13.25 
miR-193a-5p 69 13.04 78.26 8.7 
Average (for 
down-regulated 
miRNAs) 210.67 7.82 80.65 11.53 
Average (for 




Table 2.3. Summary values of IC, PC and NC targets using PicTar. MiRNA targets 
that were differentially expressed between CEPI and OSE based on t-test p <0.005 and 
fold change of at least 2 were classified as being IC or PC with their regulating miRNAs 
(while target genes that do not meet the above criteria are classified as NC). Total number 
of targets from PicTar algorithm present after removing probesets with “Absent” calls in 
all samples is shown along with fraction of IC, PC and NC targets for each of the 12 
annotated miRNAs. On average, 80.5 % of the target mRNAs are in the NC group, 9.4 % 














miR-7 235 9.79 79.57 10.64 
miR-18a 126 15.87 75.40 8.73 
miR-18b 127 17.32 74.02 8.66 
miR-126 12 0.00 100.00 0.00 
miR-128 485 13.20 77.53 9.28 
miR-141 767 13.43 77.18 9.39 
miR-205 223 12.56 77.58 9.87 















miRNAs) 282.14 11.74 80.18 8.08 
miR-383 61 1.64 78.69 19.67 
miR-320a 377 6.10 81.70 12.20 
miR-193a-5p 149 8.05 79.87 12.08 
Average (for 
down-regulated 
miRNAs) 263 7.08 80.78 12.14 
Average (for 
Up and Down) 272.57 9.41 80.48 10.11 
 
To determine if the unexpectedly low percentage of IC changes may be a 
computational artifact of our use of the miRanda algorithm to predict targeted mRNAs, 
we repeated the analysis independently using the PicTar (www.pictar.org) and 
TargetScan (www.targetscan.org) miRNA target prediction algorithms. In both instances, 
the results were consistent with our original finding that only a minority of the changes in 
mRNA expression between CEPI and OSE are inversely correlated (IC) with the 
observed changes in miRNA levels (PicTar: IC 9.4 % , PC 10.1 %, NC 80.5 %; 
TargetScan: IC 10.4 %, PC 10.3 %, NC 79.3 %; see Tables 2.2 and 2.3). To increase the 
stringency of target predictions, we reanalyzed the data using only miRNA targets that 
were commonly predicted by all three algorithms (intersection). We found that by 
overlapping the three independent prediction algorithms, each miRNA had fewer 
predicted targets, yet using these commonly predicted targets, only ~7 % of the mRNA 
changes between CEPI and OSE were found to be inversely correlated (IC) with the 
observed changes in miRNA levels (Table 2.4). We also analyzed our data using 
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intersections of predictions from two algorithms at a time (miRanda+TargetScan, 
miRanda+PicTar, and PicTar+TargetScan), and again we found that changes in levels of 
only 6-9 % of the predicted mRNA targets were inversely correlated with changes in 




Table 2.4. Summary values of IC, PC and NC targets in CEPI vs. OSE using overlap 
of miRanda, TargetScan and PicTar target predictions. MiRNA targets that were 
differentially expressed between CEPI and OSE based on t-test p <0.005 and fold change 
of at least 2 were classified as being IC or PC with their regulating miRNAs (while target 
genes that do not meet the above criteria are classified as NC). Total number of targets 
from the intersection (M_TS_PT) of miRanda (M), TargetScan (TS) and PicTar (PT) 
predictions present after removing probesets with “Absent” calls in all samples is shown 
along with fraction of IC, PC and NC targets for each miRNA. On average, 76.7 % of the 
target mRNAs are “No Change”, or do not change significantly with miRNAs, 6.8 % are 













miR-7 105 10.48 84.76 4.76 
miR-18a 59 13.56 83.05 3.39 
miR-18b 59 13.56 83.05 3.39 
miR-126 2 0.00 100.00 0.00 
miR-128 237 11.81 79.75 8.44 
miR-141 177 15.82 74.58 9.60 
miR-205 73 21.92 67.12 10.96 
Average (for 
up-regulated 
miRNAs) 101.71 12.45 81.76 5.79 
miR-383 15 0.00 80.00 20.00 
miR-320a 112 3.57 84.82 11.61 
miR-193a-5p 2 0.00 50.00 50.00 
Average (for 
down-regulated 
miRNAs) 43.00 1.19 71.61 27.20 
Average (for 




Table 2.5. Summary values of IC, PC and NC targets using overlap of miRanda and 
TargetScan predictions. MiRNA targets that were differentially expressed between 
CEPI and OSE based on t-test p <0.005 and fold change of at least 2 were classified as 
being IC or PC with their regulating miRNAs (while target genes that do not meet the 
above criteria are classified as NC). Total number of targets from the overlap of miRanda 
(M) and TargetScan (TS) algorithms present after removing probesets with “Absent” 
calls in all samples is shown along with fraction of IC, PC and NC targets for each of the 
12 annotated miRNAs. On average, 79.2 % of the target mRNAs are in the NC group, 9 













miR-7 212 12.26 79.72 8.02 
miR-18a 136 13.97 80.88 5.15 
miR-18b 135 14.07 80.74 5.19 
miR-126 6 0.00 83.33 16.67 
miR-128 447 13.20 78.75 8.05 
miR-141 383 14.88 75.20 9.92 
miR-205 199 22.11 69.35 8.54 
miR-429 620 14.68 78.06 7.26 
miR-
93*(Custom) 163 15.34 77.30 7.36 
Average (for 
up-regulated 
miRNAs) 255.67 13.39 78.15 8.46 
miR-383 73 2.74 80.82 16.44 
miR-320a 342 6.43 79.53 14.04 
miR-193a-5p 52 15.38 73.08 11.54 
Average (for 
down-regulated 
miRNAs) 155.67 4.59 80.18 15.24 
Average (for 





Table 2.6. Summary values of IC, PC and NC targets using overlap of miRanda and 
PicTar predictions. MiRNA targets that were differentially expressed between CEPI and 
OSE based on t-test p <0.005 and fold change of at least 2 were classified as being IC or 
PC with their regulating miRNAs (while target genes that do not meet the above criteria 
are classified as NC). Total number of targets from the overlap of miRanda (M) and 
PicTar (PT) algorithms present after removing probesets with “Absent” calls in all 
samples is shown along with fraction of IC, PC and NC targets for each of the 12 
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annotated miRNAs. On average, 78.3 % of the target mRNAs are in the NC group, 8.6 % 













miR-7 162 9.88 83.33 6.79 
miR-18a 84 16.67 75.00 8.33 
miR-18b 86 18.60 73.26 8.14 
miR-126 3 0.00 100.00 0.00 
miR-128 332 12.95 79.52 7.53 
miR-141 388 16.75 75.26 7.99 
miR-205 150 17.33 73.33 9.33 
Average (for 
up-regulated 
miRNAs) 172.14 13.17 79.96 6.87 
miR-383 41 0.00 73.17 26.83 
miR-320a 256 6.25 80.08 13.67 
miR-193a-5p 17 5.88 76.47 17.65 
Average (for 
down-regulated 
miRNAs) 104.67 4.04 76.57 19.38 
Average (for 
Up and Down) 138.40 8.61 78.27 13.13 
 
 
Experimental validation is currently considered the most stringent method to 
validate miRNA targets (Kuhn et al., 2008; Thomas et al., 2010). Thus, to further test the 
possibility that the low inverse correlation between changes in miRNA levels and target 
mRNAs observed in the tissue samples was merely a reflection of the limited accuracy of 
target prediction algorithms, we conducted a series of transfection experiments using two 
miRNAs that were significantly up-regulated in CEPI (miR-7 and miR-128) to identify 





Table 2.7. Summary values of IC, PC and NC targets using overlap of TargetScan 
and PicTar predictions. MiRNA targets that were differentially expressed between 
CEPI and OSE based on t-test p <0.005 and fold change of at least 2 were classified as 
being IC or PC with their regulating miRNAs (while target genes that do not meet the 
above criteria are classified as NC). Total number of targets from the overlap of 
TargetScan (TS) and PicTar (PT) algorithms present after removing probesets with 
“Absent” calls in all samples is shown along with fraction of IC, PC and NC targets for 
each of the 12 annotated miRNAs. On average, 76.8 % of the target mRNAs are in the 













miR-7 123.00 11.38 81.30 7.32 
miR-18 72.00 15.28 81.94 2.78 
miR-126 6.00 0.00 100.00 0.00 
miR-128 326.00 12.58 76.99 10.43 
miR-141 210.00 14.76 75.24 10.00 
miR-205 93.00 17.20 69.89 12.90 
Average (for 
up-regulated 
miRNAs) 138.33 11.87 80.89 7.24 
miR-383 17.00 0.00 82.35 17.65 
miR-320a 129.00 3.10 86.05 10.85 
miR-193a-5p 2.00 0.00 50.00 50.00 
Average (for 
down-regulated 
miRNAs) 49.33 1.03 72.80 26.17 
Average (for 
Up and Down) 93.83 6.45 76.85 16.70 
 
 
A series of independent transfection experiments was carried out with miR-7, 
miR-128 and a matched set of negative control miRNAs in a well-established EOC cell 
line (HEY; Buick et al., 1985). Total RNA was collected from cells 48 hrs after 
transfection and the relative levels of mRNAs present were determined by Affymetrix 




Table 2.8. Summary values of IC, PC and NC targets in transfection experiments 
using miRanda, TargetScan and PicTar target predictions. MiRNA targets that were 
differentially expressed between miR-7 or miR-128 transfected cells compared to 
negative control miRNA transfected cells, based on fold change of at least 1.4 and false 
discovery rate threshold of 5 % were classified as being IC or PC with their regulating 
miRNAs (while target genes that do not meet the above criteria are classified as NC). 
Total number of targets from miRanda (M), TargetScan (TS) and PicTar (PT) or their 
intersections (two at time and all three) present after removing probesets with “Absent” 














 miR-7 transfection 
miR-7_M 2432 7.98 91.24 0.78 
miR-7_TS 259 23.55 75.29 1.16 
miR-7_PT 238 16.39 83.19 0.42 
miR-7_M_TS 234 20.51 78.63 0.85 
miR-7_PT_TS 118 22.88 77.12 0 
miR-7_M_PT 159 20.75 79.24 0 
miR-7_M_TS_PT 99 23.23 76.77 0 
 miR-128 transfection 
miR-128_M 2744 9.55 79.15 11.30 
miR-128_TS 654 16.36 73.85 9.79 
miR-128_PT 441 15.19 74.60 10.20 
miR-128_M_TS 449 20.04 72.83 7.13 
miR-128_TS_PT 301 16.94 73.75 9.30 
miR-128_M_PT 306 17.32 74.18 8.50 





Table 2.9. Summary values of IC, PC and NC mRNAs in CEPI vs. OSE for miR-7 
and miR-128 using “experimentally validated” targets only. Targets that were 
predicted by miRanda (M), TargetScan (TS), PicTar (PT) or any combination of the three 
programs and were down-regulated (FDR <5 %, fold change ≤-1.4) in miR-7 transfection 
or in miR-128 transfection were assumed to be experimentally validated targets. The 
direction of change of these same targets in CEPI vs. OSE were then used to calculate IC, 


















miR-7_M 180 12.22 80.56 7.22 
miR-7_TS 60 6.67 88.33 5 
miR-7_PT 37 0 91.89 8.11 
miR-7_M_TS 47 6.38 87.23 6.38 
miR-7_PT_TS 27 0 96.30 3.70 
miR-7_PT_M 33 0 90.91 9.09 
miR-7_M_TS_PT 23 0 95.65 4.35 
Average for miR-7 (all 
methods) 58.14 3.61 90.12 6.26 
miR-128_M 252 11.90 74.60 13.49 
miR-128_TS 103 10.68 75.73 13.59 
miR128_PT 63 17.46 69.84 12.70 
miR-128_M_TS 87 12.64 72.41 14.94 
miR-128_PT_TS 49 16.33 69.39 14.29 
miR-128_M_PT 52 11.54 75 13.46 
miR-128_M_PT_TS 43 11.63 72.09 16.28 
Average for miR-128 (all 
methods) 92.71 13.17 72.73 14.11 
Average (overall) 75.43 8.39 81.42 10.19 
 
 
Consistent with the results from CEPI tissue samples, only a minority of predicted 
mRNA targets were found to be significantly reduced (IC) after miR-7 or miR-128 
transfection (Table 2.8). The predicted mRNA targets that were significantly down-
regulated in these transfection experiments were taken as “experimentally validated” 
mRNA targets of miR-7 and miR-128 respectively. Using only these targets, we 
reanalyzed the microarray data from the tissue samples and found that only ~8 % (range 
0-18 %) of the “experimentally validated” mRNA targets displayed changes in 
expression IC with changes in miR-7 and miR-128 expression in CEPI (Table 2.9). 
Collectively our results indicate that the low inverse correlation between changes in 
levels in miRNAs and their target mRNAs in vivo is not merely an artifact of inaccurate 
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target predictions but rather a reflection of the complexity of miRNA function in cancer 
cells. 
 
Discussion and Conclusion 
It is well known that genes and their mRNA products are subject to a vast array of 
regulatory controls. The relative contribution of malfunctions in these controls to the 
onset and progression of diseases, such as cancer, can be varied and complex (Pardee, 
2006). MiRNAs and other small non-coding RNAs recently have been shown to be 
important regulators of gene expression, and disruption of miRNA expression has been 
implicated in many diseases including cancer (Esquela-Kerscher and Slack, 2006; Lee 
and Dutta, 2009; Ventura and Jacks, 2009; Visone and Croce, 2009; Wiemer, 2007). 
While it is well established that miRNAs can serve as useful biomarkers for the diagnosis 
and staging of a variety of human cancers (e.g., Bartels and Tsongalis, 2009; Calin and 
Croce, 2006a; Lu et al., 2005), the manner and extent to which miRNAs contribute to the 
processes underlying cancer is only beginning to be understood (Calin and Croce, 2006a; 
Lee and Dutta, 2009). For example, the regulatory function of miRNAs was initially 
believed to operate exclusively at the translational level (Lee et al., 1993; Wightman et 
al., 1993), but more recent findings have demonstrated that these small regulating RNAs 
also play a role in the modulation of mRNA stability and that these two modes of control 
may be inter-related (Djuranovic et al., 2011; Valencia-Sanchez et al., 2006). 
Extensive in vitro and in vivo studies previously have demonstrated that human 
miRNAs can repress gene expression by pairing with sequences located within the 3’ 
untranslated regions of targeted messenger RNAs (mRNAs) resulting in translational 
repression and subsequent mRNA degradation (Bartel, 2004; Tang et al., 2008b; 
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Valencia-Sanchez et al., 2006). Thus far there are few examples of miRNAs increasing 
the transcription or translation of target genes (Place et al., 2008; Vasudevan et al., 2007), 
resulting in positive correlations between miRNAs and target mRNAs. Therefore, a 
generally held expectation is that changes in the expression levels of mRNAs will be 
inversely correlated with changes in the levels of their targeting miRNAs (Ritchie et al., 
2009). However, the fact that individual miRNAs may target multiple mRNAs and that 
individual mRNAs may be targeted by multiple miRNAs creates the potential for a 
complex network of interactions in cancer cells replete with a variety of positive and 
negative feedback loops (Aguda et al., 2008; Volinia et al., 2010). The extent to which 
these complexities may mitigate our ability to accurately predict the function of miRNAs 
within the context of cancer cells has relevance to the proposed use of miRNAs in cancer 
therapy. 
The purpose of the current study was to systematically evaluate the extent to 
which the regulatory consequence of changes in miRNA levels in tumors can be 
predicted from current models of miRNA function. The fact that prior efforts to obtain 
expression profiles of miRNAs and their mRNA targets were typically carried out on 
samples obtained from different patients and/or from mixed (bulk) tissues have 
contributed to inconsistent findings (e.g., Dahiya et al., 2008; Iorio et al., 2007; Nam et 
al., 2008; Wyman et al., 2009; Yang et al., 2008; Zhang et al., 2006). In an effort to 
reduce experimental variation, we assayed changes in levels of miRNA and their targeted 
mRNAs in ovarian cancer cells isolated from the same patients by LCM. Our results 
indicate that only ~11 % of the changes in levels of mRNAs are IC with changes in levels 
of their regulating miRNAs in the same ovarian cancer (CEPI) cells. To eliminate the 
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possibility that our results are merely an artifact of incorrectly identified mRNA targets 
of miRNA regulation, we repeated our analyses using targets predicted by a variety of 
prediction algorithms, as well as, targets experimentally validated in a series of 
transfection experiments conducted in an EOC cell line. Our results consistently support 
the conclusion that the expected IC between changes in miRNA levels and levels of their 
target mRNAs occurs relatively infrequently in EOC cells isolated from patient samples. 
Our findings underscore the complexities of miRNA-mediated regulation in vivo and the 
inadequacy of current models to accurately predict the molecular consequences of 
fluctuations in levels of miRNAs within the complex context of tumor cells.  
 
Materials and Methods 
Tissue samples 
Ovarian tumor samples were collected at Northside Hospital (Atlanta, GA) during 
surgery and snap frozen in liquid nitrogen within one minute of removal from patients. 
All ovarian tumor samples used in this study were from patients diagnosed with serous 
papillary epithelial ovarian carcinoma. Brushings of normal ovarian surface epithelial 
cells (OSE) were preserved immediately in RNAlater (Ambion, Austin, TX). Patient 
consent and approval from the Institutional Review Boards of Georgia Institute of 
Technology and Northside Hospital were obtained. The written consent and our protocol 
(#H09227) were approved by the IRB. Detailed clinical information for each patient used 




Laser capture micro-dissection (LCM) 
 Fresh frozen tissues from tumors were cut into seven-micron sections, applied to 
non-charged slides, then fixed in 75 % ethanol for 30 seconds, stained and dehydrated 
using the HistoGene LCM Frozen Section Staining Kit (Arcturus, Mountain View, CA). 
LCM was performed with an AutoPix Automated Laser Capture Micro-dissection System 
using the CapSure Macro Caps (Arcturus, Mountain View, CA). Approximately 10,000 
cells were captured on each of five-six caps per sample. MiRNA was extracted from 
captured cells using the mirVana miRNA Isolation Kit (Ambion, Austin, TX). MRNA 
was isolated from cells from the same patients using the PicoPure RNA Isolation Kit 
(Arcturus, Mountain View, CA). 
 
 
Table 2.10. Clinical information of patients analyzed in this study. Clinical 
information relevant to this study for each patient is shown. In addition, a legend is given 
to identify which patient was used for each microarray and qPCR experiment. 
Abbreviations used- Cerv: Cervix; Endo: Endometrium; Ov: Ovary; ca.: Carcinoma; hx: 
History. 
 




papillary serous carcinoma IIIc/IV/3 59 
588
 a,b,c
 papillary serous carcinoma IIIc/2-3 71 
489
 a,b
 papillary serous carcinoma IV/3 48 
620
 c
 papillary serous carcinoma III/IV/3 62 
434
 a
 within normal limits N/A 41 
440
 a
 within normal limits N/A 50 
475
 a
 within normal limits N/A 63 
470
 a














 within normal limits N/A 44 
665
 b
 within normal limits N/A 84 
Table 2.10 (continued) 
 45




 within normal limits N/A 52 
838
 c
 within normal limits N/A 51 
846
 c
 within normal limits N/A 51 
a: mRNA microarray; b: microRNA microarray; c: qPCR 
 
 
RNA extraction from ovarian surface epithelial (OSE) cells 
For miRNA qPCR and microarray normal ovarian surface epithelial cells were 
spun down and resuspended in lysis buffer from the mirVana miRNA Isolation Kit, 
following the manufacturer's recommended protocol (Ambion, Austin, TX). cDNA for 
quantitative real-time PCR (qPCR) was synthesized from RNA (10ng) using the TaqMan 
miRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA).  
For mRNA qPCR and microarray total RNA extraction from OSE was carried out 
using the PicoPure RNA Isolation Kit, following the manufacturer’s recommended 
protocol (Arcturus, Mountain View, CA). Due to limited number of cells collected from 
surface epithelial brushings, OSE RNA was extracted from five patients with non-
malignant ovaries for mRNA microarray and from two different sets of three patients 
with non-malignant ovaries for miRNA (one set for miRNA microarray, another for 
qPCR; see Table 2.10 for more details on patient information).  
 
Quantitative (real-time) PCR (qPCR) 
Total RNA (10ng) extracted from LCM captured ovarian tumor cells and normal 
OSE cells was converted to amplified cDNA for qPCR. TaqMan miRNA Assays 
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(Applied Biosystems, Foster City, CA) were conducted following manufacturer's 
protocol for hsa-miR-141, hsa-miR-429, hsa-miR-205, hsa-miR-320, hsa-miR-383 and 
for RNU6B endogenous control using the StepOnePlus Real-Time PCR machine 
(Applied Biosystems, Foster City, CA). For each sample miRNA expression values are 
normalized to an endogenous control (RNU6B). Statistical significance was determined 
using the Relative Expression Software Tool (REST; Pfaffl et al., 2002). Specificity of 
TaqMan miRNA assays is supported by publications from the manufacturer (Chen et al., 
2007; Liang et al., 2007; Tavazoie et al., 2008) as well as subsequent literature from 
independent groups (Huang et al., 2011; Shibata et al., 2011; Wilson et al., 2011). 
RNU6B was used as endogenous control as it was recommended by the reagent 
manufacturer (http://www.ambion.com/techlib/tn/151/3.html) and is expressed at high 
levels in ovarian tissues 
(http://www3.appliedbiosystems.com/cms/groups/mcb_marketing/documents/generaldoc
uments/cms_044972.pdf).  
For mRNA qPCR, total RNA (1-5µg) extracted from cells was converted to 
cDNA using the Superscript III First Strand synthesis system (Invitrogen). cDNA was 
then purified using the QIAGEN PCR purification kit (QIAGEN) following 
manufacturer’s instructions. QPCR experiments were carried out for the EGFR, BMI and 
GAPDH genes using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA). The sequence 
specific primers used for SYBR green assays are as follows: EGFR-forward: 
GGAGAACTGCCAGAAACTGACC, EGFR-reverse: GCCTGCAGCACACTGGTTG, 
GAPDH-forward: GGTCTCCTCTGACTTCAACA, GAPDH-reverse: 
AGCCAAATTCGTTGTCATAC, BMI1-forward: ACTTCATTGATGCCACAACC, 
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BMI1-reverse: CAGAAGGATGAGCTGCATAA. The EGFR primers were as designed 
by (Micallef et al., 2009) and GAPDH primers were as designed by (Koppelstaetter et al., 
2005). BMI1 primers were obtained from the qPCR primer database RTPrimerDB 
(Pattyn et al., 2003). The GAPDH primer efficiencies were calculated to be ~1. 
Specificity of the other primers can be obtained from the relevant publications/database. 
All reactions were optimized with non-template controls, and -RT (minus reverse 
transcriptase) controls prior to experiment. All qPCR experiments were carried out with 
at least three technical replicates and three independent biological replicates. 
 
Cell culture and miRNA transfections 
HEY cells were provided by Gordon B. Mills, Department of Systems Biology, 
the University of Texas, M. D. Anderson Cancer Center. The cells were cultured in RPMI 
1640 (Mediatech, Manassas, VA) supplemented with 10 % v/v heat-inactivated fetal calf 
serum (Invitrogen, Carlsbad, CA), 2 mM L-glutamine (Mediatech), 10 mM HEPES 
buffer (Mediatech), penicillin (100 U/ml), and streptomycin (100 µg/mL). Approximately 
12h before transfection, these cells (1.5 × 10
5
) were seeded on six-well plates (two-three 
replicates per group) in growth medium and allowed to adhere overnight at 37°C in a 5 % 
CO2 atmosphere. The following day after washing the wells with PBS and replacing the 
growth medium with reduced serum medium Opti-MEM (Invitrogen), cells were 
transfected with the miRNA [hsa-miR-7 miRIDIAN mimic, miRIDIAN miRNA mimic 
negative control #1 (miR-NC, a C.elegans miRNA, cel-miR-67, with confirmed minimal 
sequence identity in humans), or hsa-miR-128 miRIDIAN mimic (Thermo Fisher 
Scientific, Lafayette, CO)] using Lipofectamine 2000 transfection agent (Invitrogen) 
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according to the manufacturer's instructions at a final concentration of 25nM. Cells were 
incubated for 4 hours, washed with PBS, and then incubated at 37°C and 5 % CO2 for 
44h (total 48h) after adding fresh growth medium (RPMI 1640) to the wells. Transfection 
efficiency was estimated from the relative knock-down of previously validated targets 
(EGFR for miR-7 and BMI-1 for miR-128 (Godlewski et al., 2008; Webster et al., 2009), 
Figure A.1), based on recommendations by the reagent manufacturer (Thermo Fisher 
Scientific). Cell culture experiments were carried out using at least two-three independent 
biological replicates. 
 
Tissue whole genome microarray 
Biotin labeled cRNA was synthesized, hybridized to Affymetrix HG-U133 Plus 
2.0 oligonucleotide arrays and analyzed with a GeneChip Scanner 3000 (Affymetrix, 
Santa Clara, CA). 
 CEL files generated by the Affymetrix Gene Chip Operating System (GCOS) 
were converted to expression level values using the MAS 5.0 package implemented using 
the Affymetrix Expression Console software. The log base 2 transformed expression 
values were then normalized across samples by Z-score calculations using Spotfire 
DecisionSite for Microarray Analysis (DSMA). Probesets with “Absent” call in all 
groups were removed from further statistical analysis. Probeset intensities were filtered 
with DSMA using a modulation threshold of 1.0 to include only those probesets with at 
least a log base 2 expression value of ≥1.0 or fold change ≥2. Differentially expressed 
probesets were identified using the t-test function of the Profile ANOVA Tool of DSMA 





HEY cell RNA isolation and whole genome microarray 
Total RNA was isolated using the RNeasy Mini RNA isolation kit (QIAGEN, 
Valencia, CA) according to the manufacturer’s instructions. The integrity of the RNA 
was verified using an Agilent 2100 Bioanalyzer (1.8-2.0; Agilent Technologies, Palo 
Alto, CA). MRNAs were converted to double stranded (ds)-cDNA and amplified using 
Applause 3’-Amp System (NuGen, San Carlos, CA). This cDNA was then biotin labeled 
and fragmented by using Encode Biotin Module (NuGen). The labeled cDNA was 
hybridized to Affymetrix HG-U133 Plus 2.0 oligonucleotide arrays and analyzed with a 
GeneChip Scanner 3000 (Affymetrix, Santa Clara, CA). Raw data in the form of CEL 
files were produced by Affymetrix GeneChip Operating System (GCOS) software. Raw 
data from mRNA microarray were analyzed using the Expression Console software 
(Affymetrix) and using R (www.r-project.org). Normalization was performed using MAS 
5.0, and PLIER available on the Expression Console software, while GCRMA algorithm 
was implemented using the “gcrma” package on R. The log base 2 transformed 
expression values from MAS5.0 were then analyzed for Affymetrix “Present/Absent” 
calls using Spotfire DecisionSite for Microarray Analysis (DSMA). Probesets with 
“Absent” call in all groups were removed from statistical analysis. Average probeset 
intensities for each group was calculated based on the log 2 transformed values from 
PLIER and then filtered with DSMA using a modulation threshold of 0.5 to include only 
those probesets with at least a fold change ≥1.4 [log2 difference ≥0.5]. The false 
discovery rate for each probeset was calculated from the log 2 transformed values after 
 
 50
GCRMA normalization using the SAM algorithm (Tusher et al., 2001). Finally, 
differentially expressed probesets were identified using a threshold 5 % false discovery 
rate correction, a fold change ≥1.4 and at least “Present/Marginal” call in 1 sample. These 
three different filtering approaches were used based on recommendations from recent 
publication by Mieczkowski et al. (2010) and the combination of all three was used to 
achieve the most stringent filtering. 
 
MiRNA microarray 
 Samples for our miRNA profiling study were processed by Asuragen Services 
(Austin,TX), according to the company’s standard operating procedures. A custom-
manufactured Affymetrix GeneChip
®
 from Ambion was designed to miRNA probes 
derived from the Sanger miRBase and published reports (Bentwich et al., 2005; 
Berezikov et al., 2005; Griffiths-Jones, 2004; Griffiths-Jones et al., 2006; Griffiths-Jones 
et al., 2008; Xie et al., 2005). Background signal was estimated from antigenomic probe 
sequences provided by Affymetrix and derived from a larger set of controls used on the 
Affymetrix human exon array. Spike-in external reference controls were based on non-
miRNA control probes that lack homology to the human genome. Arrays within a 
specific analysis experiment were normalized according to the variance stabilization 
method described by Huber et al. (2002). A Wilcoxon rank-sum test was used to 
determine detection calls of the miRNA probe signals compared to the distribution of 
signals from GC-content matched anti-genomic probes.  
A two-sample t-test, with assumption of equal variance, was applied for statistical 
hypothesis testing. This test defined which probes are considered to be significantly 
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differentially expressed based on a p-value of 0.01 and log2 difference ≥1. The signal 
intensities from these differentially expressed probes were z-score normalized prior to 
hierarchical clustering.  
All microarray data from this study are MIAME compliant and have been 
submitted to GEO under the accession no. GSE23392 
 
MiRNA target download 
 The miRNA targets prediction file based on miRanda was downloaded from 
www.microrna.org (August 2010 release; Betel et al., 2008; Enright et al., 2003; John et 
al., 2004). Information about the prediction algorithm, parameter settings and raw data 
source is available on the above link. Only predicted targets with “good” mirSVR score 
were used. “Good” mirSVR score refers to miRNA targets with <-0.1 score, and “non-
good” mirSVR score refers to targets with >-0.1 score obtained from the support vector 
regression algorithm mirSVR, available with target predictions in the above link. The 
miRNA targets prediction file based on TargetScan (release 5.1) was downloaded from 
www.targetscan.org (Friedman et al., 2009; Grimson et al., 2007; Lewis et al., 2005). 
Targets based on PicTar (Chen and Rajewsky, 2006; Grun et al., 2005; Krek et al., 2005; 
Lall et al., 2006) prediction were also bulk downloaded from the UCSC database. 
MiRNAs for which PicTar predictions were not present in the bulk data file, were 
manually curated from the tables available on the PicTar web interface (www.pictar.org).  
 
Predicted target sites analysis 
 Target sites for 12 differentially expressed miRNAs were selected from the 
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downloaded target prediction files or from the web interface (PicTar). Of those, target 
sites with Affymetrix “Absent” call in every sample were excluded from further analysis. 
Each target mRNA was classified as IC, NC or PC depending on the direction of its 
change in level of expression between OSE and CEPI and that of each targeting miRNA. 
Predicted targets of the miRNAs miR-7 and miR-128 identified by miRanda, 
TargetScan, PicTar and all combinations of the three programs were used to calculated 
IC, NC, and PC fraction of targets in HEY cells transfected by each miRNA (miR-7 or 
miR-128) based on significance at a fold change threshold of 1.4 and maximum false 
discovery rate of 5 %. Predicted targets that were down-regulated in the transfection 
experiments were assumed to be experimentally validated and the expression patterns of 
these experimentally validated targets subsequently used in comparisons between the 
CEPI and OSE samples (as described above) to identify IC, PC and NC fractions based 




MOLECULAR ANALYSIS OF THE INDIRECT EFFECTS OF 
TARGET GENE SILENCING BY MICRORNAS 
 
Abstract 
MicroRNAs (miRNAs) are a class of small non-coding RNAs that have been 
linked to a number of diseases including cancer. The potential application of miRNAs in 
cancer diagnostics and therapeutics is an area of particular current interest. A challenge to 
the use of miRNAs in cancer therapy is our current inability to accurately predict the 
indirect or off-target consequences of exogenous modulations in the levels of potentially 
therapeutic miRNAs. In an initial effort to systematically address this issue, we 
conducted miRNA transfection experiments using two miRNAs (miR-7, miR-128) 
predicted to down-regulate expression of the epidermal growth factor receptor oncogene 
(EGFR). In addition to observing the effect of miRNA transfection on the targeted 
oncogene, we monitored and characterized changes in levels of off-target gene 
expression. While ∼ 20 % of the changes in expression patterns of hundreds to thousands 
of off-target genes could be attributed to direct miRNA-mRNA interactions, the majority 
of the changes are indirect, likely involving the downstream consequences of miRNA-
mediated changes in regulatory gene expression. We found that changes in patterns of 
off-target gene expression are not random but functionally coordinated. We conclude that 
while the molecular consequences of miRNA transfection are complex, they are not 






MicroRNAs (miRNAs) are a class of small (18-24 nt) regulatory RNAs that play 
critical roles in many essential cellular processes including development, angiogenesis, 
cell cycle and cellular migration (Bushati and Cohen, 2007; Farazi et al., 2011). These 
small RNAs are encoded in the genomes of both unicellular (Zhao et al., 2007) and 
multicellular organisms and typically act to repress gene expression at the post-
transcriptional level (Fabian et al., 2010). In mammals, miRNAs have been shown to 
repress translation and induce degradation of the target message by interacting with the 
3’untranslated region (UTR) in a sequence specific manner (Guo et al., 2010; Tang et al., 
2008b). In rare instances, miRNAs have also been reported to increase translation 
(Vasudevan et al., 2007) and/or transcription (Majid et al., 2010; Place et al., 2008) of 
target genes.  
There is a large and growing body of evidence that many diseases, including 
cancer, are associated with changes in cellular levels of miRNAs (Chang and Mendell, 
2007). In cancer, levels of specific miRNAs have been reported to be significantly down- 
or up-regulated in various cancer types indicating that these regulatory RNAs may be 
operationally defined as either tumor suppressor genes or oncogenes depending upon the 
cellular context (Chen, 2005). Based on these findings, the clinical potential of miRNAs 
as cancer biomarkers and/or therapeutic agents is being actively pursued (Tong and 
Nemunaitis, 2008; Wahid et al., 2010).  
A continuing challenge to the effective use of miRNAs in cancer therapy is our 
limited ability to accurately predict the molecular consequences of exogenous 
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perturbations in cellular levels of miRNAs (Mishra and Merlino, 2009). The difficulty in 
anticipating the full molecular consequences of miRNA therapy may be due, in part, to 
the limitations of in silico target prediction algorithms (Saito and Saetrom, 2010) and to 
the fact that miRNAs can directly and/or indirectly modulate expression levels of 
multiple genes in addition to the intended target(s) (e.g., Baek et al., 2008; Lim et al., 
2005; see also CHAPTER 2).  
In an effort to better understand the range of molecular changes potentially 
associated with miRNA therapy, we conducted a series of controlled experiments in 
which single miRNAs are targeted to a specific cellular oncogene (epidermal growth 
factor receptor, EGFR) that is over-expressed in a well-characterized human ovarian 
cancer cell line (HEY; Dickerson et al., 2010). The effect of these miRNAs on target 
gene expression, as well as, on “off-target” global patterns of gene expression was 
monitored by microarray (Affymetrix, HG-U133 Plus 2.0) and quantitative (real-time) 
polymerase chain reaction (qPCR). MiRNAs were found to have a substantially greater 
impact on global patterns of gene expression than a target gene-specific siRNA. We 
categorize the miRNA induced changes in global patterns of gene expression with respect 








EGFR is often over-expressed in ovarian and other epithelial cancers (Hynes and 
MacDonald, 2009; Normanno et al., 2006; Thaker et al., 2005) and is considered an 
attractive therapeutic target (Ciardiello and Tortora, 2008; Thaker et al., 2005; Zeineldin 
et al., 2010). We have previously shown that EGFR is over expressed in the well-
characterized HEY ovarian cancer cell line and can be effectively down-regulated by 
EGFR-specific siRNAs (Dickerson et al., 2010). Earlier studies (Webster et al., 2009; 
Weiss et al., 2008) conducted in lung, brain, breast and prostate cancer cells have shown 
that the expression of EGFR may be subject to regulation by the miRNAs miR-7 and 
miR-128. These findings are consistent with the fact that the 3’UTR of EGFR is 
predicted to contain four potential binding sites for miR-7 and two potential binding sites 
for miR-128 (Figure 3.1A and 3.1B).  
To determine if over-expression of miR-7 and miR-128 in ovarian cancer cells 
can induce down-regulation of EGFR, we independently transfected HEY cells with miR-
7 or miR-128 and measured EGFR RNA and protein levels 48 hours after transfection 
relative to negative controls (miR-NC, miRIDIAN miRNA mimic negative control, 
Thermo Fisher Scientific). The results demonstrate that over-expression of either miR-7 






Figure 3.1. MiRNAs miR-7 and miR-128 down-regulate EGFR in HEY cells. 
Predicted miR-7 and miR-128 sites (miRanda) on EGFR 3’UTR are shown in (A) and 
(B). Complementary nucleotides and their relative positions on the UTR are depicted in 
(A). Vertical lines (|) denote Watson-Crick base pairing, while the colon (:) sign denotes 
wobble between G and U on opposite strands. The relative location of each target site on 
 
 58
the EGFR gene is shown schematically in (B). Red bars show the sites with “good” 
mirSVR score (<-0.1) and purple bars show those with “non-good” scores (see methods). 
(C) and (D) show relative EGFR RNA levels following transfection of (C) miR-7 or miR-
NC, and (D) miR-128 or miR-NC in HEY cells using GAPDH as endogenous control. 
(E) and (F) show densitometric analysis of immunoblots measuring protein levels of 
EGFR following transfection of (E) miR-7 and (F) miR-128 relative to miR-NC. β-Actin 
is used as loading control for the immunoblots. The numbers in boxes are the fold change 
differences in EGFR protein levels between miR-NC and miR-7/miR-128 transfections. 
Error bars show standard deviations from the mean based on RNA/protein levels of three 
independent biological replicates. Statistical analysis for qPCR was done using 
randomization with the help of REST 2008 software with at least 1000 iterations. 




miR-7 or miR-128 transfection induces changes in expression of hundreds of off-
target genes  
To study the effect of over-expression of miR-7 or miR-128 on global patterns of 
gene expression, we isolated total RNA from cells 48 hrs after transfection and conducted 
microarray analysis (Affymetrix HG-U133 Plus 2.0). The results indicate that 
transfection of miR-7 induced significant changes in the expression of 754 genes (fold 
change ≥1.4, FDR ≤5 %; Table B.1) and that miR-128 transfection induced significant 
changes in the expression of 2338 genes (Figure 3.2A, Table B.2), both relative to 
controls. The fractions of transcripts up-regulated or down-regulated in each transfection 
were also variable. For miR-7, the majority of the differentially expressed genes (DEGs) 
were down-regulated (599, ~80 %), while for cells transfected with miR-128, most (1624, 






Figure 3.2. miR-7 and miR-128 alter the expression of hundreds to thousands of 
genes. (A) Transfection of miR-7 leads to differential expression of 754 genes and miR-
128 leads to the alteration of 2338 genes (fold change ≥1.4, FDR ≤5 %) in HEY cells 
relative to miR-NC transfection. The number of genes differentially expressed in each 
experiment and in both (286) is represented by the Venn diagram. The proportions of 
genes up-regulated or down-regulated also vary between the transfections, as shown in 
(B). The pie-charts show that the majority of the altered genes are down-regulated (dark 




Less than 1 % of the miR-7 or miR-128 induced changes in gene expression are the 
consequence of down-regulation of EGFR  
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To determine the extent to which miRNA induced changes in “off-target” gene 
expression may be explained by the down-regulation of EGFR, we monitored the effect 
of anti-EGFR siRNA transfection on global patterns of gene expression and contrasted 
the results with expression patterns observed after miR-7 or miR-128 expression.  
After verifying knock-down of EGFR by siRNA transfection (Figure 3.3) we monitored 
global patterns of gene expression by microarray. Employing identical criteria to that 
used for the detection of differentially expressed genes after the miRNA transfections 
(fold change ≥1.4, FDR ≤5 %), we found that only eight genes (in addition to EGFR) 
were significantly differentially expressed (Table 3.1). These findings indicate that the 
vast majority of changes in gene expression observed after miR-7 or miR-128 





Figure 3.3. Confirmation of EGFR down-regulation by siRNA. (A) Relative EGFR 
RNA levels determined by qPCR following transfection of anti EGFR siRNA (siRNA) or 
negative control siRNA (siNC) in HEY cells using GAPDH as endogenous control. Error 
bars show standard deviations from the mean based on RNA levels of three independent 
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biological replicates. Statistical analysis was done using randomization with the help of 
REST 2008 software with at least 1000 iterations. ** p <0.05. (B) Representative image 
of Western blot analysis of EGFR protein levels after transfection with anti-EGFR siRNA 




Table 3.1. Differentially expressed genes in siRNA transfected HEY cells. 
Significantly differentially expressed genes (fold change ≥1.4, FDR ≤5 %) following 
anti-EGFR siRNA transfection, compared to siNC transfection of HEY cells. ‘Probeset 
ID’ refers to Affymetrix HG-U133 Plus 2.0 probeset identifier. ‘Gene Symbol’ shows the 
official gene symbol for the corresponding Probeset ID. ‘siRNA-siNC’ refers to the 
difference between average log2 signal values of siRNA transfected cells and the siNC 
transfected cells. ‘q-value (%)’ shows the false discovery rate calculated using the SAM 
algorithm. All transfections were carried out in triplicates. 
 
Probeset ID Gene Symbol siRNA-siNC q-value (%) 
201110_s_at THBS1 1.15 3.43 
201109_s_at THBS1 1.06 3.43 
202310_s_at COL1A1 0.87 4.02 
201108_s_at THBS1 0.76 3.43 
207950_s_at ANK3 0.75 3.43 
203139_at DAPK1 0.57 3.43 
231618_s_at SUNC1 -0.82 0.00 
229672_at UQCC -0.96 0.00 
201983_s_at EGFR -1.04 0.00 
208885_at LCP1 -1.04 0.00 
211607_x_at EGFR -1.15 0.00 
210984_x_at EGFR -1.17 0.00 






Figure 3.4. Overlap of genes differentially expressed following miR-7, miR-128 and 
anti-EGFR siRNA transfection. Transfection of anti-EGFR siRNA results in 
differential expression of only nine genes (including EGFR, fold change ≥1.4, FDR ≤5 
%) in HEY cells relative to siNC transfection. Only two genes (including EGFR) are 
altered in all three transfections. Only three of the genes differentially expressed after 
siRNA transfection are also differentially expressed after miR-7 transfection, only five of 
the nine are also differentially expressed after miR-128 transfection, and only three were 
differentially expressed only in the siRNA transfection.  
 
 
Less than 20 % of the genes differentially expressed after miR-7 or miR-128 
transfection are predicted targets of these miRNAs 
A single miRNA can potentially target hundreds of genes (Brennecke et al., 2005; 
Krek et al., 2005; Lewis et al., 2005). To explore the possibility that the global changes in 
expression patterns observed after miR-7 or miR-128 transfection were the result of 
direct targeting, we first computed the percentage of the down-regulated genes potentially 
regulated by miR-7 or miR-128 as predicted by the three major target prediction 
algorithms (miRanda, TargetScan, and PicTar). The results indicate that on average <20 
% of the down-regulated genes differentially expressed after miR-7 or miR-128 
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transfection are direct regulatory targets of these miRNAs (Table 3.2, Figure 3.5). For 
example, of the 599 genes down-regulated after miR-7 transfection, only 194 or 32.4 % 
are predicted to be targets of this miRNA by miRanda. The percentages are lower using 
targets predicted by the PicTar (6.5 %) and TargetScan (10.2 %) algorithms.  
Although increased levels of miRNAs are generally expected to down-regulate 
the expression of target genes, there have been isolated reports of the expression of target 
genes being increased after miRNA transfection (Majid et al., 2010; Place et al., 2008). If 
we include all genes that are either down-regulated or up-regulated after miR-7 or miR-
128 expression, the percentage of predicted targets remains, on average, <20 % (Table 
3.2). We conclude that less than one-fifth of the genes differentially expressed after miR-
7 or miR-128 transfection are likely the result of regulatory effects directly exerted by 
these miRNAs.  
 
Table 3.2. Fraction of down-regulated, up-regulated and differentially expressed 
genes predicted to be targets of miRNAs. Significantly down-regulated (down), up-
regulated (up) or all differentially expressed genes (all) after miR-7 or miR-128 
transfections in HEY cells were searched for targets of the respective miRNAs using 
miRanda (M), TargetScan (TS) and PicTar (PT) algorithms. The fraction (%) of targets 
within each group and the average (AVG) of all three algorithms are reported in this 
table. 
 
 miR-7 miR-128 
 M TS PT AVG M TS PT AVG 
Down 32.4 10.2 6.5 16.4 36.0 14.7 9.1 19.9 
Up 12.3 1.9 0.6 4.9 18.8 3.8 2.6 8.4 






Figure 3.5. Contribution of canonical miRNA targeting on the number of 
differentially expressed genes. The pie-charts show the proportion of differentially 
expressed genes following miR-7 (top row) or miR-128 (bottom row) transfection that 
may be explained by direct 3’UTR targeting (dark grey), or indirect mechanisms (light 
grey). These proportions are calculated for only down-regulated (left), only up-regulated 
(middle) or all differentially expressed (right) genes. In each transfection a majority (≥80 
%) of the differentially expressed genes are not predicted to be directly regulated by the 
miRNAs. Only the average number of predictions from miRanda, TargetScan and PicTar 
algorithms were used to generate this figure. 
 
 
An indirect effect of miR-128 transfection may be the de-repression of endogenous 
miRNA targets 
It has been previously proposed that transfection of exogenous miRNA molecules 
may interfere with endogenous miRNA targeting of mRNAs due to competition for a 
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limited number of RNA-Induced Silencing Complexes (RISC; Khan et al., 2009). 
According to this model, if endogenous miRNAs are out competed for RISC complexes 
by exogenous miRNAs, the targets of the endogenous miRNAs may be expected to be 
up-regulated. In a pre-transfected cell, endogenous miRNAs with higher expression 
values are predicted to have a higher likelihood of being in the RISC complex and, thus, 
more likely to be affected by introduction of exogenous miRNAs (Khan et al., 2009; 
Landthaler et al., 2008; Sood et al., 2006; Tang et al., 2008a).  
As mentioned above, a majority (∼70 %) of the 2338 genes displaying significant 
changes in expression after miR-128 transfection were up-regulated (Figure 3.2, Table 
B.2). To determine if the RISC competition model might help explain some of these 
indirect effects of miR-128 transfection, we sought to determine if the target sequences of 
miRNAs most highly expressed in pre-transfected HEY cells were significantly enriched 
in genes up-regulated after miR-128 transfection.  
We employed a previously established gene set enrichment analysis algorithm 
(Genomica; Lubling and Segal, accessed on July 7, 2010) to identify miRNA target sites 
enriched in mRNAs up-regulated after miR-128 expression. The results indicate that 
target sites of 78 miRNAs are significantly enriched among genes (mRNAs) up-regulated 
after miR-128 expression (Tables 3.3 and B.3). [Note: A similar analysis of genes 
significantly up-regulated after miR-7 transfection (i.e., only ∼20 % of differentially 
expressed genes-see above) indicated that targets of only two miRNAs were significantly 
enriched in up-regulated genes (Table B.4)].  
 
 
Table 3.3. MiRNAs with targets enriched among up-regulated genes after miR-128 
transfection. List of genes up-regulated after miR-128 transfection into HEY cells are 
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overlapped with list of miRNA targets and the targets of 78 miRNAs are found to be 
significantly enriched (hypergeometric probability, FDR <0.05) by Genomica gene set 




hsa-let-7a hsa-miR-187 hsa-miR-29a 
hsa-let-7c hsa-miR-189# hsa-miR-29c 
hsa-let-7d hsa-miR-18a hsa-miR-302a* 
hsa-let-7e hsa-miR-18b hsa-miR-30a-3p 
hsa-let-7f hsa-miR-191 hsa-miR-30b 
hsa-let-7g hsa-miR-192 hsa-miR-30c 
hsa-let-7i hsa-miR-193 hsa-miR-30d 
hsa-miR-1 hsa-miR-194 hsa-miR-30e 
hsa-miR-106a hsa-miR-199 hsa-miR-324-3p 
hsa-miR-122a hsa-miR-19a hsa-miR-329 
hsa-miR-135 hsa-miR-19b hsa-miR-33 
hsa-miR-136 hsa-miR-20 hsa-miR-335 
hsa-miR-137 hsa-miR-205 hsa-miR-363 
hsa-miR-139 hsa-miR-206 hsa-miR-377 
hsa-miR-140 hsa-miR-208 hsa-miR-378 
hsa-miR-145 hsa-miR-21 hsa-miR-409-5p 
hsa-miR-146a hsa-miR-210 hsa-miR-452 
hsa-miR-146b hsa-miR-217 hsa-miR-485-3p 
hsa-miR-148 hsa-miR-219 hsa-miR-485-5p 
hsa-miR-150 hsa-miR-22 hsa-miR-486 
hsa-miR-15a hsa-miR-221 hsa-miR-503 
hsa-miR-15b hsa-miR-222 hsa-miR-542-3p 
hsa-miR-17 hsa-miR-23b hsa-miR-7 
hsa-miR-181a hsa-miR-26a hsa-miR-9 
hsa-miR-183 hsa-miR-26b hsa-miR-93 
hsa-miR-185 hsa-miR-299 hsa-miR-98 
* miRNA* strand; # This miRNA has recently been removed from miRBase as it was 




To test whether these 78 miRNAs were expressed at higher levels in pre-
transfected HEY cells relative to all expressed miRNAs, we measured levels of human 
miRNAs in pre-transfected HEY cells by microarray (Affymetrix GeneChip miRNA 
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array; Table B.5). Out of 847 human miRNAs present on the Affymetrix chip, 281 were 
found to be expressed in pre-transfected HEY cells, and out of the 78 miRNAs with 
target sites enriched among up-regulated genes after miR-128 transfection, 45 were 
expressed in pre-transfected HEY cells. Figure 3.6 displays a histogram of log2 signal 
values for all expressed miRNAs (281) and for the subset of miRNAs (45) with target 
sites significantly enriched in genes/mRNAs up-regulated after miR-128 transfection. 
The results demonstrate that miRNAs with binding sites significantly enriched in up-
regulated genes display a significantly greater fraction of signal values above log2(10) 
relative to all miRNAs (Mann-Whitney p-value <0.0001) indicating a generally higher 
level of expression in pre-transfected HEY cells. These findings are consistent with the 
hypothesis that a significant fraction of the increased level of gene expression observed 
after miR-128 transfection may be the indirect effect of the displacement of endogenous 





Figure 3.6. Endogenous miRNAs targeting up-regulated genes are expressed at 
higher levels than other miRNAs. Frequency distribution of log2 signal values for all 
281 miRNAs expressed in HEY cells (grey) compared with signal value distribution for 
45 miRNAs expressed among those targeting up-regulated genes after miR-128 
transfection (black). The bar chart shows that the 45 miRNAs targeting up-regulated 
genes have a higher frequency of being expressed at log2 signal value >10, while most 
miRNAs frequently have log2 (signal value) ≤10 (Mann-Whitney p-value <0.0001). 
 
 
miR-7 or miR-128 transfection can trigger cascades of indirect regulatory changes 
in gene expression 
GeneGo functional network analysis was used to identify genes with the most 
significant number of interactions (“hub genes”) among genes differentially expressed 
after miR-7 or miR-128 transfection. Hub genes typically encode transcription factors or 
other regulatory proteins (or RNAs) capable of trans-regulating down-stream genes (Seo 
et al., 2009; Wang et al., 2007). MiRNA induced changes in the expression level of hub 
genes are expected to induce subsequent changes in the expression of genes regulated by 
these hub-genes. If these regulated genes include other hub genes, the regulatory “ripple 
effect” can be significant. 
  
 
Table 3.4. Hub genes identified among differentially expressed genes after miR-7 
transfection. Genes connected via network interactions with the most significant number 
(FDR <0.05) of genes (nodes) among the list of differentially expressed genes following 
miR-7 transfection are listed. Genes which are predicted to be miR-7 targets by miRanda 
or may act as transcription factors are marked with ‘x’.  
 
 
Gene Symbol [Designated GeneGo 
Object Name] miR-7tgts_miRanda 
Transcription 
Factor 
RELA [RelA (p65 NF-kB subunit)] x x 
MMP14 [MMP-14]   
CASP1 [Caspase-1] x  
Table 3.4 (continued) 
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Gene Symbol [Designated GeneGo 
Object Name] miR-7tgts_miRanda 
Transcription 
Factor 
EHD1 [EHD1] x  
CDKN1B [p27KIP1]   
VLDLR [VLDLR]   
EGFR [EGFR] x  
TCF7L2 [TCF7L2 (TCF4)]  x 
FMR1 [FMR1]   
PPHLN1 [PPHLN1]   
 
 
Table 3.5. Hub genes identified among differentially expressed genes after miR-128 
transfection. Genes connected via network interactions with the most significant number 
(FDR <0.05) of genes (nodes) among the list of differentially expressed genes following 
miR-128 transfection are listed. Genes which are predicted to be miR-128 targets by 
miRanda or may act as transcription factors are marked with ‘x’. 
 
Gene Symbol [Designated GeneGo 
Object Name] miR-128tgts_miRanda 
Transcription 
Factor 
CASP1 [Caspase-1] x  
SH3KBP1 [CIN85]   
EGFR [EGFR]   
SKP1 [SKP1] x  
PPP1CC [PP1-cat gamma] x  
PTP4A1 [PTP4A1]   
ODC1 [DCOR]   
FKBP4 [FKBP4]   
PXN [Paxillin]   
TUBA1B [Tubulin alpha-1B]   
NFKBIA [NFKBIA]   
EGR1 [EGR1]  x 
LRRFIP1 [LRRFIP1] x x 
PLK1 [PLK1]   
FOXM1 [FOXM1]  x 
PIAS3 [PIAS3]  x 
CAV1 [Caveolin-1] x  
CDK1 [CDK1 (p34)]   
SPRY2 [SPRY2] x  
AURKA [Aurora-A]   
HEC [HEC]   
VDR [VDR]  x 
Table 3.5 (continued) 
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Gene Symbol [Designated GeneGo 
Object Name] miR-128tgts_miRanda 
Transcription 
Factor 
PLCG2 [PLC-gamma 2]   
BTRC [beta-TrCP]   
CENPA [CENP-A]   
CENPE [CENP-E]   
ITGB3BP [NRIF3]  x 
XIAP [XIAP]   
SERPINH1 [HSP47] x  
SEPHS1 [SEPHS1]   
STAT3 [STAT3]  x 
TSC1 [Hamartin]   
PAK1 [PAK1]   
TAPBP [Tapasin]   
ERAP1 [ARTS-1]   
MAPK14 [p38alpha (MAPK14)] x x 
CAMKK2 [CaMKK2] x x 
PTBP1 [PTBP1]   
PTPN2 [PTPN2]   
CCNA2 [Cyclin A2]  x 
SRC [c-Src]   
PCBP2 [PCBP-2]   
CTTN [Cortactin]   
BUB1 [BUB1] x  
RBX1 [RING-box protein 1] x  
SMAD3 [SMAD3]  x 
CCRN4L [Nocturnin]   
HNRNPA1 [hnRNP A1] x  
CTNNB1 [Beta-catenin]  x 
FOXO3 [FOXO3A]  x 
MIR21 [microRNA 21]   
PDPK1 [PDK (PDPK1)]   
VAPA [VAPA]   
TSEN15 [Sen15]   
CREB1 [CREB1]  x 
SMAD2 [SMAD2]  x 
RPS6KB1 [p70 S6 kinase1] x  
SYTL4 [SYTL4] x  
ARHGEF7 [BETA-PIX]   
MED6 [MED6]  x 




Functional network analysis identified 10 hub genes among those differentially 
expressed after miR-7 transfection and 61 among genes differentially expressed after 
miR-128 transfection (FDR <0.05; Tables 3.4, 3.5, B.6 and B.7). Many of these hub 
genes are predicted to be direct targets of miR-7 or miR-128 regulation (Tables 3.4 and 
3.5). For example, the gene encoding the RELA component of the NF-κB regulatory 
protein is a predicted target of miR-7 and was significantly down-regulated after miR-7 
transfection (Table B.1). Consistent with the hypothesis that down-stream effects of 
RELA may be contributing to indirect changes in expression levels, we found that a 
number of the genes differentially expressed after miR-7 transfection are documented 
targets of NF-κB regulation. Among these is the cytokine IL-1 beta (Basak et al., 2005; 
Goto et al., 1999) that, in turn, is predicted to regulate genes that were also differentially 
expressed after miR-7 transfection (Figure 3.7, Table 3.6).  
Similar changes in patterns of gene expression were observed after miR-128 
transfection. For example, Caveolin-1 (CAV1) is a negative regulator of the Ras-p42/44 
MAP kinase cascade (Williams and Lisanti, 2005). Levels of CAV1 were significantly 
reduced after miR-128 transfection and down-stream targets of CAV1 were among those 
genes significantly differentially expressed (Tables 3.7 and B.2). Among the CAV1 
regulated genes displaying significant changes in expression after miR-128 transfection is 
another hub gene, the transcription factor SMAD2 (Razani et al., 2001). Genes known to 
be trans-regulated by SMAD2 were also differentially expressed after miR-128 
transfection (Table 3.7, Figure 3.8). Collectively, our results are consistent with the 
hypothesis that a majority of the changes in expression induced after miR-7 or miR-128 
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Table 3.6. Differentially expressed genes that are targeted by NF-κB or IL-1 Beta. 
Differentially expressed genes following miR-7 transfection in HEY cells that are 
directly regulated by NF-κB, by IL-1 beta, or by both are listed. IL-1 beta (IL1B) is a 
transcriptional target of NF-κB and both are significantly down-regulated following miR-
7 transfection. The genes that are only targeted by IL-1 beta may be differentially 
expressed because RELA/NF-κB is a target of miR-7 and in turn regulates IL-1 beta.  
 
 
NF-κB only IL1-β only 
Common 
targets 
ACO2 KCTD12 CASP1 ASS1 
ADAM19 LIFR DPP4 BID 
ASPH LITAF IGFBP3 BMP2 
ATXN3 MAT2A IL1RAP CXCL1 
BACE1 MATR3 IL7 CXCL2 
CALM1 NQO1 IRS1 DDIT3 
CALM3 OGT LAMC1 FN1 
CBS PAX6 ME1 HBEGF 
CCND2 PCK2 MMP14 ICAM1 
CCRL2 PDPN NFKBIZ IL8 
CDK6 PHLDA1 NR1H3 MIR21 
CDKN1B PMEPA1 NRP1 NUPR1 
CSNK1A1 PSME3 NRP2 PTX3 
DDIT4 RRM2 PAPPA RUNX2 
DDX21 S100A6 PRLR SAA1 
DLG1 SH2B3 SERPINH1 SAA2 
DTNA SLC11A2 SLC38A2 SERPINE2 
EHD1 SLC44A1 SLC7A2 SOD2 
EIF4A1 ST6GAL1 SOCS7 SPP1 
ERAP1 ST8SIA1 THBD TGFA 
GAS5 TFRC THBS1 TGFB2 
GFPT2 TGM2 TIMP3 TGFBR2 
GLO1 TNIP1  VEGFA 
GREM1 TXNIP  VEGFC 
HSPA9 VIM  XIAP 
IL1B ZBED4   






Figure 3.7. miR-7 regulation of NF-κB may cause down-regulation of IL-1 beta, 
which may target additional differentially expressed genes. Among genes 
differentially expressed after miR-7 transfection, RELA/NF-κB (circled in red) acts as a 
hub gene, and is found to target many of the differentially expressed genes. One of these, 
IL1-beta (circled in red) is significantly down-regulated and targets additional 
differentially expressed genes, thus, multiplying the effect of NF-κB down-regulation. 
Key: blue filled circle - significantly down-regulated gene; red filled circle – significantly 
up-regulated gene; green edges: activating interaction; red edges: inhibitory interaction; 
grey edges: unknown interaction. 
 
 
Table 3.7. Direct downstream targets of Caveolin-1 and SMAD2. Caveolin-1 and 
SMAD2 are both identified as “hub genes” among the genes differentially expressed after 
miR-128 transfection. CAV1 is a predicted target of miR-128 but SMAD2 is not. By 
targeting CAV1, miR-128 indirectly regulates SMAD2 and triggers the differential 
expression of genes regulated by SMAD2 as well. Differentially expressed genes that are 
direct targets of either Caveolin-1 or SMAD2 are listed. The relative fold change of these 




Caveolin-1 and its direct targets SMAD2 and its direct targets 
Gene Symbol Fold change Gene Symbol Fold change 
CAV1 -2.44 BUB3 -1.65 
CD40 2.25 COL1A1 2.40 
CFL1 -1.70 DAB2IP 2.06 
ENO2 1.78 DCAF7 -1.61 
EPHB1 -2.66 DOCK9 1.57 
FLNA -2.09 ERC1 1.80 
FOLR1 -1.86 FGFBP1 -1.55 
GNAQ 1.53 HMGA2 -1.64 
ITGA2 2.00 HMGN3 -1.49 
ITPR1 2.09 ITGB5 -1.60 
MAPK14 -1.83 KLF4 -1.42 
NEDD8 -1.57 NEDD9 1.97 
NGFRAP1 -1.79 NFIB -1.54 
NT5E -1.73 OPA1 -2.03 
PDE3B -1.59 PKNOX1 1.58 
PTEN -2.74 PLIN3 -1.54 
PTGS1 4.12 PRKAR1A 2.84 
SEPT7 -1.98 SERPINE1 2.23 
SLC9A7 1.71 SMAD2 -1.59 
SMAD2 -1.59 ST13 -1.95 
SPRY4 1.71 SURF6 1.55 
STMN1 -1.72 TAF3 1.53 
TNFRSF10A 1.70 TIMP3 -2.99 
  TNFRSF11B 1.47 
  TOB1 -1.69 
  VEGFA 2.15 
  WRNIP1 1.48 
  WWP2 1.73 
  ZFP106 2.10 








Figure 3.8. miR-128 may target the hub gene CAV1 which may regulate another 
hub gene SMAD2. Caveolin-1 (circled in red) is a significantly down-regulated hub gene 
and a predicted target of miR-128. One of its many direct downstream target genes is 
SMAD2 (also circled in red; regulation shown by arrow/edge pointing from Caveolin-1 
to SMAD2), which itself acts as another hub gene. Several downstream targets of 
SMAD2 are also differentially expressed following miR-128 transfection. Thus by 
targeting the hub gene CAV1, miR-128 regulates the non-target hub gene SMAD2 and 
triggers a ripple effect on down-stream genes. Key: blue filled circle - significantly down-
regulated gene; red filled circle – significantly up-regulated gene; green edges: activating 
interaction; red edges: inhibitory interaction; grey edges: unknown interaction. 
 
 
miR-7 and miR-128 transfection modulates changes in the expression of genes 
involved in distinct developmental and cell cycle related pathways  
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While transfection of miR-7 or miR-128 were both found to significantly down-
regulate EGFR expression, their direct and indirect effects on the expression of other 
genes were quite distinct. Of the 754 genes differentially expressed after miR-7 
transfection and 2338 genes differentially expressed after miR-128 transfection, only 286 
genes were in common among those differentially expressed by the two miRNAs. To 
evaluate the potential functional significance of the genes uniquely differentially 
expressed after miRNA transfection, we subjected the data to GeneGo pathway 
enrichment analysis.  
The results of our functional pathway analysis indicate that genes differentially 
expressed after miR-7 transfection are significantly over-represented in 91 functional 
pathways (Figure 3.9A, Table B.8). The 20 most significantly over-represented pathways 
are listed in Table 3.8 and include several cell adhesion and developmental functions 
previously associated with aberrant levels of miR-7 expression in a variety of cancers 
(Chen et al., 2010a; Chou et al., 2010; Webster et al., 2009). We found that genes 
differentially expressed after miR-128 transfection are over-represented in 231 pathways 
(Figure 3.9B, Table B.9). The 20 most significantly over-represented pathways listed in 
Table 3.9 include a variety of pathways associated with cell cycle control consistent with 
previous studies linking miR-128 with cell proliferation functions in several cancers 
(Ciafre et al., 2005; Evangelisti et al., 2009; Godlewski et al., 2008; Guidi et al., 2010; 





Figure 3.9. Pathways regulated by differentially expressed genes after miR-7 or 
miR-128 transfection. The majority of pathways enriched (FDR <0.05) among 
differentially expressed genes after either (A) miR-7 or (B) miR-128 transfection are 
related to development. However cell cycle, cytoskeleton remodeling, apoptosis and 




Table 3.8. Twenty most significantly enriched pathways among differentially 
expressed genes after miR-7 transfection into HEY cells. The 20 most significantly 
enriched (FDR <0.05) GeneGo pathway maps among the significantly differentially 
expressed genes after miR-7 transfection into HEY cells. The pathways that are also 




Cell adhesion_Chemokines and adhesion 1.31E-07 
Cell cycle_Regulation of G1/S transition (part 1) 8.68E-07 
Cell adhesion_Ephrin signaling 3.96E-06 
Development_EGFR signaling pathway 1.02E-05 
Development_ERBB-family signaling 1.13E-05 
Development_WNT signaling pathway. Part 1. Degradation of beta-
catenin in the absence WNT signaling 1.42E-05 
Development_VEGF-family signaling 1.68E-05 
Cytoskeleton remodeling_Cytoskeleton remodeling 3.13E-05 
Neurophysiological process_Receptor-mediated axon growth 
repulsion 3.43E-05 
Proteolysis_Putative ubiquitin pathway 3.44E-05 
Development_TGF-beta-dependent induction of EMT via RhoA, PI3K 
and ILK.  4.05E-05 
Cell adhesion_Plasmin signaling 4.85E-05 
Development_TGF-beta-dependent induction of EMT via SMADs  4.85E-05 
Table 3.8 (continued) 
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Maps p-value 
Transport_RAB5A regulation pathway 5.75E-05 
Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 7.29E-05 
Cell cycle_Regulation of G1/S transition (part 2) 7.30E-05 
Apoptosis and survival_HTR1A signaling 7.54E-05 
Development_Regulation of epithelial-to-mesenchymal transition (EMT) 7.67E-05 
Translation _Regulation of EIF2 activity 1.01E-04 




Table 3.9. Twenty most significantly enriched pathways among differentially 
expressed genes after miR-128 transfection into HEY cells. The 20 most significantly 
enriched (FDR <0.05) GeneGo Pathway maps among the significantly differentially 
expressed genes after miR-128 transfection into HEY cells. The pathways that are also 





Cell cycle_The metaphase checkpoint 1.01E-11 
Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 1.29E-09 
Cell cycle_Role of Nek in cell cycle regulation 1.77E-09 
Transport_Clathrin-coated vesicle cycle 4.15E-09 
Cell cycle_Initiation of mitosis 4.37E-09 
Immune response_Histamine H1 receptor signaling in immune response 1.78E-07 
Cell cycle_Role of APC in cell cycle regulation 1.79E-07 
Cell cycle_Spindle assembly and chromosome separation 2.75E-07 
Cytoskeleton remodeling_Cytoskeleton remodeling 2.98E-07 
Proteolysis_Role of Parkin in the Ubiquitin-Proteasomal Pathway 3.68E-07 
Cytoskeleton remodeling_Neurofilaments 6.14E-07 
Cell cycle_Chromosome condensation in prometaphase 8.18E-07 
Immune response_Gastrin in inflammatory response 1.85E-06 
Neurophysiological process_Receptor-mediated axon growth repulsion 2.69E-06 
Translation_Non-genomic (rapid) action of Androgen Receptor 3.55E-06 
Development_PIP3 signaling in cardiac myocytes 4.80E-06 
Cytoskeleton remodeling_Role of Activin A in cytoskeleton remodeling 5.34E-06 
Apoptosis and survival_Apoptotic Activin A signaling 5.76E-06 
Apoptosis and survival_BAD phosphorylation 6.54E-06 




Of the 252 pathways (not additive due to overlap) significantly over-represented 
among genes differentially expressed after miR-7 or miR-128 transfection, only 71 
pathways were found to overlap (including the EGFR pathway). Among the 20 most 
significantly enriched pathways only 3 were found to overlap. Among genes down-
regulated following miR-7 transfection most pathways are involved in development, 
while among those down-regulated following miR-128 transfection most pathways are 
involved in cell cycle regulation (Figure 3.10, Tables B.10 and B.11) [Note a similar 
analysis of enriched pathways among up-regulated genes revealed only 1 pathway 
enriched for miR-7 and 70 pathways enriched for miR-128 (Tables B.12 and B.13)]. 
These results are consistent with the view that the targets of miRNA regulation are often 
functionally distinct (He et al., 2010). 
 
 
Figure 3.10. Pathways regulated by down-regulated genes after miR-7 or miR-128 
transfection. Distribution of groups of pathways enriched among down-regulated genes 
after (A) miR-7 or (B) miR-128 transfection. While pathways involved in development 
made up the largest fraction of enriched pathways for miR-7, the genes down-regulated 
by miR-128 were enriched for more pathways involved in cell cycle regulation, revealing 





Discussion and Conclusion 
Although the role of miRNAs and other non-encoding RNAs in the regulation of 
cellular function is only beginning to be understood, the diagnostic and therapeutic 
potential of these regulatory RNAs is already widely recognized and accepted (Garofalo 
and Croce, 2011; Kota et al., 2009). Indeed, a number of pre-clinical diagnostic and 
therapeutic trials of miRNAs are currently in progress (Wahid et al., 2010). The initial 
results of these studies appear to be generally supportive of the diagnostic potential of 
miRNAs (Chan et al., 2011; Krutovskikh and Herceg, 2010; Metias et al., 2009), but 
significant questions remain with respect to their potential therapeutic value.  
One of the challenges to the use of miRNAs as therapeutic agents is technical in 
nature and deals with the problems of the packaging and the targeted delivery of miRNAs 
to cancer cells. Significant progress has been made in this area in recent years and all 
indications are that these technical challenges are not insurmountable (Chen et al., 2010b; 
Esau and Monia, 2007; Liu et al., 2011). The second challenge is more scientific in 
nature and centers around our current inability to precisely predict the molecular 
consequences of modulating miRNA levels on cell function. While the exogenous 
administration of miRNAs (or miRNA-antagomirs) have been shown to be capable of 
effectively regulating targeted oncogenes and tumor suppressor genes in specific cellular 
contexts (Garofalo and Croce, 2011), the off-target or indirect effects of perturbing 
miRNA levels remain difficult to predict. Since this molecular unpredictability could 
translate into clinically unanticipated side-effects, it may significantly mitigate the 
intended therapeutic benefits (Barh et al., 2010; Mishra and Merlino, 2009; Small et al., 
2010). It is generally agreed that increased therapeutic predictability of miRNAs and 
 
 81
other regulatory RNAs will require a better understanding of the processes underlying the 
molecular function of these molecules in vivo (Budhu et al., 2010; Mishra and Merlino, 
2009; Phalon et al., 2010). 
In an initial effort to systematically dissect the molecular consequences of 
exogenously modulating levels of miRNA in cancer cells, we transfected two distinct 
human miRNAs, miR-7 and miR-128, into a well-characterized ovarian cancer cell line 
and monitored the consequent changes on endogenous levels of gene expression. These 
specific miRNAs were chosen because they have both been previously implicated in 
ovarian cancer (Sorrentino et al., 2008; Wyman et al., 2009, see also CHAPTER 2) and 
because both are predicted to regulate the expression of EGFR (Webster et al., 2009; 
Weiss et al., 2008), the oncogene selected for targeting in our study. EGFR is known to 
be over-expressed in ovarian and many other cancers and is often selected for targeted 
chemotherapy (Thaker et al., 2005; Zeineldin et al., 2010).  
We found that transfection of miR-7 and miR-128 were equally effective at 
knocking down EGFR expression and that both resulted in significant changes in 
expression of hundreds of “off-target” genes. We tested the hypothesis that these off-
target effects were not simply the downstream consequences of the knock-down of EGFR 
by transfecting HEY cells with an siRNA specifically designed against EGFR. The 
siRNA transfection also resulted in effective knock-down of EGFR, but in addition, 
significant changes in the expression of only eight off-target genes. Thus, the observed 
changes in expression of hundreds of off-target genes after the miRNA transfections are 
not merely the down-stream consequences of reduced EGFR expression.  
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Consistent with the fact that miR-7 is predicted to target fewer genes than miR-
128 (using miRanda, TargetScan or PicTar), we found that the number of genes 
differentially expressed after miR-7 transfection was substantially less (approximately 
one-third) than the number differentially expressed after miR-128 transfection. To 
determine if the large number of genes differentially expressed after the miRNA 
transfections were likely due to the direct regulatory action of the miRNAs, we computed 
the proportion of differentially expressed genes that are direct targets of miR-7 or miR-
128 regulation as predicted by the three major target prediction algorithms. On average, 
the percentage of differentially expressed genes that are predicted to be directly regulated 
by either miRNA was less than one-fifth indicating that most of the off-target changes in 
gene expression induced by the miRNA transfections are indirect.  
One recently described model to account for indirect effects of miRNA 
transfection postulates that transfected miRNAs may out compete endogenous miRNAs 
for available RISC complexes (Khan et al., 2009). Under this model mRNA targets of the 
displaced miRNAs are expected to experience lower levels of degradation and thus 
display an increase in relative abundance after miRNA transfection. Accordingly, those 
genes targeted by miRNAs in high abundance in pre-transfected cells are predicted to 
experience the greatest change in expression (Khan et al., 2009; Landthaler et al., 2008; 
Sood et al., 2006; Tang et al., 2008a). This model may be particularly relevant with 
respect to our miR-128 transfection experiment where the majority (80 %) of 
differentially expressed genes displayed a significant increase in gene expression.  
Consistent with the predictions of the RISC-competition model, we found that 
mRNAs enriched for binding sites of those miRNAs most highly expressed in pre-
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transfected HEY cells were significantly over-represented among mRNAs up-regulated 
after miR-128 transfection. These results indicate that the RISC-competition model is a 
plausible explanation of the high proportion of genes displaying increased expression 
after miR-128 transfection. The fact that we observed a much lower proportion of genes 
displaying increased levels of expression after miR-7 transfection suggests that the 
relative importance of RISC-competition may be miRNA dependent.  
Perhaps the most commonly observed mechanism underlying coordinated 
changes in global patterns of gene expression involves the modulation of centralized or 
“hub” regulatory genes (Seo et al., 2009; Shalgi et al., 2007). Hub genes have the 
potential to exert control on suites of down-stream genes thereby inducing cascades of 
regulatory mediated changes in patterns of gene expression (Wang et al., 2007). Our 
network analyses revealed that a substantial number of genes differentially expressed 
after miR-7 or miR-128 transfection (and predicted to be targeted by these miRNAs) are 
regulatory hubs capable of controlling many of the down-stream genes that were 
differentially expressed after miR-7 and miR-128 transfection. These findings indicate 
that miRNAs can both directly and indirectly induce changes in cellular regulatory 
networks that may be responsible for a significant fraction of the off-target effects 
associated with miRNA transfection. 
In general, our experiments demonstrate that exogenous expression of miRNAs 
induce regulatory changes far in excess of those on the intended target. From the clinical 
perspective, this begs the question as to whether miRNAs are appropriate agents for 
cancer therapy. Clearly, if the clinical intent is to precisely silence a specific gene and if 
the collateral off-target effects induced by miRNAs are counter-therapeutic, the answer 
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would be “no”. However, it is important to keep in mind that miRNAs have been 
evolving as essential components of the eukaryotic regulatory system for millions of 
years. Thus, the network of regulatory effects exerted by miRNAs is unlikely to be 
random and indeed may eventually provide clinicians with a strategy to treat cancer cells 
from a systems rather than a single gene perspective.  
Our functional analysis of the pathways most significantly affected by miR-7 and 
miR-128 transfection demonstrate that while both miRNAs can effectively down-regulate 
the targeted EGFR gene, the off-target changes are significantly diverse in their predicted 
functional consequences. The pathways most significantly affected by miR-7 transfection 
are predicted to be involved with cell adhesion and other developmental networks 
previously associated with epithelial-to-mesenchymal transitions (EMT) and other 
processes linked with metastasis (Yang and Weinberg, 2008). In contrast, the pathways 
most significantly affected by miR-128 transfection are more focused on cell cycle 
control and other processes commonly linked with cellular replication (Hanahan and 
Weinberg, 2011). Although both sets of functions are generally characteristic of cancer 
cells, particular pathways may be relatively more important in particular tumors. As we 
learn more about the functional specialization of different families of miRNAs, we will 
be in a better position to interpret the significance of changes in miRNA expression in 
particular cancer types and to become more precise in our selection of miRNAs for 
possible use in targeted cancer therapy. 
In summary, we have confirmed earlier studies showing that miRNAs can be 
effectively used to knock-down the expression of specific genes implicated in cancer. We 
have additionally shown that changes in the expression of off-target genes is not merely 
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the down-stream consequence of target gene inactivation but the result of direct and 
indirect regulatory effects mediated by the transfected miRNAs. We found that these off-
target effects are not random but can be explained, in large measure, by molecular models 
derived from our current understanding of miRNA function. Clearly, additional studies 
will be required to further evaluate the validity of these and other explanatory models in 
various types of cancer cells and other families of miRNAs. Nevertheless, the results of 
our preliminary studies indicate that while the molecular regulatory mechanisms 
underlying miRNA functions in vivo are extremely complex, they are not intractable. 
Validated models that can be used today to retrospectively explain the impact of 
exogenously expressed miRNAs, may be used in the future to prospectively design 
optimal system-wide strategies for the effective treatment of cancer.  
 
Materials and Methods 
Cell culture and miRNA/siRNA transfections 
HEY cells were provided by Gordon B. Mills, Department of Systems Biology, 
the University of Texas, M. D. Anderson Cancer Center and were cultured according to 
methods described in CHAPTER 2. Briefly, the cells were transfected with the miRNA 
hsa-miR-7 miRIDIAN mimic, miRIDIAN miRNA mimic negative control #1 (miR-NC, 
a C.elegans miRNA, cel-miR-67, with confirmed minimal sequence identity in humans), 
hsa-miR-128 miRIDIAN mimic (same negative control transfected cells were used to 
compare miR-7 and miR-128 transfected cells), ON-TARGET plus Anti-EGFR siRNA or 
ON-TARGET plus non-targeting siRNA (siNC) (Thermo Fisher Scientific, Lafayette, 
CO) using Lipofectamine 2000 transfection agent (Invitrogen) according to the 
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manufacturer's instructions at a final concentration of 25nM (or left untransfected for 
naïve cells). All transfections were carried out with two or three replicates. The cells were 
incubated with the reduced serum transfection medium (Opti-MEM, Invitrogen) for 4 
hours, washed and then allowed to grow in growth medium (RPMI 1640, Mediatech, 
Manassas, VA) for 44 hours before collecting RNA or protein. Transfection efficiency 
was estimated from the relative knock-down of EGFR for miR-7 and the anti-EGFR 
siRNA, and for BMI1 for miR-128 (Figure A.1), based on recommendations by the 
siRNA/miRNA reagent manufacturer (Thermo Fisher Scientific). 
 
RNA isolation and whole genome microarray 
Total RNA was isolated using the RNeasy Mini RNA isolation kit (QIAGEN, 
Valencia, CA) according to the manufacturer’s instructions. The integrity of the RNA 
was verified using an Agilent 2100 Bioanalyzer (1.8-2.0; Agilent Technologies, Palo 
Alto, CA). MRNAs were converted to double stranded (ds)-cDNA and amplified using 
Applause 3’-Amp System (NuGen, San Carlos, CA). This cDNA was then biotin labeled 
and fragmented by using Encode Biotin Module (NuGen). The labeled cDNA was 
hybridized to Affymetrix HG-U133 Plus 2.0 oligonucleotide arrays and analyzed with a 
GeneChip Scanner 3000 (Affymetrix, Santa Clara, CA). 
 
RNA isolation and miRNA microarray 
Total RNA was isolated from two independent samples of HEY cells using the 
mirVana miRNA isolation kit according to the manufacturer's instructions (Applied 
Biosystems, Foster City, CA). The quantity and size of microRNA was verified using an 
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Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). MiRNAs were labeled 
with Genisphere FlashTag HSR Biotin RNA labeling kit (Genisphere, Hatfield, PA) 
followed by hybridization with GeneChip miRNA Array chips (Affymetrix, Santa Clara, 
CA) according to the manufacturer's instructions. The chips were washed and then 
scanned with a GeneChip Scanner 3000 (Affymetrix). Raw data in the form of CEL files 
were produced by the Affymetrix GeneChip Operating System (GCOS) software.  
 
Quantitative (real-time) PCR (qPCR) 
Total RNA (1-5 µg) extracted from cells (three biological replicates) was 
converted to cDNA using the Superscript III First Strand synthesis system (Invitrogen). 
cDNA was then purified using the QIAGEN PCR purification kit (QIAGEN) following 
manufacturer’s instructions. QPCR experiments were carried out for the EGFR, BMI1 
and GAPDH genes using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA). The 
sequence specific primers used for SYBR green assays are as follows: EGFR-forward: 
GGAGAACTGCCAGAAACTGACC, EGFR-reverse: GCCTGCAGCACACTGGTTG, 
GAPDH-forward: GGTCTCCTCTGACTTCAACA, GAPDH-reverse: 
AGCCAAATTCGTTGTCATAC. The EGFR primers were as designed by (Micallef et 
al., 2009) and GAPDH primers were as designed by (Koppelstaetter et al., 2005). 
Description of BMI1 primers is provided in CHAPTER 2. The GAPDH primer 
efficiencies were calculated to be ~1. All reactions were optimized with non-template 
controls, and -RT (minus reverse transcriptase) controls prior to experiment. 
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All qPCR reactions were carried out using at least three technical replicates and 
three biological replicates on the CFX96 Real Time PCR detection system (Bio-Rad). 
Expression values were normalized to an endogenous control (GAPDH). Relative fold 
change of target RNA level between transfection groups was determined by the ∆∆Ct 
method. Statistical significance was determined using the pair-wise fixed reallocation 




Immunoblotting for EGFR and β-Actin was performed as described previously 
(Blackburn et al., 2009) with the following modifications. The blots were washed three 
times with TBST and probed with goat antirabbit IgG (Southern Biotech, Birmingham, 
AL) linked to Fluorescein (FITC), or with donkey antimouse IgG (Southern Biotech) 
linked to Phycoerythrin (PE) secondary antibodies [primary anti-EGFR antibodies are 
described in (Blackburn et al., 2009)]. Bands were visualized using a Typhoon 9400 
Imager (GE Healthcare, Piscataway, NJ) followed by densitometric analysis using the 
ImageQuant TL Software (GE Healthcare). Statistical significance of difference between 
average levels from at least three replicates quantified by densitometry was determined 
using a 2-tailed unpaired Student’s t-test. 
 
Microarray data analysis 
Raw data from miRNA microarray were analyzed using miRNA QC Tool 
software (Affymetrix, Santa Clara, CA). Normalization was performed using the default 
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workflow of the miRNA QC Tool software. Briefly, probesets were tested for detection 
above background using a Wilcoxon Rank-Sum test (p <0.06) and then normalized using 
quantile normalization. Probesets with ‘FALSE’ call in all groups were removed from 
statistical analysis. A constant (16) is added for variance stabilization and then values are 
summarized using the median polish method. The log base 2 transformed expression 
values were then used for calculations. Annotations for probesets were obtained from the 
Affymetrix website (http://www.affymetrix.com).  
MRNA microarray data were normalized and processed according to the 
procedure described in CHAPTER 2. 
 
Frequency distribution of miRNA signal values 
Only miRNAs with at least one ‘TRUE’ detection call across all samples and 
‘hsa’- prefix in probeset names were used for plotting the distribution of signal values. A 
histogram of signal value distribution was plotted using the ‘data analysis’ package in 
Microsoft Excel. Percentage of values within each bin were then calculated and plotted 
on a chart in Excel. 
 
Venn diagram of differentially expressed genes 
A Venn diagram of the different number of DEGs was plotted using the PAST 
toolkit Venn Diagram Plotter downloaded from the http://omics.pnl.gov website (also 
www.pnl.gov) 
 
Pathway enrichment analysis, identification of hub genes and network building  
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After identification of differentially expressed genes, GeneGo Pathway Maps 
analyses, and GeneGo Process Networks analyses were carried out using GeneGo 
(http://www.GeneGo.com/) gene ontology software. Hub genes were identified using the 
GeneGo interactome analyses with the ‘Significant interactions within sets’ algorithm. In 
all cases significance was based on a false discovery rate filter at a stringency of q-value 
<0.05. Networks were built using functional and binding interactions unless 
transcriptional regulation is specified.  
 
MiRNA target download 
 The miRNA targets prediction files based on miRanda were downloaded from 
www.microrna.org (August 2010 release; Betel et al., 2008; Enright et al., 2003; John et 
al., 2004). “Good” mirSVR score refers to miRNA targets with <-0.1 score, and “non-
good” mirSVR score refers to targets with >-0.1 score obtained from the support vector 
regression algorithm mirSVR, available with target predictions in the above link. 
Information about the prediction algorithm, parameter settings and raw data source is 
available on the above link. Target predictions based on TargetScan were downloaded 
from www.targetscan.org (Friedman et al., 2009; Grimson et al., 2007; Lewis et al., 
2005) and predictions for PicTar were obtained from www.pictar.org (Ge and Manley, 
1990; Krainer et al., 1990; Krek et al., 2005; Zhou et al., 2002).  
 
MiRNA target enrichment analysis among up-regulated genes  
Gene set enrichment analysis for predicted microRNA targets among 
differentially expressed genes was carried out using the web interface of Genomica, a 
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software for analysis and visualization of genomic data available at 
http://genomica.weizmann.ac.il/ (Lubling and Segal). All parameters were kept in default 
settings for our analyses. Differentially expressed genes were divided into up-regulated 
and down-regulated gene sets, uploaded onto the Genomica server for analysis, and 
finally enrichment was performed against the ‘Human MicroRNA RNA’ gene set with a 
FDR correction threshold of 0.05. When only a miRNA family is identified (without 
specifying the identity of the paralog) all members of the family were considered (e.g., 









MicroRNAs (miRNAs) are a class of regulatory RNAs that control the expression 
of genes critical to cell function. Ectopic expression of miRNAs has been shown to result 
in genome-wide changes in patterns of gene expression. While the reasons for these 
global alterations in gene expression patterns have been attributed to the ability of 
miRNAs to target multiple genes, and/or to induce indirect effects downstream of target 
genes, the molecular basis of indirect effects of miRNA regulation remains poorly 
understood. In this study, we demonstrate the potential of miRNAs to regulate other 
miRNAs. Using miRNA microarray analysis, we show that over 70 different miRNAs are 
differentially expressed (fold change ≥1.4, FDR ≤5 %) in human ovarian cancer cells 
after transfection with a single miRNA (miR-7). We present evidence that a major 
component of miR-7 induced changes in levels of miRNAs is the indirect consequence of 
miR-7 mediated alterations in levels of protein coding genes (e.g., transcription and 
splicing factors) that exert trans-regulatory control on miRNAs.  
 
Introduction 
MicroRNAs (miRNAs) are a conserved class of small RNAs that can regulate 
gene expression by altering the translation and/or mRNA stability of target genes (Bartel, 
2004; Fabian et al., 2010). Since miRNAs are differentially expressed in cancer and other 
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diseases (Calin and Croce, 2006a; Esquela-Kerscher and Slack, 2006; Farazi et al., 2011; 
Lee and Dutta, 2009; Visone and Croce, 2009; Wiemer, 2007), they may have clinical 
potential as diagnostic, prognostic and/or therapeutic agents (Garofalo and Croce, 2011; 
Wahid et al., 2010). However, the molecular causes and consequences of perturbations in 
levels of miRNAs in cancer cells can be varied and complex (e.g., Baek et al., 2008; Lim 
et al., 2005; Selbach et al., 2008; see also CHAPTER 3). Thus, the potential clinical 
impact that miRNAs will ultimately have in cancer medicine rests heavily upon our 
ability to understand the basis of this complexity. We report here that perturbations in 
levels of a single miRNA can not only induce significant changes in levels of mRNAs but 
also significantly modulate levels of other miRNAs. We discuss the potential significance 
of miRNA-miRNA regulation in cancer cells and present evidence for molecular 
mechanisms that may underlie the process.  
 
Results 
Ectopic expression of miR-7 alters the levels of endogenous microRNAs  
To study the effect of changes in levels of a single microRNA on expression 
levels of other miRNAs in cancer cells, we transfected a well-characterized ovarian 
cancer cell line (HEY) with a miRNA (miR-7) previously shown to be significantly up-
regulated in ovarian and other cancers (Chou et al., 2010; Jiang et al., 2010; Kefas et al., 
2008; Reddy et al., 2008; Saydam et al., 2010; Veerla et al., 2009; Webster et al., 2009; 
Wyman et al., 2009; see also CHAPTER 2). To assess the biological effectiveness of our 
transfection, we monitored changes in levels of EGFR, a previously validated target of 
miR-7 (Kefas et al., 2008; Webster et al., 2009). Since it has previously been 
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demonstrated that EGFR is highly expressed in HEY cells (Dickerson et al., 2010), we 
expected levels of EGFR mRNA and protein to be significantly reduced after a successful 
miR-7 transfection. Our results confirm that levels of EGFR mRNA and protein are both 
significantly reduced after miR-7 transfection (Figure 4.1) relative to a negative control 




Figure 4.1. Confirmation of successful transfection of miR-7 into HEY cells. 
Successful transfection of miR-7 into HEY cells is confirmed by measuring the level of 
EGFR RNA (A) by qPCR and (B) protein by Western blot analysis. In both cases EGFR 
expression is down-regulated significantly (*** p <0.001, ** p <0.05) after miR-7 
transfection compared to negative control (miR-NC) transfection. The bars in (B) reflect 
relative quantitation of the bands of the immunoblot using densitometry (based on three 
replicate samples). Relative expression values are shown on the Y-axis. EGFR expression 
is normalized to (A) GAPDH used as endogenous control, or (B) β-Actin used as loading 
control. Error bars reflect standard deviation of the means calculated from three 
independent replicate samples. The number in the box is the fold change difference in 






Figure 4.2. MicroRNAs differentially expressed after miR-7 transfection in HEY 
cells. (A) List of differentially expressed (fold change ≥1.4 and FDR ≤5 %) miRNAs 
following transfection of hsa-miR-7 into HEY cells compared to miR-NC transfected 
cells. There were 40 different human miRNAs significantly down-regulated and 31 
miRNAs significantly up-regulated (excluding miR-7) after miR-7 transfection. (B) 
Hierarchical clustering of significantly differentially expressed miRNAs between cells 
transfected with either miR-7 or miR-NC. Each column of the heat map corresponds to a 
sample. The two negative control samples are on the left and the two miR-7 transfected 
samples are on the right. Selected IDs of the human miRNAs homologous to the 
sequences specified by the probesets are shown on the right side of the heat map. [Note 
some of the miRNA names have an asterisk (*) indicating miRNA star strand].  
 
 
To evaluate the effect of miR-7 transfection on global miRNA expression 
profiles, we isolated total RNA from cells transfected with either miR-7 or a negative 
control miRNA (miR-NC) 48h after transfection and monitored changes in levels of 
miRNA expression by microarray analysis. The results demonstrate that 259 distinct 
miRNA probesets corresponding to 71 mature miRNAs (excluding miR-7) were 
significantly altered in expression (31 up-regulated; 40 down-regulated) in the miR-7 
transfected cells relative to controls (Figure 4.2, Table C.1). Eight of the miRNAs 
displaying significant changes in expression by microarray (hsa-miR-198, hsa-miR-628-
3p, hsa-miR-149, hsa-miR-10b, hsa-let-7f, hsa-miR-503, hsa-miR-218 and hsa-miR-224) 
were randomly selected for confirmatory qPCR analysis. The results were uniformly 






Figure 4.3. Quantitative PCR confirmation of miRNAs differentially expressed after 
miR-7 transfection. Quantitative (real-time) PCR analysis of (A) hsa-miR-198, (B) hsa-
miR-628-3p, (C) hsa-miR-149, (D) hsa-miR-10b, (E) hsa-let-7f, (F) hsa-miR-503, (G) 
hsa-miR-218, and (H) hsa-miR-224 in HEY ovarian cancer cells 48h after transfecting 
hsa-miR-7 or miR-NC. RNA expression levels were normalized to human U6 small 
nucleolar RNA (RNU6B) used as the endogenous control. Relative expression values are 
shown on the Y-axis. The relative fold change of each miRNA is also shown (in text 
box). Error bars reflect standard deviation of the means calculated from three 
independent replicate samples. *** p <0.001, ** p <0.05. 
 
 
The majority of genes in which differentially expressed miRNAs are embedded do 
not display correlated changes in expression  
Human miRNAs have been mapped to exons and introns of protein coding and 
non-protein coding genes (i.e. embedded in genes), as well as to intergenic miRNA 
encoding loci (Kim and Nam, 2006). Some embedded miRNAs have been shown to 
display changes in expression levels that positively correlate with those of their host 
genes. Such correlated patterns of expression are consistent with the hypothesis that 
embedded miRNAs and their host genes are under the same and/or coordinated 
regulatory controls (Baskerville and Bartel, 2005; Rodriguez et al., 2004). In other cases, 
changes in patterns of embedded miRNAs do not correlate with those of their host genes 
(Bargaje et al., 2010) indicating that at least some embedded miRNAs are under 








Figure 4.4. Genomic location of differentially expressed miRNAs between miR-7 
transfected and negative control transfected HEY cells. The pie-chart on the left 
shows the proportion of differentially expressed miRNAs that are either embedded in 
known genes or intergenic. The pie-chart on the right shows that the embedded miRNAs 
can be classified further based on whether they come from intronic, exonic or anti-sense 
regions. MiRNAs that can be either from intron or exon are counted under both 




Table 4.1. MiRNAs embedded in protein coding and non-protein coding genes. 
Differentially expressed embedded miRNAs (fold change ≥1.4, FDR ≤5 %) and their 
respective host genes are listed. The difference between log2 average expression values of 
miR-7 and miR-NC transfected cells calculated from microarray analysis is shown for 
both the miRNAs (miRNA LR) and their host genes (Gene LR). Transcripts with 
Affymetrix “Absent” calls in every sample are marked absent. MiRNAs encoded from 
the same cluster are in cells shaded using the same color. MiRNAs with putative 
independent promoters are also marked with the letters a, b, or c in superscript (see 
references at bottom of table). The number (#) of NF-κB sites near pre-miRNAs and 
SFRS1 binding sites overlapping pri-miRNAs are listed. The direction of change of 
miRNAs following RELA knockdown (k.d.) or SF2 induction experiments are also 
shown with arrows pointing down (↓) for down-regulation or upwards (↑) for up-
regulation. Host genes with miRanda predicted miR-7 sites are demarcated with a 
superscript (
T













sites , SF2 
induction 
↑↓ 











(IN)  -1.195 n.s., n.c. n.s., ↓ 
hsa-let-7f-2 
b, c
 -0.76342 HUWE1 (IN) -0.177 1, n.c. 21, n.c. 
hsa-miR-98 
b, c





 (IN) -0.28 4, n.c. n.s., n.c. 
hsa-miR-10a  -0.54619 HOXB3
T
 (IN) -0.574 8, n.c. 1, n.c. 
hsa-miR-10b -0.6476 HOXD3 (IN)  0.348 2, n.c. 1, n.c. 




 -0.5179 VWA5B2 (IN) Absent 1, n.c. n.s., n.c. 
hsa-miR-126 
b
 -0.52106 EGFL7 (IN) 0.1913 1, n.c. n.s., n.c. 
hsa-miR-1274a -0.94684 PLCXD3 (AS) 0.212 n.s., n.c. n.s., n.c. 
hsa-miR-139-5p  -0.62283 PDE2A (IN)  -1.227 3, n.c. n.s., n.c. 
hsa-miR-140-5p  0.596344 WWP2 (IN) 0.286 1, ↓ 3, ↓ 
hsa-miR-149 
b, c
 6.223235 GPC1 (IN) 0.042 n.s., ↑ n.s., n.c. 
hsa-miR-15b 
b
 -0.52393 SMC4 (IN) -0.0699 6, n.c. 5, n.c. 




3'UTR)  -0.822 1, n.c. 2, n.c. 
hsa-miR-199a-1 
(3p)  -1.1451 DNM2
T
 (AS) -0.185 n.s, ↓  n.s., n.c. 
hsa-miR-199a-1 
(5p)  -0.54362 DNM2
T
 (AS) -0.185 n.s., ↓  n.s., n.c. 
hsa-miR-199b-
3p -1.1451 DNM1 (AS) 0.291 n.s., n.c. n.s., n.c. 
hsa-miR-204 -0.79504 TRPM3 (IN) 0.0536 n.s., n.c. n.s., n.c. 
hsa-miR-218-1 
b
 -0.72675 SLIT2 (IN) -0.419 n.s., n.c. 15, n.c. 
hsa-miR-218-2 
b
 -0.72675 SLIT3 (IN)  Absent n.s., n.c. n.s., n.c. 
hsa-miR-224 
b
 -0.96649 GABRE (IN/EX)  -0.868 n.s., n.c. n.s., ↓ 
hsa-miR-26b* 0.533673 CTDSP1 (IN) -0.402 5, n.c. n.s., n.c. 









 -0.54983 NFYC (IN) -0.166 4, ↓ 2, n.c. 
hsa-miR-330-3p 
c, b
 0.911218 EML2 (IN) -0.509 7, n.c. n.s., n.c. 



































(IN)  -1.903 5, ↓  n.s., n.c. 
hsa-miR-425* 0.589535 DALRD3 (IN) -0.1346 7, n.c. 1, n.c. 
hsa-miR-550a-1 0.518992 ZNRF2
T
 (IN) -0.206 3, n.c.  n.s., n.c. 
hsa-miR-550a-2 0.518992 AVL9 (IN)  -0.684 1, n.c. 1, n.c. 





 (IN) -0.398 n.s., n.c. 7, n.c. 
hsa-miR-628-3p  0.911418 CCPG1 (IN) 0.0708 1, n.c. n.s., n.c. 





(IN/EX) -0.099 3, n.c. 8, n.c. 
hsa-miR-877 
b
 0.582268 ABCF1 (IN) -0.419 n.s., n.c. 6, n.c. 
hsa-miR-93* 
b
 0.577574 MCM7 (IN) -0.317 3, n.c. 7, n.c. 





(EX) -0.5 3, n.c. n.s, ↑ 
hsa-miR-155 -0.69576 
MIR155HG 
(EX) -0.842 8, n.c. n.s, ↑ 
hsa-miR-17 -0.50919 MIR17HG (IN) -1.23 5, ↓ 2, n.c. 
hsa-miR-92a-1 
b, c
 -0.59852 MIR17HG (IN) -1.23 5, n.c. 2, ↓ 
hsa-miR-92a-1* 
b, c




(IN) 0.912 1, n.c. n.s., n.c. 
hsa-miR-181b-2 0.706968 
MIR181A2HG 

















IN) 0.7498 1, ↓ n.s., n.c. 






















 Absent n.s., n.c. 1, ↓ 
(IN) intron, (EX) exon, (IN/EX) intron or exon, and (AS) antisense strand. *** 
hypothetical protein may exist. 
a
 Fujita and Iba (2008); 
b
 Monteys et al. (2010); 
c
 Ozsolak 
et al. (2008). n.s. = no sites; n.c. = no change. 
p 
This mRNA is designated as a 
pseudogene/non-coding RNA on the UCSC genome browser and does not have any 
predicted protein sequences, although microRNA.org predicts a miR-7 binding site on 
this transcript using miRanda. 
 
 
Table 4.2. MiRNAs mapped to intergenic regions. Differentially expressed miRNAs 
(fold change ≥1.4, FDR ≤5 %) transcribed from intergenic regions are listed. The 
difference between log2 average expression values of miR-7 and miR-NC transfected 
cells calculated from microarray analysis is shown for the miRNAs (miRNA LR). 
MiRNAs encoded from the same cluster are in cells shaded using the same color. The 
number (#) of NF-κB sites near pre-miRNAs and SFRS1 binding sites overlapping pri-
miRNAs are listed. The direction of change of miRNAs following RELA knockdown or 
SF2 induction experiments is also shown with arrows pointing down (↓) for down-





# NF-κB sites, RELA 
k.d. ↑↓ 
# of SFRS1 sites, SF2 
induction ↑↓ 
hsa-let-7a-1 -0.59325 7, n.c. n.s., n.c. 
hsa-let-7f-1 -0.76342 7, n.c. n.s., n.c. 
hsa-let-7a-2 -0.59325 n.s., n.c. n.s., n.c. 
hsa-miR-100* -0.50474 n.s., n.c. n.s., n.c. 
hsa-let-7i* 0.505132 3, n.c. 1, n.c. 
hsa-miR-1246 1.415944 n.s., n.c. n.s, ↑ 
hsa-miR-1303 0.60768 1, n.c. n.s., n.c. 
hsa-miR-142-
5p 0.54093 2, n.c. n.s., n.c. 
hsa-miR-146a 0.506805 11, ↓ n.s., n.c. 
hsa-miR-181c 0.546773 3, ↓ n.s, ↓ 
hsa-miR-181d 0.57838 3, n.c. n.s., n.c. 
hsa-miR-193a-
3p -0.53848 2, ↓ n.s., n.c. 
hsa-miR-200b 2.113596 3, n.c. n.s., n.c. 
hsa-miR-20b -0.50919 5, n.c. n.s., n.c. 





# NF-κB sites, RELA 
k.d. ↑↓ 
# of SFRS1 sites, SF2 
induction ↑↓ 
hsa-miR-92a-2 -0.59852 5, n.c. n.s, ↓ 
hsa-miR-210 0.526599 6, ↓ 1, ↓ 
hsa-miR-221* -0.68268 2, n.c. n.s., n.c. 
hsa-miR-223 -0.62695 8, n.c. n.s., n.c. 
hsa-miR-30d* -0.84209 n.s., n.c. n.s., n.c. 
hsa-miR-337-
5p 1.314976 n.s., n.c. n.s., n.c. 
hsa-miR-374b -0.63622 n.s., n.c. n.s, ↓ 
hsa-miR-421 0.531948 n.s., n.c. n.s., n.c. 




 0.607361 5, n.c. n.s., n.c. 
hsa-miR-99b* 0.819847 1, ↓ n.s., n.c. 
cl 
This miRNA is clustered with 3 other miRNAs differentially expressed in our 
experiment, miR-424, miR-424* and miR-503; all 3 are expressed from a hypothetical 
protein coding gene MGC16121. n.s. = no sites; n.c. = no change. 
 
 
Of the 71 miRNAs differentially expressed after miR-7 transfection, 50 were 
found to map to annotated genes (55 including paralogs) and 21 (25 including paralogs) 
map to intergenic miRNA genes (Figure 4.4, Tables 4.1 and 4.2). To determine if 
changes in miRNA levels are correlated with changes in mRNA levels of the 50 genes in 
which miRNAs are embedded, we compared changes in miRNA profiles with changes in 
the mRNA levels of host genes in miR-7 transfected HEY cells (Figure 4.5, Table C.2). 
We found that 9 of the 50 host genes were significantly differentially expressed (fold 
change ≥1.3, p <0.05) in miR-7 transfected cells relative to controls (Table 4.3, Figure 
4.6). Eight of these nine genes displayed changes in expression positively correlated with 
thirteen embedded miRNAs while one of the genes displayed a change in expression 
inversely correlated with a single embedded miRNA (Table 4.3). The majority of genes 
(41/50) hosting differentially expressed miRNAs did not display a significant change in 





Figure 4.5. Significantly differentially expressed mRNAs following miR-7 
transfection into HEY cells. Hierarchical clustering of significantly differentially 
expressed genes (fold change ≥1.3, p <0.05) between cells transfected with either miR-7 
or miR-NC. There were 403 mRNAs significantly up-regulated and 965 different 
mRNAs significantly down-regulated after miR-7 transfection. Each column of the heat 
map corresponds to a sample. Three independent samples transfected with negative 
control are on the left and three independent samples transfected with miR-7 are on the 
right. Selected gene symbols corresponding to the Affymetrix probeset ID are shown on 




Table 4.3. Significantly differentially expressed embedded miRNA-mRNA pairs. 
Embedded miRNAs and their host genes are listed when both the miRNA (fold change 
≥1.4 and FDR ≤5 %) and the host gene (fold change ≥1.3, t-test p-value <0.05) are 
detected to be significantly changing in the same direction (positively correlated) or 
opposite direction (inversely correlated) after transfecting HEY cells with miR-7 or miR-
NC. For two of these mRNAs (as well as the miRNAs) differential expression was 





miRNA mRNA/ncRNA Host gene detection method 
miRNAs positively correlated in expression with host genes 
hsa-let-7c  C21orf34
T
 (IN)  Microarray 
hsa-miR-139-5p  PDE2A (IN)  Microarray 
hsa-miR-198 FSTL1
T
 (EX-3'UTR)  Microarray and qPCR 
hsa-miR-30a* C6orf155 (IN) Microarray 
hsa-miR-424  MGC16121 (EX) Microarray and qPCR 
hsa-miR-424* MGC16121 (EX) Microarray and qPCR 
hsa-miR-503  MGC16121 (EX) Microarray and qPCR 
hsa-miR-155 MIR155HG (EX-ncRNA) Microarray 
hsa-miR-181a-2* MIR181A2HG (IN-ncRNA)  Microarray 
hsa-miR-181b-2 MIR181A2HG (IN-ncRNA)  Microarray 
hsa-miR-17 MIR17HG (IN-ncRNA)  Microarray 
hsa-miR-92a-1  MIR17HG (IN-ncRNA)  Microarray 
hsa-miR-92a-1* MIR17HG (IN-ncRNA)  Microarray 
miRNAs inversely correlated in expression with host genes 
hsa-miR-550a-2 AVL9 (IN) Microarray 
IN: intron, EX: exon. 
T








Figure 4.6. Quantitative PCR confirmation of host mRNAs differentially expressed 
after miR-7 transfection. Quantitative (real-time) PCR analysis of (A) FSTL1, and (B) 
MGC16121 expression in HEY ovarian cancer cells 48h after transfection with either 
hsa-miR-7 or miR-NC. RNA expression levels were normalized to human GAPDH used 
as the endogenous control. Relative expression values are shown on the Y-axis. Error 






miR-7 regulates expression of some miRNAs by altering the level of the 
transcription factor RELA/NF-κB 
We found that transfection of miR-7 into HEY cells results in significant changes 
in the expression levels of 1368 genes including genes known to encode transcription 
factors previously linked with cancer onset and progression (Figure 4.5, Table C.2; Karin 
and Greten, 2005). Since miRNAs are under transcriptional regulatory control (Krol et 
al., 2010), transcription factor genes regulated by miR-7 may exert indirect regulatory 
effects on other miRNAs. To explore this possibility, we selected RELA, one of the 
transcription factor coding genes that were significantly differentially expressed after 
miR-7 transfection in HEY cells (Table 4.4) and in A549 lung cancer cells (Webster et 
al., 2009; see also Table C.3). Moreover, RELA is a component of the well-studied 
transcription factor NF-κB that is a well-documented regulator of miRNA expression 
(Mott et al., 2010; Pacifico et al., 2010; Zhou et al., 2009). Significant down-regulation of 
RELA in miR-7 transfected HEY cells was confirmed by quantitative real-time PCR 
(Figure 4.7A). 
We found that 17 (68 %) of the 25 intergenic miRNAs and 38 (69 %) of our 55 
embedded miRNAs (Tables 4.1, 4.2, Figure 4.8; Table C.4) map to within 10 kb of 
experimentally validated (ChIP-seq) RELA/NF-κB binding sites (Birney et al., 2007). In 
addition, nearly half (33 out of 71) of the miRNAs that were differentially expressed in 
our miR-7 transfection experiment have previously been reported to be altered when NF-
κB is induced or inhibited in other cellular contexts (Gao et al., 2010; Kluiver et al., 
2007; Mott et al., 2010; Pacifico et al., 2010; Wang et al., 2009; Wang et al., 2010; Zhou 
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et al., 2009). Collectively, these findings suggest that at least some of the changes in 
miRNA levels observed after miR-7 transfection into HEY cells may be mediated by 
RELA/NF-κB transcription factor.  
 
 
Table 4.4. Differentially expressed transcription factors following miR-7 
transfection. These 22 transcription factors were identified as being significantly 
differentially expressed (1.3 fold change, p <0.05) in miR-7 transfected HEY cells and 
A549 lung cancer cells (Webster et al., 2009). The difference between the log2 signal 
values for each gene in HEY cells transfected with either miR-7 or miR-NC is given in 
the ‘miR7-miR-NC’. Out of the 22, only 8 have miRanda predicted miR-7 binding sites 
(marked with ‘x’) and only 2, RELA and SP1 have ChIP-seq data showing genome-wide 
binding sites (marked with ‘E’). 
 
 





BACH1 -0.45255   
CNOT6 -0.60309 x  
CNOT8 -1.26668 x  
CREBL2 0.433388   
IFT57 0.664064   
IRF2BP2 -0.43606   
KLF3 -0.60824   
KLF4 -1.06432 x  
LITAF -1.52641   
NOTCH2 -0.7116 x  
PBX1 1.134572 x  
PPM1A -0.52971   
RELA -1.08425 x E 
SETD8 -1.07335 x  
SP1 -0.42641 x E 
TAF4B -0.54876   
TLE4 -0.61978   
UBTF 0.614296   
VGLL4 -0.72098   
ZBTB20 0.399861   
ZNF512 -0.49876   






Figure 4.7. Confirmation of RELA down-regulation following miR-7 or anti-RELA 
siRNA transfection. QPCR confirms successful down-regulation of RELA expression 
48 hours after transfection of HEY cells with A. miR-7 or miR-NC, and B. anti-RELA 
siRNA or siNC. Relative expression of RELA was measured using GAPDH as 
endogenous control. Error bars reflect standard deviation of the means calculated from 





Figure 4.8. Distribution of NF-κB binding sites near embedded and intergenic 
miRNAs. Number of embedded and intergenic differentially expressed miRNAs with 
(dark grey) or without (light grey) NF-κB binding sites within ±10 kb. The number of 
differentially expressed miRNAs (fold change ≥1.4, FDR ≤5 %) following miR-7 
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transfection that are either embedded in coding/non-coding genes or intergenic is 
represented by the height of the bars.  
 
 
To further investigate this hypothesis, we transfected HEY cells with RELA 
siRNA or a negative control siRNA and collected total RNA (48 hrs post-transfection) 
for microarray analysis (Affymetrix GeneChip miRNA array). Knock down of RELA 
expression was confirmed by qPCR (Figure 4.7B). The results of the microarray analysis 
demonstrated that 235 miRNA probesets corresponding to 51 known human miRNAs 
(Figure 4.9; Table C.5) were significantly differentially expressed (fold change ≥1.4, 
FDR ≤5 %) after RELA-siRNA transfection relative to controls. Seven of the miRNAs 
displaying changes in expression after miR-7 transfection displayed similar changes in 
expression after transfection with RELA-siRNA (Table 4.5). Twenty additional miRNAs 
that displayed significant changes in expression after RELA siRNA transfection either 
originate from the same pre-miRNA transcript or are clustered within the same locus 
(<10 kb) with 19 miRNAs displaying significant changes in expression after miR-7 
transfection (Table 4.5). Our findings are consistent with the hypothesis that at least some 
of the changes in miRNA levels observed after miR-7 transfection into HEY cells are 







Figure 4.9. Differentially expressed miRNAs in HEY cells following anti-RELA 
siRNA transfection. Significantly differentially expressed (fold change ≥1.4 and FDR 
≤5 %) miRNAs in HEY cells following transfection with anti-RELA siRNA or siNC 
were used for hierarchical clustering of samples. Each column of the heat map 
corresponds to a sample. Two samples transfected with siNC are on the left and the two 
anti-RELA siRNA transfected samples are on the right. Some of the IDs of the human 
miRNAs homologous to the sequences specified by the probesets are shown on the right 





Table 4.5. Significantly differentially expressed miRNAs altered by both miR-7 
transfection and RELA knock-down. The lists of miRNAs that were significantly 
differentially expressed (fold change ≥1.4, FDR ≤5 %) after either miR-7 or RELA-
siRNA transfection were compared and the miRNAs that were altered in both, had the 
Table 4.5 (continued) 
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same pre-miRNA, or that originated in the same cluster are listed. MiRNA names 
followed by parenthesis containing a number refers to a corresponding paralogous 












miRNAs transcribed from the same pre-miRNA 





hsa-miR-199a-5p hsa-miR-199a-3p, hsa-miR-199a-5p 
hsa-miR-30a hsa-miR-30a* 
hsa-miR-30e hsa-miR-30e* 
miRNAs transcribed from the same cluster  
Cluster RELA knock down miR-7 transfection 
miR-17~92 hsa-miR-17* hsa-miR-17 
miR-17~92 hsa-miR-18a* hsa-miR-92a(-1) 
miR-17~92 hsa-miR-18a hsa-miR-92a-1* 
miR-17~92 hsa-miR-19a  
miR-17~92 hsa-miR-19b(-1)  
miR-18~106 hsa-miR-18b hsa-miR-20b 
miR-18~106 hsa-miR-19b(-2) hsa-miR-92a(-2) 
miR-15-16 hsa-miR-16(-2) hsa-miR-15b 
let-7c, miR-99a hsa-miR-99a hsa-let-7c 
miR-181a-1, miR-181b-1 hsa-miR-181a* hsa-miR-181b(-1) 
miR-130b, miR-301b hsa-miR-130b hsa-miR-301b 
miR-424~542 hsa-miR-503 hsa-miR-424, hsa-miR-
424*, hsa-miR-503 






miR-7 may regulate expression of miRNAs by altering levels of the splicing factor 
SF2/ASF 
Wu et al. (2010) have recently reported that SF2, a gene involved in the splicing 
of pre-mRNAs (Ge and Manley, 1990; Krainer et al., 1990; Zhou et al., 2002), can form a 
negative feedback circuit with miR-7. Over-expression of SF2 in HeLa cells was shown 
to result in significant alterations in levels of several (40) miRNAs including a significant 
elevation in levels of miR-7. Wu et al. (2010) go on to show that elevation in levels of 
miR-7 results in the down-regulation of SF2 (a predicted target of miR-7) indicating a 
negative feed-back loop.  
 
 
Figure 4.10. Quantitative PCR confirmation of SFRS1 down-regulation in miR-7 
transfected HEY cells. Quantitative (real-time) PCR of SFRS1 expression in HEY cells 
48h after transfection with miR-7 or miR-NC. Relative expression of SFRS1 was 
normalized to human GAPDH expression used as endogenous control. Error bars reflect 





Since our microarray results (confirmed by qPCR, Figure 4.10) indicate that 
expression levels of the gene (SFRS1) encoding SF2 is significantly down-regulated in 
miR-7 transfected cells, it is possible that at least some of the miR-7 induced changes in 
levels of miRNAs in these cells may have been mediated by SF2. Consistent with this 
hypothesis, we found that 12 of the 40 miRNAs reported by Wu et al. (2010) to display 
significant changes in levels of expression in HeLa cells after SF2 over-expression also 
display significant changes in expression after miR-7 transfection in HEY cells (Table 
4.6). In addition, we found that nine additional miRNAs differentially expressed after 
miR-7 transfection map to primary transcripts containing eight of the differentially 
expressed miRNAs detected in the Wu et al. (2010) study (Table 4.6; also Tables 4.1 and 
4.2). 
To further explore the possibility that some of the miR-7 induced changes in 
miRNA levels in transfected HEY cells may have been mediated by SF2, we overlaid the 
positions of experimentally validated (CLIP-seq or cross-linked immunoprecipitation and 
sequencing) SF2 binding sites (Sanford et al., 2009) with the genomic locations of 
miRNAs displaying significant changes in levels of expression after miR-7 transfection. 
The results indicate that SF2 binding sites are located within the pri-miRNAs of 25 
miRNAs (23 embedded, 2 intergenic) displaying significant changes in expression after 
miR-7 transfection (Tables 4.1, 4.2, C.6 and C.7). Collectively, our findings are 
consistent with the hypothesis that some of the miR-7 induced changes in miRNA levels 





Table 4.6. Significantly differentially expressed miRNAs altered by both miR-7 
transfection and SF2 induction. The miRNAs that were significantly differentially 
expressed in either HEY cells after miR-7 transfection (fold change ≥1.4, FDR ≤5 %) or 
in HeLa cells following SF2 induction (fold change ≥1.5, FDR ≤1 %, criterion used in the 
Wu et al. (2010) study) were compared and the miRNAs that were altered in both or had 
the same putative pri-miRNA are listed. Mature miRNAs differentially expressed after 
both miR-7 transfection and SF2 induction are written in bold letters.  
 










hsa-miR-181c hsa-miR-181c, hsa-miR-181d 












Discussion and Conclusion 
 
Previously it has been shown that a single miRNA can alter the expression of 
hundreds of genes (Baek et al., 2008; Lim et al., 2005; Selbach et al., 2008). While some 
of these changes can be attributed to canonical 3’ UTR miRNA targeting, the vast 
majority (~70 %) of genes altered by a miRNA may be indirectly regulated (Chen et al., 
2011; see also CHAPTER 3). In this study, we explore the possibility that one 
 
 115
mechanism that may be contributing to these “off-target” effects is miRNA-miRNA 
regulation.  
Our experimental approach was to transfect a well-characterized ovarian cancer 
cell line (HEY) with a single miRNA and to monitor the effect on the expression levels of 
other miRNAs and mRNAs by microarray analysis. We selected miR-7 for use in our 
transfection experiments because levels of this miRNA previously have been shown to be 
significantly changed in ovarian (Wyman et al., 2009; see also CHAPTER 2) and other 
cancers (Chou et al., 2010; Foekens et al., 2008; Jiang et al., 2010; Kefas et al., 2008; 
Reddy et al., 2008; Veerla et al., 2009; Webster et al., 2009) relative to normal tissue. 
Gene expression profiling by microarray revealed that transfection of miR-7 into HEY 
cells resulted in significant changes in expression levels of 71 miRNAs and 1370 
mRNAs.  
In principle, miRNAs may regulate expression of other miRNAs either directly or 
indirectly. For example, it has been proposed that if miRNAs share significant sequence 
complementarity with other miRNAs, the resulting nucleotide pairing could serve as the 
basis of direct miRNA-miRNA regulation (Lai et al., 2004). We found that among 71 
miRNAs differentially expressed in our study, only 3 displayed even partial (38-62 %, 
Figure 4.11) Watson-Crick complementarity to miR-7 indicating that miRNA-miRNA 
pairing is unlikely to be a significant mechanism used by miR-7 to regulate other 





Figure 4.11. Alignment of three differentially expressed miRNAs with partial 
complementarity to miR-7. Sequences of three miRNAs (hsa-miR-7-1*, hsa-miR-224 
and hsa-miR-92a) are aligned with miR-7 based on BLAST alignment. Vertical straight 




The primary mechanism by which miRNAs regulate expression of mRNA-
encoding genes is through translational inhibition and associated mRNA degradation 
(Djuranovic et al., 2011; Fabian et al., 2010). While this mechanism is presumably not 
applicable to miRNAs and other untranslated RNAs, there have been reports of miRNAs 
directly serving as activators (Majid et al., 2010; Place et al., 2008) and repressors (Kim 
et al., 2008) of transcriptional initiation. It is certainly possible that miRNAs may directly 
influence the expression of other miRNAs by regulating or co-regulating promoters of 
miRNA genes and/or protein coding genes in which miRNAs are embedded. However, 
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current evidence suggests that a direct role of miRNAs in promotional control occurs 
relatively infrequently (Tang et al., 2008b; Tang and Zen, 2011). Thus, we believe it is 
more likely that miRNAs may modulate the expression of other miRNAs indirectly by 
regulating transcription factors or other regulatory proteins that, in turn, exert direct 
regulatory control on miRNA expression.  
We observed significant changes in expression of 188 transcription factor coding 
genes after miR-7 transfection. Forty-nine of these, including RELA/NF-κB, are 
predicted targets of miR-7 regulation (Table C.8). We selected RELA/NF-κB for further 
investigation because this transcription factor has been previously implicated in miRNA 
regulation (Mott et al., 2010; Pacifico et al., 2010; Zhou et al., 2009) and was also down-
regulated in a lung cancer cell line following miR-7 transfection (Webster et al., 2009). 
We found that siRNA knockdown of RELA resulted in a significant change in expression 
of 51 miRNAs, many of which were also significantly differentially expressed after miR-
7 transfection. These results coupled with our finding that ~70 % of the miRNAs 
differentially expressed after miR-7 transfection map to within 10 kb of RELA/NF-κB 
binding sites suggest that this transcription factor plays a significant indirect role in miR-
7 induced changes in miRNA expression.  
Further support for the hypothesis that miR-7 induced changes in the expression 
levels of protein coding regulatory genes may play a significant role in affecting changes 
in levels of miRNAs comes from our analysis of another direct target of miR-7 
regulation, the splicing factor SF2. We found that SF2 binding sites are located within the 
pri-miRNAs of 25 miRNAs that displayed significant changes in expression after miR-7 
transfection into HEY cells. This result coupled with previous findings implicating SF2 
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in the regulation of miR-7 in HeLa cells (Wu et al., 2010a) suggests that SF2 may also be 
playing a role in miR-7 induced changes in the expression of miRNAs in HEY cells.  
Once considered “junk” DNA, a large component of the non-protein coding 
human genome is now known to encode untranslated RNAs that play important, albeit 
diverse, roles in gene regulation (Eddy, 2001; Mattick, 2007). Among the most 
intensively studied of these regulatory molecules are short (~22 nucleotides) regulatory 
RNAs, called miRNAs. This class of small regulatory RNAs inhibits the translation 
and/or facilitates the degradation of their targeted messenger RNAs (Fabian et al., 2010). 
The fact that miRNAs are aberrantly expressed in many cancers has made them attractive 
candidates for potential use in cancer therapy (Garofalo and Croce, 2011). However, the 
clinical utility of miRNAs in cancer therapy rests heavily upon our ability to understand 
and accurately predict the consequences of fluctuations in levels of miRNAs within the 
context of complex tumor cells. While the regulatory effects of miRNAs in tumor cells is 
known to be complex (Farazi et al., 2011; Lee and Dutta, 2009) the molecular basis of 
this complexity is only beginning to be explored (Chang et al., 2007; Farazi et al., 2011; 
Hatley et al., 2010; He et al., 2007b; He et al., 2005; Huang et al., 2009). In this paper, 
we present evidence that a significant component of this complexity may involve the 
ability of miRNAs to regulate other miRNAs indirectly through the action of trans-
regulatory proteins. Our findings underscore the complexity of miRNA-mediated 
regulation in cancer cells and the necessity of better understanding the basis of this 





Materials and Methods 
Cell culture and miRNA/siRNA transfections 
Cell culture conditions and miRNA/siRNA transfection procedures were done as 
described previously (CHAPTER 2 and CHAPTER 3). Briefly, the cells were transfected 
with the miRNA hsa-miR-7 miRIDIAN mimic, miRIDIAN miRNA mimic negative 
control #1 (miR-NC, a C.elegans miRNA, cel-miR-67, with confirmed minimal sequence 
identity in humans), ON-TARGET plus Anti-EGFR siRNA, ON-TARGET plus Anti-
RELA siRNA or ON-TARGET plus non-targeting siRNA (siNC; Thermo Fisher 
Scientific, Lafayette, CO) using Lipofectamine 2000 transfection agent (Invitrogen, 
Carlsbad, CA) according to the manufacturer's instructions at a final concentration of 
25nM. All transfections were carried out with at least two to three independent replicates. 
The cells were incubated with the reduced serum transfection medium (Opti-MEM, 
Invitrogen) for 4 hours, washed and then allowed to grow in growth medium (RPMI 
1640, Mediatech, Manassas, VA) for 44 hours before collecting RNA or protein. 
Transfection efficiency was estimated from the relative knock-down of EGFR/RELA, 
based on recommendations by the reagent manufacturer (Thermo Fisher Scientific). 
 
Quantitative (real-time) PCR  
For miRNA qPCR, total RNA was extracted from HEY cells using the mirVana 
miRNA isolation kit according to the manufacturer's instructions (Applied Biosystems, 
Foster City, CA). The RNA (10 ng) was then converted to amplified cDNA for qPCR by 
using the TaqMan miRNA Reverse Transcription Kit and miRNA specific primers 
(Applied Biosystems, Foster City, CA) following manufacturer’s protocols. TaqMan 
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miRNA assays (Applied Biosystems) were conducted following manufacturer's protocol 
for hsa-miR-198, hsa-miR-628-3p, hsa-miR-149, hsa-miR-10b, hsa-let-7f, hsa-miR-503, 
hsa-miR-218, hsa-miR-224, and for RNU6B. Specificity of TaqMan miRNA assays is 
supported by publications from the manufacturer (Chen et al., 2007; Liang et al., 2007; 
Tavazoie et al., 2008) as well as subsequent literature from independent groups (Huang et 
al., 2011; Shibata et al., 2011; Wilson et al., 2011). 
For mRNA qPCR, total RNA (1-5µg) extracted from cells was converted to 
cDNA using the Superscript III First Strand synthesis system (Invitrogen). cDNA was 
then purified using the QIAGEN PCR purification kit (QIAGEN) following 
manufacturer’s instructions. TaqMan gene expression assays were conducted following 
manufacturer’s protocol for MGC16121, FSTL1, GAPDH, RELA, and SFRS1. QPCR 
experiments were also carried out for the EGFR and GAPDH genes as described in 
CHAPTER 3. All reactions were optimized with non-template controls, and -RT (minus 
reverse transcriptase) controls prior to experiment. Specificity of TaqMan gene 
expression assays is supported by thousands of independent citations (e.g., Bergmann et 
al., 2011; Colazzo et al., 2011; Hevir et al., 2011; Lossos et al., 2004) 
All qPCR experiments were carried out using at least three technical replicates 
and two-three independent biological replicates on the CFX96 Real Time PCR detection 
system (Bio-Rad). For each target expression values were normalized to an endogenous 
control (RNU6B/GAPDH). Relative fold change of target RNA level between 
transfection groups was determined by the ∆∆Ct method. Statistical significance was 
determined using the pair-wise fixed reallocation randomization test in the Relative 





Immunoblotting for EGFR and β-Actin was performed as described previously in 
CHAPTER 3.  
 
RNA isolation for miRNA microarray 
Total RNA was isolated from HEY cells (two replicates per group) using the 
mirVana miRNA isolation kit according to the manufacturer's instructions (Applied 
Biosystems, Foster City, CA). The quantity and size of miRNA was verified using an 
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). MiRNAs were labeled 
with Genisphere FlashTag HSR Biotin RNA labeling kit (Genisphere, Hatfield, PA) 
followed by hybridization with GeneChip miRNA Array chips (Affymetrix, Santa Clara, 
CA) according to the manufacturer's instructions. The chips were washed and then 
scanned with a GeneChip Scanner 3000 (Affymetrix). Raw data in the form of CEL files 
were produced by the Affymetrix GeneChip Operating System (GCOS) software.  
 
RNA isolation for whole genome microarray 
Total RNA isolation for whole genome microarray was performed as described in 
CHAPTER 2 using the RNeasy Mini RNA isolation kit (QIAGEN, Valencia, CA) 
according to the manufacturer’s instructions. The integrity of the RNA was verified using 
an Agilent 2100 Bioanalyzer (1.8-2.0; Agilent Technologies, Palo Alto, CA). 
Subsequently cDNA synthesis, amplification and hybridization on Affymetrix HG-U133 




Microarray data analysis 
Raw data from miRNA microarray were analyzed using miRNA QC Tool 
software (Affymetrix, Santa Clara, CA). Normalization was performed using the default 
workflow of the miRNA QC Tool software. The log base 2 transformed expression 
values were then normalized across samples by Z-score calculations using Spotfire 
DecisionSite for Microarray Analysis (DSMA). Probesets with ‘FALSE’ call in all 
groups were removed from statistical analysis. Probeset intensities were filtered with 
DSMA using a modulation threshold of 0.5 to include only those probesets with at least a 
fold change ≥1.4. Differentially expressed probesets were identified using the SAM 
algorithm at a threshold 5 % false discovery rate correction. Sequence of each 
differentially expressed miRNA probeset was then used to find the corresponding human 
miRNA using BLASTN algorithm available on the miRBase webpage with the default E-
value cut-off of 10. In each case, only the human miRNA with the highest score and 
lowest E-value was considered. If two miRNAs had the same high score, then both were 
included. Sequences with 1<E-value<10 were included in the table but were excluded 
from further analysis because of their “poor homology”. Sequences with E-value >10 for 
human miRNAs are ignored and marked with “N/A” under the ‘homolog’ columns of 
Tables C.1 and C.5. Genomic locations of miRNA paralogs were obtained from the 
miRBase registry as well. In the miR-7 transfection experiment these probesets 
correspond to seventy-one unique mature human miRNAs (excluding miR-7), three 
sequences with very poor (BLASTN E-value >1) homology to human miRNAs, two 
snoRNAs, one vault RNA (a type of small RNA), one tRNA, an mRNA (KIAA1407) 
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fragment, and some sequences that we could not map to the human genome (E-value 
>10).  
Raw data from mRNA microarray were analyzed using the Expression Console 
software (Affymetrix) and using R (www.r-project.org) as described previously in 
CHAPTER 2 with the following modifications. Average probeset intensities for each 
group were calculated based on the log 2 transformed values from PLIER and then 
filtered with DSMA using a modulation threshold of 0.379 to include only those 
probesets with a fold change ≥1.3. The Student’s t-test p-value for each probeset was 
calculated by using the log 2 transformed values after GCRMA normalization. Raw data 
from a previous miR-7 transfection paper (Webster et al., 2009) were downloaded from 
GEO and processed in a similar fashion.  
 
Identification of transcription factors 
Transcription factors were identified by searching for the Gene Ontology (GO) 
biological process annotation “regulation of transcription” for every probeset 
differentially expressed after miR-7 transfection.  
 
MiRNA target download 
  The miRNA target prediction file based on miRanda-mirSVR was downloaded 
from www.microrna.org (August 2010 release; Betel et al., 2008; Enright et al., 2003; 
John et al., 2004). Information about the prediction algorithm, parameter settings and raw 




Identification of putative NF-κB regulated miRNAs 
The coordinates of the putative NF-κB binding sites identified by ChIP-seq in the 
ENCODE project (Birney et al., 2007) were downloaded from the UCSC table browser 
(http://genome.ucsc.edu) based on the NCBI36/hg18 assembly of the human genome for 
each miRNA using a window of ±10 kb around the locus of each pre-miRNA 
corresponding to the differentially expressed miRNAs following miR-7 transfection. 
 
Identification of putative SFRS1 regulated miRNAs 
SFRS1 binding sites identified by (Sanford et al., 2009) using genome-wide 
cross-linked immunoprecipitation and sequencing (CLIP-seq) were downloaded from the 
authors website (with authors permission; 
http://sanfordlab.mcdb.ucsc.edu/Sanford_Lab/Datasets.html). For miRNAs embedded in 
known transcriptional units the SFRS1 sites were searched within the genomic 
coordinates of the host transcript. For intergenic miRNAs, length of the pri-miRNA was 
assumed to be ~4 kb on average with the transcription start site located ~2 kb upstream 
and the poly(A) signal located ~2 kb downstream of the pre-miRNA, and thus the SFRS1 
sites were searched within ±2 kb around each pre-miRNA, based on the average lengths 
of pri-miRNAs described by (Saini et al., 2007). Coordinates of coding transcriptional 
units and pre-miRNAs were obtained from the UCSC genome browser 
(http://genome.ucsc.edu) based on the NCBI36/hg18 assembly of the human genome. 
 
BLAST alignment of miRNAs 
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Sequences of miRNA probesets obtained from the Affymetrix annotation file 
corresponding to the differentially miRNAs following miR-7 transfection were searched 
for significant complementarity to miR-7 using NCBI nucleotide BLAST algorithm 
(http://blast.ncbi.nlm.nih.gov) with the following parameter settings. Under program 
selection optimize for “more dissimilar sequences” was selected, and under algorithm 












 Because miRNAs can affect the expression of hundreds of genes, we sought to 
identify the molecular consequences of miRNA expression pattern changes in an ovarian 
cancer model and the mechanisms responsible for these consequences. The reductionist 
view of single-miRNA/single-target interaction may be inadequate for analyzing 
regulatory networks inside the cell (Shalgi et al., 2009). Hence we took a systems 
approach to identify and characterize the miRNA-mRNA interactions in the preceding 
chapters. In the first study (CHAPTER 2), the global miRNA and mRNA expression 
patterns in ovarian cancer cells were profiled to reveal the underlying complexity of 
miRNA regulation in vivo. Building upon our results, miRNA regulation was examined 
in more detail (CHAPTER 3) uncovering both direct and indirect mechanisms used by 
miRNAs to alter the levels of their target mRNAs. In the final chapter (CHAPTER 4), we 
present the novel finding that miRNA mediated gene regulation has the ability to affect 
the levels of other miRNAs.  
 Until recently, regulators of gene expression were thought to be proteins, such as 
transcription factors, activators and repressors (Mattick, 2007). However this paradigm 
was challenged with the discovery of RNA silencing (Napoli et al., 1990). The genomic 
regions encoding non-coding RNAs (ncRNA), once considered “junk” DNA (Doolittle 
and Sapienza, 1980; Orgel and Crick, 1980), have now been demonstrated to be capable 
of regulating the expression of their protein coding counterparts (Friedman and Jones, 
2009). MiRNAs have emerged as an important class of ncRNAs regulating gene 
expression and affecting pathways important in mammalian development and disease 
(Friedman and Jones, 2009). Because the basic principles of miRNA-target interaction 
are still only partially understood (Brodersen and Voinnet, 2009) and because the indirect 
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effects induced by miRNAs can sometimes mask the predicted direct effects of miRNAs, 
the molecular consequences of altered miRNA levels can be hard to predict and interpret. 
Nevertheless, such knowledge is essential in order to translate the discovery of miRNAs 
and their targets from the bench to life saving drugs at the bedside. 
 The study of these miRNA-target mRNA interactions and subsequent downstream 
effects become even more complex when examined in vivo. This is especially true in the 
context of cancer where genetic mutations, epigenetic modifications, altered protein and 
metabolic networks further add to the regulatory complexity (Volinia et al., 2010; Wang 
et al., 2007). With the advent of high throughput transcriptome analysis in the form of 
microarray and new generation sequencing technologies, changes in the cancer cell have 
been found to occur not only in protein coding genes, but also in the non-coding parts of 
the genome. Understanding the effects of such large-scale changes using a reductionist 
approach is challenging and even impractical (McDonald, in press). However, the 
argument for this ‘bottom-up’ approach is that it allows us to understand the mechanisms 
of regulation with a significant degree of detail. Here, molecular biology and systems 
level analysis were used in combination to analyze the global changes in miRNA and 
mRNA expression in ovarian cancer. The finding described in CHAPTER 2 that only 11 
% of changes in miRNA targets can be attributed to the existing model of miRNA 
regulation is consistent with the ever expanding complexity found in cancer, and it 
suggests the involvement of additional regulatory modalities in the control of transcript 
levels. In light of this finding, the naïve expectation that miRNA up-regulation or down-
regulation in cancer would result in inversely correlated changes in its target genes is 
inadequate. Our results therefore necessitate a more detailed analysis of miRNA 
regulatory networks in the cancer cell. 
 In CHAPTER 3, just such an undertaking is accomplished by using microarray 
analysis to assay changes in global mRNA output caused by single miRNA transfections. 
The results of our analyses suggest that the direct effects of miRNA targeting on the 
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transcriptome are magnified by 3-4 fold because of mRNA changes that occur 
downstream of the initial target(s). While changes in such a large number of transcripts 
potentially could disrupt a large number of pathways, enrichment analysis of pathways 
and network analysis of differentially expressed genes suggest miRNAs are likely to 
affect specific pathways by regulating key genes. In combination with the recent findings 
that miRNAs tend to regulate functionally related genes (He et al., 2010), our results 
suggest that these molecules could be used in a therapeutic setting to target specific 
disease related processes when the genome-wide effects of miRNAs are not counter-
therapeutic and modulate pathways implicated in diseases. 
  The reasons for the large numbers of downstream effects described and presented 
in CHAPTER 3 led us to conclude that there are modes of regulation by miRNAs that 
were previously uncharacterized. In CHAPTER 4, we designed studies to test the 
hypothesis that miRNAs may affect the levels of other mature miRNAs and the data 
presented are consistent with this hypothesis. As each miRNA is predicted to target 
hundreds of genes (Trang et al., 2011), this novel finding may help explain the altered 
expression of thousands of transcripts by a single miRNA. We propose that by having the 
capability to trigger such large scale changes, miRNAs ensure that they maintain cellular 
homeostasis, especially in the face of potential insults from the environment, as well as 
metabolic and inflammatory pathways (Bates et al., 2009). This model is consistent with 
recent reports suggesting several miRNAs may act in a coordinated manner to ensure the 
regulation of target genes and corresponding cellular processes (Volinia et al., 2010; Xu 
et al., 2011). 
 These studies provide new insights on the mechanisms used by miRNAs to 
regulate gene expression and their consequences on the transcriptome and other cellular 
processes. While the discovery of these small regulatory RNAs holds great promise for 
fighting cancer and other diseases, therapeutic success will come only from a systems 
level understanding of the consequences of altering the miRNA levels within the cell. 
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The results presented here suggest that despite the large numbers of off-target transcripts 
altered by miRNAs, they may regulate specific functions within the cell. Recent genomic 
studies of cancer suggest that it is not a disease with random disruptions in genes, but 
rather involves multiple genes within specific regulatory pathways (Jones et al., 2008; 
Parsons et al., 2008). Thus, using miRNAs therapeutically may be a useful strategy as 
they have evolved over millions of years to regulate multiple genes in pathways 
important for eukaryotic development. Future studies need to address the cell and tissue 
specific effects of these molecules in vivo. Additionally, novel delivery tools must be able 
to specifically direct miRNAs to the target sites to avoid the potential harmful effects of 
disrupting miRNA levels in the surrounding cells. Questions related to dosage, kinetics, 
and targeting efficacy also need to be addressed in detail before these miRNAs can be 
used with confidence in the clinic. In combination with existing chemotherapy regimens, 
miRNA based therapy may emerge as an effective strategy for treating cancer and other 















SUPPLEMENTARY INFORMATION FOR CHAPTER 2 
 
Table A.1. Differentially expressed miRNA probesets detected by microarray. Forty-two differentially expressed miRNA 
probesets in three CEPI and three OSE samples as analyzed by microarray (Ambion miRChip V1). These probesets were selected 
based on a p-value <0.01, log2 difference ≥1, and Affymetrix “Present/Marginal” call in at least 1 sample. The mature miRNA names 
and the sequences corresponding to each probeset, the average log expression values from the OSE and CEPI samples, as well as, the 
log2 difference and t-test p-value calculated from these are given. Probesets that do not refer to miRNAs currently annotated in Sanger 


























NA (has been removed from database 
due to changes in annotation) 0.007681288 12.425 10.358 -2.068 
hsa-miR-
320_st1 hsa-miR-320a AAAAGCUGGGUUGAGAGGGCGAA 0.002455114 10.227 8.363 -1.864 
hsa-asg-
5208_st1 Exploratory UUCUAGUGGGGGGUAGAUGUCA 0.001721781 6.827 4.985 -1.842 
hsa-asg-
4118_st1 Exploratory UUGGAAAGGGGGUUUGGGACUC 0.001094825 7.325 5.825 -1.500 















11500_st1 Exploratory AGGAGCAGGCUGUGUGGGCCUC 0.00650681 6.053 4.677 -1.375 
hsa-asg-
3670_st1 Exploratory GGAGGUGGAGGGGAGCAGGAUU 9.07E-05 9.369 8.184 -1.185 
hsa-asg-
6021_st2 Exploratory UGGGGGAGGAGGUCAGUGAGGC 0.0055479 8.550 7.412 -1.138 
hsa-asg-
11373_st1 Exploratory UUGUGAGAGGGGAGACUUGGCA 0.001975077 7.042 8.174 1.132 
hsa-asg-
13500_st1 Exploratory GGUGGCCAGGUGCAUAUCUUGG 0.004985624 7.302 9.039 1.737 
hsa-asg-
3101_st2 Exploratory AAAUGGGGAGAAGGCAGG 0.008239333 5.341 7.195 1.854 
hsa-asg-
8336_st2 Exploratory UGUUGAAUCUGAGGGCCAGGCU 0.003692066 6.330 8.236 1.905 
hsa-asg-
5405_st2 Exploratory UAGGCUGAGCUCAGGGUUCAGG 0.005112173 3.859 5.838 1.980 
hsa-asg-
11695_st2 Exploratory CCUGGCAAGGCUUGAUUGCUUU 0.001549414 2.365 4.521 2.156 
hsa-asg-




38_st1 cel-miR-38 UCACCGGGAGAAAAACUGGAGU 0.009709809 4.452 6.911 2.459 
hsa-
cand493_st1 Exploratory UAAAAUAUGCCUGUGGGGAGC 0.006326216 6.025 8.552 2.527 















12049_st2 Exploratory UAAUCACUAGAGCGGGGACUCA 0.006562359 6.340 8.929 2.589 
hsa-asg-
9752_st2 Exploratory UAGAGCAAUGUGUAGGAGAGGC 0.006853174 3.575 6.488 2.913 
hsa-asg-
6879_st1 Exploratory CCAAACUAUGGAUGGACGAAGA 9.79E-05 4.339 7.468 3.129 
hsa-asg-
1514_st1 Exploratory GCCUAGUCCCAGGGAGACAGCC 0.006838428 3.014 6.266 3.252 
hsa-asg-
6932_st1 Exploratory CAGGGAGCCUGAGUAACUGGAA 0.002984173 5.404 8.947 3.543 
hsa-asg-
5640_st1 Exploratory UCCCAGCGGUGCCUCCA 0.003286316 11.494 15.040 3.547 
hsa-asg-
11988_st1 Exploratory GGUGCUGUUUAUGGGAGCAGGG 0.005693259 3.996 7.630 3.635 
hsa-
cand794_st2 Exploratory CUCCAGCGGGGAGUUUGCCAG 0.005342086 3.267 7.249 3.981 
hsa-asg-
8711_st1 Exploratory CAAGGCCAGAGGGCAUUCAAGU 0.001001302 2.150 6.281 4.131 
hsa-asg-
2267_st2 Exploratory UGUCAUUUGGGCUGGGCU 0.008303415 2.825 7.124 4.299 
hsa-miR-
128a_st2 hsa-miR-128 UCACAGUGAACCGGUCUCUUUU 0.009837739 2.968 7.907 4.938 
hsa-miR-
18b_st1 hsa-miR-18b UAAGGUGCAUCUAGUGCAGUUA 0.00085144 1.732 6.893 5.162 
hsa-miR-
7_st1 hsa-miR-7 UGGAAGACUAGUGAUUUUGUUG 0.000683997 1.824 7.210 5.386 















7839_st2 Exploratory CCUGGGACUCUGAAUCCAGCUG 0.003526797 1.924 7.334 5.410 
hsa-
cand497_st1 hsa-miR-126 UCGUACCGUGAGUAAUAAUGC 0.008383114 3.526 8.970 5.444 
hsa-miR-
429_st1 hsa-miR-429 UAAUACUGUCUGGUAAAACCGU 0.004302851 2.322 7.773 5.451 
hsa-asg-
2025_st2 hsa-miR-93* ACUGCUGAGCUAGCACUUCCCG 0.005915096 0.164 5.811 5.647 
ppy-miR-
141_st1 ppy-miR-141 AACACUGUCUGGUAAAGAUGG 0.002244399 3.149 8.835 5.686 
hsa-miR-
18a_st1 hsa-miR-18a UAAGGUGCAUCUAGUGCAGAUA 0.00182884 1.569 7.354 5.785 
hsa-asg-
14002_st1 Exploratory CCUCUCAGUUUAGGAGGGCCGU 0.002658157 3.071 8.922 5.851 
hsa-asg-
10048_st1 Exploratory AUCACCCAGGUGACAGCGAGCA 0.005840041 0.423 6.538 6.115 
hsa-miR-
141_st1 hsa-miR-141 UAACACUGUCUGGUAAAGAUGG 0.000944845 2.852 9.210 6.358 
hsa-miR-
205_st1 hsa-miR-205 UCCUUCAUUCCACCGGAGUCUG 0.004225528 1.901 8.409 6.507 
hsa-miR-
126_st2 hsa-miR-126 UCGUACCGUGAGUAAUAAUGC 0.000925874 1.922 9.057 7.135 
** miR-768 overlaps an annotated snoRNA, HBII-239. Phylogenetic analysis in all vertebrates supports the snoRNA annotation, with 
poor conservation of the reported mature miRNA sequence (Weber M, pers comm). It is therefore removed from miRBase.
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Table A.2. Differentially expressed mRNA probes in CEPI compared to OSE. 
Differentially expressed mRNA probesets between three CEPI samples and OSE from 
five normal samples as analyzed by microarray (Affymetrix HG-U133 Plus 2.0). These 
probesets were selected based on a p-value <0.005, fold change ≥2, and Affymetrix 
“Present/Marginal” call in at least 1 sample. The gene symbols corresponding to each 
probeset ID, the average log expression values from the OSE and CEPI samples as well 
as the log2 difference and t-test p-value calculated from these are given. 
 
Please see table on our website: 
http://www.mcdonaldlab.biology.gatech.edu/shubin_shahab.htm 
 
Table A.3. IC, PC and NC targets of miRNAs in tissue samples. Target predictions 
from miRanda (M), TargetScan (TS) and PicTar (PT) programs were downloaded (see 
methods for details) for each of the 12 annotated miRNAs. MiRNA targets that were 
differentially expressed between CEPI and OSE based on t-test p <0.005 and fold change 
of at least 2 were classified as being IC or PC with their regulating miRNAs (while target 
genes that do not meet the above criteria are classified as NC). The IC targets are shown 
in green, PC targets are shown in red, and blue represents NC targets. Targets with 
“Absent” calls in all samples have been removed. For miR-93*, TargetScan custom 
(TScustom; http://www.targetscan.org/vert_50/seedmatch.html) was used to generate 
TargetScan predictions. For hsa-miR-429 and hsa-miR-93* there were no PicTar 
predictions and thus targets of these miRNAs were excluded for analysis when 
calculating intersections. 
 
Please see table on our website: 
http://www.mcdonaldlab.biology.gatech.edu/shubin_shahab.htm 
 
Table A.4. Differentially expressed genes between miR-7 transfected and negative 
control transfected HEY cells. Differentially expressed genes (fold change ≥1.4, FDR 
≤5%) in three samples of miR-7 transfected cells compared to three samples of miR-NC 
transfected cells. ‘Probeset ID’ refers to Affymetrix HG-U133 Plus 2.0 probeset 
identifier. ‘Gene Symbol’ shows the official gene symbol for the corresponding Probeset 
ID. ‘Log difference (miR7-miR-NC)’ refers to the difference between average log2 signal 
values of miR-7 transfected group and the miR-NC transfected group. ‘q-value (%)’ 
shows the false discovery rate calculated using the SAM algorithm. Targets of miR-7 




Please see table on our website: 
http://www.mcdonaldlab.biology.gatech.edu/shubin_shahab.htm 
 
Table A.5. Differentially expressed genes between miR-128 transfected and negative 
control transfected HEY cells. Differentially expressed genes (fold change ≥1.4, FDR 
≤5 %) between two samples of miR-128 transfected cells compared to three samples of 
miR-NC transfected cells. ‘Probeset ID’ refers to Affymetrix HG-U133 Plus 2.0 probeset 
identifier. ‘Gene Symbol’ shows the official gene symbol for the corresponding Probeset 
ID. ‘Log difference (miR128-miR-NC)’ refers to the difference between average log2 
signal values of miR-128 transfected group and the miR-NC transfected group. ‘q-value 
(%)’ shows the false discovery rate calculated using the SAM algorithm. Predicted 
targets from miRanda (M), TargetScan (TS), and PicTar (PT) are also shown. 
 






Figure A.1. Confirmation of successful miR-7 and miR-128 transfection into HEY 
cells. Successful transfection of miR-7 and miR-128 was confirmed by assaying the 
relative down-regulation of their respective validated targets EGFR and BMI1. Here we 
confirmed successful transfection of the miRNAs into HEY cells by measuring EGFR 
and BMI1 RNA levels using qPCR following transfection of either miR-NC or 
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miR7/miR-128 into HEY cells. Transfection of miR-7 or miR-128 down-regulated EGFR 




SUPPLEMENTARY INFORMATION FOR CHAPTER 3 
 
Table B.1. Differentially expressed genes in miR-7 transfected HEY cells. Genes 
differentially expressed (fold change ≥1.4, FDR ≤5 %) in three samples of HEY ovarian 
cancer cells transfected with miR-7 compared to three samples of HEY cells transfected 
with negative control miRNA (miR-NC). ‘Probeset ID’ refers to Affymetrix HG-U133 
Plus 2.0 probeset identifier. ‘Gene Symbol’ shows the official gene symbol for the 
corresponding Probeset ID. ‘miR7-miR-NC’ refers to the difference between average 
log2 signal values (i.e. the log2 of the ratio of signal values) of miR-7 transfected group 
and the miR-NC transfected group. ‘q-value (%)’ shows the false discovery rate 
calculated using the SAM algorithm. miRanda predicted targets of miR-7 are listed in the 
column titled ‘miR7tgts_M’, TargetScan predicted targets of miR-7 are listed under the 
heading miR-7tgts_TS, and predicted PicTar targets of miR-7 are listed under the 
heading miR-7tgts_PT. 
 
Please see our table on our website: 
http://www.mcdonaldlab.biology.gatech.edu/shubin_shahab.htm 
 
Table B.2. Differentially expressed genes in miR-128 transfected HEY cells. 
Differentially expressed genes (fold change ≥1.4, FDR ≤5 %) between two samples of 
miR-128 transfected cells, compared to three samples of miR-NC transfected cells. 
‘Probeset ID’ refers to Affymetrix HG-U133 Plus 2.0 probeset identifier. ‘Gene Symbol’ 
shows the official gene symbol for the corresponding Probeset ID. ‘miR128-miR-NC’ 
refers to the difference between average log2 signal values of miR-128 transfected group 
and the miR-NC transfected group. ‘q-value (%)’ shows the false discovery rate 
calculated using the SAM algorithm. miRanda predicted targets of miR-128 are listed in 
the column titled ‘miR-128tgts_M’, TargetScan predicted targets of miR-128 are listed 
under the heading miR-128tgts_TS, and PicTar predicted targets of miR-128 are listed 
under the heading miR-128tgts_PT. 
 





Table B.3. MiRNA target enrichment analysis among up-regulated genes following 
miR-128 transfection. Genomica enrichment (FDR <0.05) of miRNA targets among 
significantly up-regulated genes following miR-128 transfection into HEY cells. 
Regulating miRNAs are predicted based on prediction programs miRanda (those with the 
prefix John04 or SloanKettering), TargetScan or PicTar. The sets are classified into either 
Table B.3 (continued) 
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targeting “down” genes, i.e. down-regulated in the transfection, or “up” genes. The other 
columns show the p-value of enrichment, the number of genes that are in each set in our 
dataset, compared to the number of genes in each set in the background Affymetrix chip. 
The percentages calculated from raw numbers of genes that belong in each set are also 
shown.  
 










































































































































8 3.08 868 43407 2 
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8 2.66 739 43407 1.71 
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8 2.29 561 43407 1.3 
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8 2.61 664 43407 1.53 
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8 3.08 943 43407 2.18 
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8 0.56 57 43407 0.14 
 
 
Table B.4. MiRNA target enrichment analysis among up-regulated genes following 
miR-7 transfection. Genomica enrichment (FDR <0.05) of miRNA targets among 
significantly up-regulated genes following miR-7 transfection into HEY cells. Regulating 
miRNAs are predicted based on prediction programs miRanda (those with the prefix 
John04 or SloanKettering), TargetScan or PicTar. The sets are classified into either 
targeting “down” genes, i.e. down-regulated in the transfection, or “up” genes. The other 
columns show the p-value of enrichment, the number of genes that are in each set in our 
dataset, compared to the number of genes in each set in the background. The percentages 




































-06 11 174 6.33 471 43407 1.09 
 
Table B.5. Microarray expression levels of untransfected HEY cell miRNAs. Signal 
values from Affymetrix microarray analysis of miRNA expression from two independent 
samples of untransfected HEY cells. ‘Probeset name’ refers to the unique Affymetrix 
identifier for sequences on the chip. The log2 transformed signal values for each cell 
sample and the p-value of detection is also shown. Signal values with Wilcoxon p <0.06 
of detection are called “TRUE”. The ‘mean signal’ column shows the average of the log2 
signal values from the two HEY cell signal columns.  
 
Please see table on our website: 
http://www.mcdonaldlab.biology.gatech.edu/shubin_shahab.htm 
 
Table B.6. Hub genes and their targets affected by miR-7 in HEY cells. GeneGo was 
used to analyze the most significant interactions within the set of differentially expressed 
genes following miR-7 transfection. The analysis gives a list of “hub” genes interacting 
with other differentially expressed genes (i.e. nodes) which suggests that miRNA are 
regulating the node genes indirectly through regulating the hubs. ‘IDs in active dataset’ 
refer to the Probeset IDs in the dataset that passed the GeneGo FDR threshold of 5 % and 
are acting as hubs. Corresponding GeneGo gene identifiers are given in ‘Object name’ 
column. ‘IDs of corresponding network object from GeneGo network’ refer to probeset 
IDs of objects in the dataset that the hubs are interacting with in GeneGo networks. The 
names of these nodes are given in the last column. If a hub gene is found to regulate 
another gene which may also act as a hub then the row is shaded. 
 




IDs of corresponding 
network object from 
GeneGo network 
Corresponding 










subunit) 1564907_s_at; 242260_at Matrin-3 
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IDs of corresponding 
network object from 
GeneGo network 
Corresponding 






































































subunit) 205067_at; 39402_at IL-1 beta 
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IDs of corresponding 
network object from 
GeneGo network 
Corresponding 











































































subunit) 217996_at PHLDA1 
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IDs of corresponding 
network object from 
GeneGo network 
Corresponding 


















































subunit) 240221_at Casein kinase I alpha 
202827_s_at MMP-14 201010_s_at TXNIP (VDUP1) 







202827_s_at MMP-14 201920_at; 230494_at GLVR1 
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IDs of corresponding 
network object from 
GeneGo network 
Corresponding 
network object name 
202827_s_at MMP-14 202007_at Nidogen 
202827_s_at MMP-14 202267_at LAMC2 
202827_s_at MMP-14 202443_x_at; 212377_s_at NOTCH2 
202827_s_at MMP-14 202620_s_at PLOD2 
202827_s_at MMP-14 202859_x_at; 211506_s_at IL-8 
202827_s_at MMP-14 203821_at; 38037_at HB-EGF 
202827_s_at MMP-14 203888_at Thrombomodulin 
202827_s_at MMP-14 205227_at IL1RAP 
202827_s_at MMP-14 207332_s_at; 208691_at TfR1 
202827_s_at MMP-14 209281_s_at PMCA1 
202827_s_at MMP-14 
210495_x_at; 211719_x_at; 
212464_s_at; 216442_x_at Fibronectin 
202827_s_at MMP-14 211607_x_at EGFR 
202827_s_at MMP-14 212097_at Caveolin-1 
202827_s_at MMP-14 212761_at TCF7L2 (TCF4) 
202827_s_at MMP-14 224953_at YIPF5 
202827_s_at MMP-14 226217_at ZnT7 
202827_s_at MMP-14 226545_at; 229900_at CD109 
202827_s_at MMP-14 232231_at RUNX2 
202827_s_at MMP-14 239627_at TMED9 
202827_s_at MMP-14 34478_at Rab-11B 
Table B.6 (continued) 
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IDs of corresponding 
network object from 
GeneGo network 
Corresponding 
network object name 
206011_at Caspase-1 1554479_a_at; 204950_at CARD8 




206011_at Caspase-1 1564907_s_at; 242260_at Matrin-3 
206011_at Caspase-1 200681_at Glyoxalase I 
206011_at Caspase-1 
200755_s_at; 200756_x_at; 
200757_s_at; 214845_s_at Calumenin 
206011_at Caspase-1 203555_at PTPN18 
206011_at Caspase-1 205067_at; 39402_at IL-1 beta 
206011_at Caspase-1 205416_s_at MJD (ataxin-3) 
206011_at Caspase-1 208374_s_at CAPZA1 
206011_at Caspase-1 209615_s_at; 226507_at PAK1 
206011_at Caspase-1 209822_s_at VLDLR 
206011_at Caspase-1 214291_at RPL17 
206011_at Caspase-1 218850_s_at LIMD1 




209037_s_at EHD1 201783_s_at; 230202_at 
RelA (p65 NF-kB 
subunit) 
209037_s_at EHD1 222597_at SNAP-29 
209037_s_at EHD1 226581_at Rabenosyn-5 
Table B.6 (continued) 
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IDs of corresponding 
network object from 
GeneGo network 
Corresponding 
network object name 
209037_s_at EHD1 227428_at GABP alpha 
209112_at p27KIP1 200952_s_at Cyclin D2 
209112_at p27KIP1 201549_x_at; 211202_s_at PLU-1 
209112_at p27KIP1 201783_s_at; 230202_at 
RelA (p65 NF-kB 
subunit) 
209112_at p27KIP1 203358_s_at EZH2 
209112_at p27KIP1 204254_s_at VDR 
209112_at p27KIP1 204872_at TLE4 
209112_at p27KIP1 205899_at Cyclin A1 
209112_at p27KIP1 210743_s_at CDC14a 




209112_at p27KIP1 220266_s_at; 221841_s_at KLF4 
209112_at p27KIP1 224851_at CDK6 
209112_at p27KIP1 225984_at AMPK alpha 1 subunit 
209112_at p27KIP1 232466_at Cullin 4A 
209822_s_at VLDLR 201042_at TGM2 
209822_s_at VLDLR 201109_s_at Thrombospondin 1 
209822_s_at VLDLR 209676_at; 213258_at TFPI 
209822_s_at VLDLR 223130_s_at MIR (Idol) 
211607_x_at EGFR 1564907_s_at; 242260_at Matrin-3 
Table B.6 (continued) 
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IDs of corresponding 
network object from 
GeneGo network 
Corresponding 
network object name 
211607_x_at EGFR 200690_at GRP75 
211607_x_at EGFR 200998_s_at; 200999_s_at CLIMP-63 
211607_x_at EGFR 201096_s_at ARF4 
211607_x_at EGFR 201244_s_at c-Raf-1 
211607_x_at EGFR 202267_at LAMC2 
211607_x_at EGFR 203821_at; 38037_at HB-EGF 
211607_x_at EGFR 204011_at SPRY2 
211607_x_at EGFR 204254_s_at VDR 
211607_x_at EGFR 204686_at IRS-1 
211607_x_at EGFR 205016_at; 211258_s_at TGF-alpha 
211607_x_at EGFR 205447_s_at ZPK(MAP3K12) 
211607_x_at EGFR 206011_at Caspase-1 
211607_x_at EGFR 208958_at ERp44 
211607_x_at EGFR 209409_at GRB10 
211607_x_at EGFR 209615_s_at; 226507_at PAK1 
211607_x_at EGFR 
210495_x_at; 211719_x_at; 
212464_s_at; 216442_x_at Fibronectin 
211607_x_at EGFR 210517_s_at AKAP12 
211607_x_at EGFR 211063_s_at NCK1 
211607_x_at EGFR 212097_at Caveolin-1 
211607_x_at EGFR 212761_at TCF7L2 (TCF4) 
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IDs of corresponding 
network object from 
GeneGo network 
Corresponding 
network object name 
211607_x_at EGFR 212870_at SOS2 
211607_x_at EGFR 213070_at 
PI3K class II (CII-
alpha) 
211607_x_at EGFR 215485_s_at ICAM1 
211607_x_at EGFR 216971_s_at Plectin 1 
211607_x_at EGFR 218310_at RABGEF1 
211607_x_at EGFR 224657_at MIG6 
211607_x_at EGFR 224844_at SLAIN2 
211607_x_at EGFR 224938_at NUFIP2 
211607_x_at EGFR 225231_at; 243475_at c-Cbl 
211607_x_at EGFR 226572_at SOCS7 
211607_x_at EGFR 226934_at CPSF6 
211607_x_at EGFR 234932_s_at CDCP1 
211607_x_at EGFR 235057_at Itch 
211607_x_at EGFR 238855_at AHNAK 








(TCF4) 1555938_x_at Vimentin 
212761_at 
TCF7L2 
(TCF4) 1568574_x_at; 209875_s_at Osteopontin 
212761_at 
TCF7L2 
(TCF4) 200794_x_at DAZAP2 
212761_at 
TCF7L2 
(TCF4) 200952_s_at Cyclin D2 
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IDs of corresponding 
network object from 
GeneGo network 
Corresponding 
network object name 
212761_at 
TCF7L2 
(TCF4) 202859_x_at; 211506_s_at IL-8 
212761_at 
TCF7L2 








(TCF4) 209383_at C/EBP zeta 
212761_at 
TCF7L2 
(TCF4) 210172_at ZNF162 
212761_at 
TCF7L2 
(TCF4) 210255_at RAD51B 
212761_at 
TCF7L2 
(TCF4) 211527_x_at VEGF-A 
212761_at 
TCF7L2 
(TCF4) 220266_s_at; 221841_s_at KLF4 
212761_at 
TCF7L2 
(TCF4) 222449_at PMEPA1 
212761_at 
TCF7L2 
(TCF4) 224851_at CDK6 
212761_at 
TCF7L2 
(TCF4) 224994_at; 225019_at CaMK II delta 
212761_at 
TCF7L2 
(TCF4) 228938_at Myelin basic protein 
212761_at 
TCF7L2 
(TCF4) 232231_at RUNX2 
212761_at 
TCF7L2 




215245_x_at FMR1 202920_at; 202921_s_at Ankyrin-B 
215245_x_at FMR1 209615_s_at; 226507_at PAK1 
215245_x_at FMR1 220099_s_at LUC7L2 
215245_x_at FMR1 220563_s_at SHANK1 
215245_x_at FMR1 222576_s_at eIF2C1 (Argonaute-1) 
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IDs of corresponding 
network object from 
GeneGo network 
Corresponding 
network object name 
215245_x_at FMR1 222956_at Fidgetin 
215245_x_at FMR1 224662_at KIF5B 
215245_x_at FMR1 224938_at NUFIP2 
215245_x_at FMR1 225984_at AMPK alpha 1 subunit 
215245_x_at FMR1 228938_at Myelin basic protein 
215245_x_at FMR1 235057_at Itch 
227025_at PPHLN1 1555938_x_at Vimentin 
227025_at PPHLN1 201042_at TGM2 
227025_at PPHLN1 206011_at Caspase-1 
227025_at PPHLN1 237833_s_at Synphilin 1 
 
 
Table B.7. Hub genes and their targets affected by miR-128 in HEY cells. GeneGo 
was used to analyze the most significant interactions within the set of differentially 
expressed genes following miR-128 transfection. The analysis gives a list of “hub” genes 
interacting with other differentially expressed genes (i.e. nodes) which suggests that 
miRNA are regulating the node genes indirectly through regulating the hubs. ‘IDs in 
active dataset’ refer to the probeset IDs in the dataset that passed the GeneGo FDR 
threshold of 5 % and are acting as hubs. Corresponding GeneGo gene identifiers are 
given in ‘object name’ column. ‘IDs of corresponding network object from GeneGo 
network’ refer to probeset IDs of objects in the dataset that the hubs are interacting with 
in GeneGo networks. The names of these nodes are given in the last column. If a hub 
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Please see table on our website: 
http://www.mcdonaldlab.biology.gatech.edu/shubin_shahab.htm 
 
Table B.8. Significantly enriched GeneGo pathway maps among the differentially 
expressed genes following miR-7 transfection into HEY cells. GeneGo pathway maps 
significantly enriched (FDR <0.05) among the differentially expressed genes after miR-7 
transfection into HEY cells are listed. Also shown are the hypergeometric distribution p-
values of enrichments from GeneGo and the ratio of number of genes actually present in 
the dataset to the number of genes in the Affymetrix array that are in each pathway. 
Pathways are sorted based on p-values.  
 
Maps p-value ratio 
Cell adhesion_Chemokines and adhesion 1.31E-07 15/100 
Cell cycle_Regulation of G1/S transition (part 1) 8.68E-07 9/38 
Cell adhesion_Ephrin signaling 3.96E-06 9/45 
Development_EGFR signaling pathway 1.02E-05 10/63 
Development_ERBB-family signaling 1.13E-05 8/39 
Development_WNT signaling pathway. Part 1. Degradation of 
beta-catenin in the absence WNT signaling 1.42E-05 6/20 
Development_VEGF-family signaling 1.68E-05 8/41 
Cytoskeleton remodeling_Cytoskeleton remodeling 3.13E-05 12/102 
Neurophysiological process_Receptor-mediated axon growth 
repulsion 3.43E-05 8/45 
Proteolysis_Putative ubiquitin pathway 3.44E-05 6/23 
Development_TGF-beta-dependent induction of EMT via RhoA, 
PI3K and ILK.  4.05E-05 8/46 
Cell adhesion_Plasmin signaling 4.85E-05 7/35 
Development_TGF-beta-dependent induction of EMT via SMADs  4.85E-05 7/35 
Transport_RAB5A regulation pathway 5.75E-05 6/25 
Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 7.29E-05 12/111 
Cell cycle_Regulation of G1/S transition (part 2) 7.30E-05 6/26 
Apoptosis and survival_HTR1A signaling 7.54E-05 8/50 
Development_Regulation of epithelial-to-mesenchymal transition 
(EMT) 7.67E-05 9/64 
Translation _Regulation of EIF2 activity 1.01E-04 7/39 
Cell adhesion_ECM remodeling 1.01E-04 8/52 
Translation _Regulation of EIF4F activity 1.16E-04 8/53 
Translation_Non-genomic (rapid) action of Androgen Receptor 1.19E-04 7/40 
Apoptosis and survival_NO synthesis and signaling 1.51E-04 8/55 
Immune response_Neurotensin-induced activation of IL-8 in 
colonocytes 1.64E-04 7/42 
Apoptosis and survival_TNFR1 signaling pathway 1.91E-04 7/43 
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Role of alpha-6/beta-4 integrins in carcinoma progression 2.57E-04 7/45 
Development_EPO-induced MAPK pathway 2.57E-04 7/45 
dCTP/dUTP metabolism 2.66E-04 9/75 
Development_GDNF family signaling 2.95E-04 7/46 
Signal transduction_PTEN pathway 2.95E-04 7/46 
Cytoskeleton remodeling_CDC42 in cellular processes 3.24E-04 5/22 
Development_TGF-beta-dependent induction of EMT via MAPK  3.39E-04 7/47 
Development_Gastrin in cell growth and proliferation 3.54E-04 8/62 
Proteolysis_Role of Parkin in the Ubiquitin-Proteasomal Pathway 4.99E-04 5/24 
Development_Dopamine D2 receptor transactivation of EGFR 4.99E-04 5/24 
Development_TGF-beta receptor signaling 5.00E-04 7/50 
Transport_RAB3 regulation pathway 5.20E-04 4/14 
Development_IGF-1 receptor signaling 5.66E-04 7/51 
Membrane-bound ESR1: interaction with G-proteins signaling 5.66E-04 7/51 
Immune response_Role of integrins in NK cells cytotoxicity 6.57E-04 6/38 
Development_WNT signaling pathway. Part 2 7.18E-04 7/53 
Neurophysiological process_Dopamine D2 receptor 
transactivation of PDGFR in CNS 7.36E-04 5/26 
Immune response_Gastrin in inflammatory response 7.37E-04 8/69 
Transcription_Receptor-mediated HIF regulation 7.58E-04 6/39 
Regulation of degradation of deltaF508 CFTR in CF 8.83E-04 5/27 
PGE2 pathways in cancer 9.00E-04 7/55 
Regulation of lipid metabolism_Stimulation of Arachidonic acid 
production by ACM receptors 9.80E-04 8/72 
Development_Mu-type opioid receptor regulation of proliferation 1.05E-03 5/28 
Cytoskeleton remodeling_FAK signaling 1.12E-03 7/57 
Apoptosis and survival_BAD phosphorylation 1.14E-03 6/42 
Development_Role of IL-8 in angiogenesis 1.24E-03 7/58 
Development_VEGF signaling and activation 1.29E-03 6/43 
Regulation of degradation of wt-CFTR 1.45E-03 4/18 
Immune response_IL-4 - antiapoptotic action 1.45E-03 5/30 
dATP/dITP metabolism 1.64E-03 9/96 
Cytoskeleton remodeling_Fibronectin-binding integrins in cell 
motility 1.69E-03 5/31 
Cytoskeleton remodeling_Reverse signaling by ephrin B 1.69E-03 5/31 
Development_Alpha-2 adrenergic receptor activation of ERK 1.84E-03 7/62 
Development_Endothelin-1/EDNRA transactivation of EGFR 1.84E-03 6/46 
Development_PDGF signaling via STATs and NF-kB 1.96E-03 5/32 
Development_EGFR signaling via small GTPases 1.96E-03 5/32 
Transport_Macropinocytosis regulation by growth factors 2.02E-03 7/63 
Development_FGF2-dependent induction of EMT 2.20E-03 4/20 
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Immune response_CD40 signaling 2.22E-03 7/64 
Development_Angiotensin activation of ERK 2.26E-03 5/33 
Development_A3 receptor signaling 2.56E-03 6/49 
Development_PEDF signaling 2.56E-03 6/49 
G-protein signaling_G-Protein beta/gamma signaling cascades 2.59E-03 5/34 
Cell cycle_Cell cycle (generic schema) 2.66E-03 4/21 
Development_EPO-induced Jak-STAT pathway 2.95E-03 5/35 
Development_EGFR signaling via PIP3 3.76E-03 4/23 
Development_Beta-adrenergic receptors transactivation of EGFR 3.78E-03 5/37 
Development_FGFR signaling pathway 3.82E-03 6/53 
Cell cycle_Influence of Ras and Rho proteins on G1/S Transition 3.82E-03 6/53 
Regulation of lipid metabolism_Regulation of lipid metabolism 
via LXR, NF-Y and SREBP 4.25E-03 5/38 
Regulation of lipid metabolism_Insulin regulation of glycogen 
metabolism  4.61E-03 6/55 
Cell adhesion_PLAU signaling 4.77E-03 5/39 
G-protein signaling_K-RAS regulation pathway 5.13E-03 4/25 
Cytoskeleton remodeling_Neurofilaments 5.13E-03 4/25 
Development_Prolactin receptor signaling 5.99E-03 6/58 
Regulation of CFTR activity (norm and CF) 5.99E-03 6/58 
Translation_Insulin regulation of translation 6.57E-03 5/42 
Immune response_Signaling pathway mediated by IL-6 and IL-1 6.81E-03 4/27 
Immune response_IL-17 signaling pathways 7.07E-03 6/60 
Development_ACM2 and ACM4 activation of ERK 7.27E-03 5/43 
Signal transduction_AKT signaling 7.27E-03 5/43 
Immune response_IL-4 signaling pathway 8.01E-03 5/44 
Development_Flt3 signaling 8.01E-03 5/44 
Development_Activation of Erk by ACM1, ACM3 and ACM5 8.01E-03 5/44 
Development_Ligand-independent activation of ESR1 and ESR2 8.01E-03 5/44 
Transcription_CREB pathway 8.01E-03 5/44 
 
 
Table B.9. Significantly enriched GeneGo pathway maps among the differentially 
expressed genes following miR-128 transfection into HEY cells. GeneGo pathway 
maps significantly enriched (FDR <0.05) among the differentially expressed genes after 
miR-128 transfection into HEY cells are listed. Also shown are the hypergeometric 
distribution p-values of enrichments from GeneGo and the ratio of number of genes 
actually present in the dataset to the number of genes in the Affymetrix array that are in 
each pathway. Pathways are sorted based on p-values.  
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Cell cycle_The metaphase checkpoint 1.01E-11 18/36 
Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 1.29E-09 29/111 
Cell cycle_Role of Nek in cell cycle regulation 1.77E-09 15/32 
Transport_Clathrin-coated vesicle cycle 4.15E-09 22/71 
Cell cycle_Initiation of mitosis 4.37E-09 13/25 
Immune response_Histamine H1 receptor signaling in immune 
response 1.78E-07 16/48 
Cell cycle_Role of APC in cell cycle regulation 1.79E-07 13/32 
Cell cycle_Spindle assembly and chromosome separation 2.75E-07 13/33 
Cytoskeleton remodeling_Cytoskeleton remodeling 2.98E-07 24/102 
Proteolysis_Role of Parkin in the Ubiquitin-Proteasomal Pathway 3.68E-07 11/24 
Cytoskeleton remodeling_Neurofilaments 6.14E-07 11/25 
Cell cycle_Chromosome condensation in prometaphase 8.18E-07 10/21 
Immune response_Gastrin in inflammatory response 1.85E-06 18/69 
Neurophysiological process_Receptor-mediated axon growth 
repulsion 2.69E-06 14/45 
Translation_Non-genomic (rapid) action of Androgen Receptor 3.55E-06 13/40 
Development_PIP3 signaling in cardiac myocytes 4.80E-06 14/47 
Cytoskeleton remodeling_Role of Activin A in cytoskeleton 
remodeling 5.34E-06 9/20 
Apoptosis and survival_Apoptotic Activin A signaling 5.76E-06 10/25 
Apoptosis and survival_BAD phosphorylation 6.54E-06 13/42 
Immune response_Fc epsilon RI pathway 7.40E-06 15/55 
Cytoskeleton remodeling_Reverse signaling by ephrin B 7.70E-06 11/31 
Development_Gastrin in cell growth and proliferation 8.04E-06 16/62 
Immune response_Function of MEF2 in T lymphocytes 1.07E-05 14/50 
Development_Activation of Erk by ACM1, ACM3 and ACM5 1.16E-05 13/44 
Immune response_CD40 signaling 1.25E-05 16/64 
Cell cycle_Role of 14-3-3 proteins in cell cycle regulation 1.38E-05 9/22 
Cell adhesion_Histamine H1 receptor signaling in the interruption 
of cell barrier integrity 1.52E-05 13/45 
Signal transduction_Calcium signaling 1.52E-05 13/45 
Development_TGF-beta-dependent induction of EMT via RhoA, 
PI3K and ILK.  1.98E-05 13/46 
Proteolysis_Putative ubiquitin pathway 2.12E-05 9/23 
Cell cycle_Influence of Ras and Rho proteins on G1/S Transition 2.22E-05 14/53 
Cell cycle_Role of SCF complex in cell cycle regulation 2.69E-05 10/29 
Development_Role of HDAC and calcium/calmodulin-dependent 
kinase (CaMK) in control of skeletal myogenesis 2.79E-05 14/54 
Development_Angiopoietin - Tie2 signaling 2.88E-05 11/35 
Neurophysiological process_EphB receptors in dendritic spine 
morphogenesis and synaptogenesis 2.88E-05 11/35 
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Development_Slit-Robo signaling 3.76E-05 10/30 
Cell adhesion_Chemokines and adhesion 3.83E-05 20/100 
Signal transduction_AKT signaling 4.73E-05 12/43 
Development_A2A receptor signaling 4.73E-05 12/43 
Development_Regulation of epithelial-to-mesenchymal transition 
(EMT) 5.28E-05 15/64 
Cytoskeleton remodeling_FAK signaling 5.37E-05 14/57 
Cell adhesion_Cadherin-mediated cell adhesion 6.61E-05 9/26 
Development_Role of IL-8 in angiogenesis 6.61E-05 14/58 
Role of alpha-6/beta-4 integrins in carcinoma progression 7.72E-05 12/45 
Development_Endothelin-1/EDNRA transactivation of EGFR 9.75E-05 12/46 
Cytoskeleton remodeling_CDC42 in cellular processes 1.14E-04 8/22 
Development_Leptin signaling via PI3K-dependent pathway 1.22E-04 12/47 
Immune response_CD28 signaling 1.23E-04 13/54 
Cell adhesion_Alpha-4 integrins in cell migration and adhesion 1.25E-04 10/34 
G-protein signaling_G-Protein alpha-q signaling cascades 1.25E-04 10/34 
Development_Role of CDK5 in neuronal development 1.25E-04 10/34 
Immune response_IL-15 signaling via JAK-STAT cascade 1.63E-04 8/23 
Cytoskeleton remodeling_Regulation of actin cytoskeleton by Rho 
GTPases 1.63E-04 8/23 
Delta508-CFTR traffic / ER-to-Golgi in CF 1.82E-04 6/13 
Normal wtCFTR traffic / ER-to-Golgi  1.82E-04 6/13 
Immune response_Neurotensin-induced activation of IL-8 in 
colonocytes 1.83E-04 11/42 
Immune response_TREM1 signaling pathway 1.83E-04 13/56 
Immune response_IL-2 activation and signaling pathway 1.88E-04 12/49 
Signal transduction_IP3 signaling 1.88E-04 12/49 
Immune response_IL-15 signaling 2.05E-04 14/64 
Immune response_IL-7 signaling in B lymphocytes 2.29E-04 11/43 
Apoptosis and survival_Anti-apoptotic action of Gastrin 2.29E-04 11/43 
Development_A2B receptor: action via G-protein alpha s 2.31E-04 12/50 
Immune response_CCR5 signaling in macrophages and T 
lymphocytes 2.66E-04 13/58 
wtCFTR and delta508 traffic / Clathrin coated vesicles formation 
(norm and CF) 2.82E-04 7/19 
Development_IGF-1 receptor signaling 2.82E-04 12/51 
Mucin expression in CF via TLRs, EGFR signaling pathways 2.82E-04 12/51 
Development_Flt3 signaling 2.86E-04 11/44 
Transcription_CREB pathway 2.86E-04 11/44 
Cytoskeleton remodeling_Fibronectin-binding integrins in cell 
motility 3.04E-04 9/31 
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Development_Leptin signaling via JAK/STAT and MAPK 
cascades 3.15E-04 8/25 
Signal transduction_Activation of PKC via G-Protein coupled 
receptor 3.42E-04 12/52 
Immune response_Human NKG2D signaling 3.43E-04 10/38 
Regulation of lipid metabolism_Regulation of lipid metabolism 
via LXR, NF-Y and SREBP 3.43E-04 10/38 
Cell cycle_Regulation of G1/S transition (part 1) 3.43E-04 10/38 
Development_Angiotensin signaling via STATs 3.96E-04 9/32 
Development_FGFR signaling pathway 4.13E-04 12/53 
Development_A1 receptor signaling 4.13E-04 12/53 
Development_Cross-talk between VEGF and Angiopoietin 1 
signaling pathways 4.26E-04 8/26 
Immune response_IL-10 signaling pathway 4.26E-04 8/26 
Development_GDNF family signaling 4.33E-04 11/46 
Immune response_MIF - the neuroendocrine-macrophage 
connector 4.33E-04 11/46 
Signal transduction_PTEN pathway 4.33E-04 11/46 
Immune response _IFN gamma signaling pathway 4.96E-04 12/54 
Immune response_BCR pathway 4.96E-04 12/54 
Signal transduction_Activin A signaling regulation 5.08E-04 9/33 
Neurophysiological process_Circadian rhythm 5.28E-04 11/47 
Cytoskeleton remodeling_Role of PKA in cytoskeleton 
reorganization 5.37E-04 10/40 
Reproduction_Progesterone-mediated oocyte maturation 5.37E-04 10/40 
Apoptosis and survival_Anti-apoptotic TNFs/NF-kB/IAP pathway 5.66E-04 8/27 
PGE2 pathways in cancer 5.92E-04 12/55 
Apoptosis and survival_NO synthesis and signaling 5.92E-04 12/55 
Development_EGFR signaling pathway 6.26E-04 13/63 
Transport_Macropinocytosis regulation by growth factors 6.26E-04 13/63 
Cell adhesion_Integrin-mediated cell adhesion and migration 6.40E-04 11/48 
Development_NOTCH1-mediated pathway for NF-KB activity 
modulation 6.46E-04 9/34 
Transport_ACM3 in salivary glands 6.64E-04 10/41 
Muscle contraction_ACM regulation of smooth muscle contraction 7.03E-04 12/56 
Development_A3 receptor signaling 7.71E-04 11/49 
Cell cycle_Sister chromatid cohesion 7.83E-04 7/22 
Transcription_Role of heterochromatin protein 1 (HP1) family in 
transcriptional silencing 7.83E-04 7/22 
Development_EPO-induced Jak-STAT pathway 8.14E-04 9/35 
Immune response_PIP3 signaling in B lymphocytes 8.14E-04 10/42 
Development_TGF-beta receptor signaling 9.23E-04 11/50 
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Regulation of CFTR activity (norm and CF) 9.79E-04 12/58 
Development_VEGF signaling and activation 9.92E-04 10/43 
Cytoskeleton remodeling_Keratin filaments 1.01E-03 9/36 
Development_EGFR signaling via PIP3 1.05E-03 7/23 
Muscle contraction_ GPCRs in the regulation of smooth muscle 
tone 1.07E-03 15/83 
Immune response_NFAT in immune response 1.10E-03 11/51 
Transport_Macropinocytosis 1.15E-03 5/12 
Immune response_IL-1 signaling pathway 1.20E-03 10/44 
Muscle contraction_EDG5-mediated smooth muscle contraction 1.22E-03 8/30 
Cell adhesion_Gap junctions 1.22E-03 8/30 
G-protein signaling_G-Protein alpha-12 signaling pathway 1.25E-03 9/37 
Cell adhesion_Role of tetraspanins in the integrin-mediated cell 
adhesion 1.25E-03 9/37 
Development_Hedgehog and PTH signaling pathways in bone and 
cartilage development 1.25E-03 9/37 
Development_Glucocorticoid receptor signaling 1.39E-03 7/24 
Immune response_Inhibitory action of Lipoxins on pro-
inflammatory TNF-alpha signaling 1.44E-03 10/45 
Development_VEGF signaling via VEGFR2 - generic cascades 1.44E-03 10/45 
Immune response _CCR3 signaling in eosinophils 1.46E-03 14/77 
Development_WNT signaling pathway. Part 2 1.54E-03 11/53 
Development_Gastrin in differentiation of the gastric mucosa 1.54E-03 9/38 
Development_Angiotensin activation of Akt 1.72E-03 10/46 
Immune response_ICOS pathway in T-helper cell 1.72E-03 10/46 
Development_WNT5A signaling 1.72E-03 10/46 
Transcription_Transcription regulation of aminoacid metabolism 1.81E-03 7/25 
Translation _Regulation of EIF2 activity 1.87E-03 9/39 
G-protein signaling_Regulation of p38 and JNK signaling 
mediated by G-proteins 1.87E-03 9/39 
Development_TGF-beta-dependent induction of EMT via MAPK  2.04E-03 10/47 
Neurophysiological process_NMDA-dependent postsynaptic long-
term potentiation in CA1 hippocampal neurons 2.14E-03 14/80 
Development_Role of Activin A in cell differentiation and 
proliferation 2.25E-03 9/40 
Immune response_MIF in innate immunity response 2.25E-03 9/40 
Regulation of lipid metabolism_Stimulation of Arachidonic acid 
production by ACM receptors 2.28E-03 13/72 
DNA damage_ATM / ATR regulation of G2 / M checkpoint 2.32E-03 7/26 
Development_EDG5 and EDG3 in cell proliferation and 
differentiation 2.32E-03 7/26 
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Normal and pathological TGF-beta-mediated regulation of cell 
proliferation 2.38E-03 8/33 
Development_Keratinocyte differentiation 2.45E-03 11/56 
Development_WNT signaling pathway. Part 1. Degradation of 
beta-catenin in the absence WNT signaling 2.62E-03 6/20 
Development_FGF2-dependent induction of EMT 2.62E-03 6/20 
Neurophysiological process_Netrin-1 in regulation of axon 
guidance 2.70E-03 9/41 
Development_Melanocyte development and pigmentation 2.83E-03 10/49 
Development_PEDF signaling 2.83E-03 10/49 
Signal transduction_Erk Interactions: Inhibition of Erk 2.91E-03 8/34 
G-protein signaling_RhoA regulation pathway 2.91E-03 8/34 
Neurophysiological process_GABA-A receptor life cycle 2.94E-03 7/27 
Regulation of degradation of deltaF508 CFTR in CF 2.94E-03 7/27 
Development_Prolactin receptor signaling 3.27E-03 11/58 
Development_EDNRB signaling 3.31E-03 10/50 
Apoptosis and survival_HTR1A signaling 3.31E-03 10/50 
Immune response_Histamine signaling in dendritic cells 3.31E-03 10/50 
Development_GM-CSF signaling 3.31E-03 10/50 
Blood coagulation_GPIb-IX-V-dependent platelet activation 3.32E-03 13/75 
Cell cycle_Cell cycle (generic schema) 3.45E-03 6/21 
Atherosclerosis_Role of ZNF202 in regulation of expression of 
genes involved in Atherosclerosis 3.45E-03 6/21 
Apoptosis and survival_Anti-apoptotic action of membrane-bound 
ESR1 3.53E-03 8/35 
Development_Regulation of telomere length and cellular 
immortalization 3.53E-03 8/35 
Development_Growth hormone signaling via STATs and PLC/IP3 3.53E-03 8/35 
Development_EDG3 signaling pathway 3.80E-03 9/43 
Immune response_HTR2A-induced activation of cPLA2 3.80E-03 9/43 
Signal transduction_PKA signaling 3.85E-03 10/51 
Membrane-bound ESR1: interaction with G-proteins signaling 3.85E-03 10/51 
Chemotaxis_Inhibitory action of lipoxins on IL-8- and 
Leukotriene B4-induced neutrophil migration 3.85E-03 10/51 
Some pathways of EMT in cancer cells 3.85E-03 10/51 
Immune response_IL-17 signaling pathways 4.29E-03 11/60 
Apoptosis and survival_nAChR in apoptosis inhibition and cell 
cycle progression 4.53E-03 7/29 
NGF activation of NF-kB 4.53E-03 7/29 
Immune response_CD137 signaling in immune cell 4.53E-03 7/29 
Cytoskeleton remodeling_ACM3 and ACM4 in keratinocyte 
migration 5.08E-03 8/37 
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Development_Delta-type opioid receptor mediated 
cardioprotection 5.08E-03 8/37 
Development_Beta-adrenergic receptors transactivation of EGFR 5.08E-03 8/37 
Development_Endothelin-1/EDNRA signaling 5.14E-03 10/53 
Neurophysiological process_Glutamate regulation of Dopamine 
D1A receptor signaling 5.23E-03 9/45 
Transcription_Androgen Receptor nuclear signaling 5.23E-03 9/45 
Cell adhesion_Ephrin signaling 5.23E-03 9/45 
Development_Thrombopoietin-regulated cell processes 5.23E-03 9/45 
Cytoskeleton remodeling_RalA regulation pathway 5.54E-03 7/30 
Immune response_Role of DAP12 receptors in NK cells 5.90E-03 10/54 
Immune response_Role of integrins in NK cells cytotoxicity 6.02E-03 8/38 
Immune response_IL-7 signaling in T lymphocytes 6.02E-03 8/38 
Development_Mu-type opioid receptor signaling 6.02E-03 8/38 
Chemotaxis_Lipoxin inhibitory action on fMLP-induced 
neutrophil chemotaxis 6.09E-03 9/46 
Neurophysiological process_ACM regulation of nerve impulse 6.09E-03 9/46 
Reproduction_GnRH signaling 6.49E-03 12/72 
Transcription_Transcription factor Tubby signaling pathways 6.59E-03 5/17 
Development_HGF signaling pathway 7.04E-03 9/47 
Development_Dopamine D2 receptor transactivation of EGFR 7.06E-03 6/24 
Apoptosis and survival_NO signaling in survival 7.06E-03 6/24 
HIV-1 signaling via CCR5 in macrophages and T lymphocytes 7.09E-03 8/39 
Development_ERBB-family signaling 7.09E-03 8/39 
Cell adhesion_PLAU signaling 7.09E-03 8/39 
Muscle contraction_Regulation of eNOS activity in endothelial 
cells 7.11E-03 11/64 
Cell adhesion_Integrin inside-out signaling 7.67E-03 10/56 
Development_PDGF signaling via STATs and NF-kB 8.05E-03 7/32 
Development_Neurotrophin family signaling 8.30E-03 8/40 
Inhibitory action of Lipoxins on neutrophil migration 8.70E-03 10/57 
Immune response_IL-23 signaling pathway 8.71E-03 6/25 
Development_Angiotensin signaling via beta-Arrestin 8.71E-03 6/25 
Cytoskeleton remodeling_Integrin outside-in signaling 9.30E-03 9/49 
Immune response_Bacterial infections in normal airways 9.30E-03 9/49 
Development_Angiotensin activation of ERK 9.57E-03 7/33 
Development_Activation of astroglial cells proliferation by ACM3 9.57E-03 7/33 
Development_Signaling of Beta-adrenergic receptors via Beta-
arrestins 1.06E-02 6/26 
Cytoskeleton remodeling_Alpha-1A adrenergic receptor-
dependent inhibition of PI3K 1.09E-02 5/19 
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G-protein signaling_G-Protein beta/gamma signaling cascades 1.13E-02 7/34 
wtCFTR and deltaF508 traffic / Membrane expression (norm and 
CF) 1.13E-02 7/34 
Muscle contraction_Oxytocin signaling in uterus and mammary 
gland 1.24E-02 10/60 
Immune response_CD16 signaling in NK cells 1.24E-02 11/69 
G-protein signaling_G-Protein alpha-i signaling cascades 1.28E-02 6/27 
Development_ACM2 and ACM4 activation of ERK 1.29E-02 8/43 
Development_Angiotensin signaling via PYK2 1.29E-02 8/43 
Cell adhesion_Plasmin signaling 1.32E-02 7/35 
Development_TGF-beta-dependent induction of EMT via SMADs  1.32E-02 7/35 
G-protein signaling_EDG5 signaling 1.32E-02 7/35 
ENaC regulation in airways (normal and CF) 1.37E-02 9/52 
Immune response_T cell receptor signaling pathway 1.37E-02 9/52 
G-protein signaling_Proinsulin C-peptide signaling 1.37E-02 9/52 
Cytoskeleton remodeling_ESR1 action on cytoskeleton 
remodeling and cell migration 1.37E-02 5/20 
Translation_IL-2 regulation of translation 1.37E-02 5/20 
Regulation of lipid metabolism_Alpha-1 adrenergic receptors 
signaling via arachidonic acid 1.38E-02 11/70 
Development_Ligand-independent activation of ESR1 and ESR2 1.47E-02 8/44 
Immune response_IL-5 signalling 1.47E-02 8/44 
Blood coagulation_GPCRs in platelet aggregation 1.53E-02 11/71 
Development_Delta-type opioid receptor signaling via G-protein 
alpha-14 1.53E-02 6/28 
Translation _Regulation of EIF4F activity 1.54E-02 9/53 
Immune response_IL-9 signaling pathway 1.54E-02 7/36 
Cell adhesion_Tight junctions 1.54E-02 7/36 
G-protein signaling_Regulation of RAC1 activity 1.54E-02 7/36 
G-protein signaling_RAC1 in cellular process 1.54E-02 7/36 
Development_Alpha-2 adrenergic receptor activation of ERK 1.55E-02 10/62 
Cell cycle_Nucleocytoplasmic transport of CDK/Cyclins 1.67E-02 4/14 
Immune response_Delta-type opioid receptor signaling in T-cells 1.81E-02 6/29 
 
 
Table B.10. Significantly enriched GeneGo pathway maps among the down-
regulated genes following miR-7 transfection into HEY cells. Significantly enriched 
(FDR <0.05) GeneGo pathway maps among the down-regulated genes after miR-7 
transfection into HEY cells are listed. Also shown are the hypergeometric distribution p-
values of enrichments from GeneGo and the ratio of number of genes actually present in 
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the dataset to the number of genes in the Affymetrix array that are in each pathway. 
Pathways are sorted based on enrichment p-values. 
 
Maps p-value Ratio 
Cell adhesion_Chemokines and adhesion 6.99E-08 14/100 
Cell adhesion_Ephrin signaling 7.47E-07 9/45 
Development_EGFR signaling pathway 1.70E-06 10/63 
Development_ERBB-family signaling 2.57E-06 8/39 
Development_VEGF-family signaling 3.83E-06 8/41 
Cytoskeleton remodeling_Cytoskeleton remodeling 4.10E-06 12/102 
Development_WNT signaling pathway. Part 1. Degradation of 
beta-catenin in the absence WNT signaling 4.47E-06 6/20 
Neurophysiological process_Receptor-mediated axon growth 
repulsion 7.97E-06 8/45 
Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 9.97E-06 12/111 
Apoptosis and survival_HTR1A signaling 1.80E-05 8/50 
Transport_RAB5A regulation pathway 1.85E-05 6/25 
Cell cycle_Regulation of G1/S transition (part 1) 2.35E-05 7/38 
Cell adhesion_ECM remodeling 2.42E-05 8/52 
Translation _Regulation of EIF4F activity 2.79E-05 8/53 
Translation _Regulation of EIF2 activity 2.81E-05 7/39 
Translation_Non-genomic (rapid) action of Androgen Receptor 3.33E-05 7/40 
Apoptosis and survival_NO synthesis and signaling 3.69E-05 8/55 
Immune response_Neurotensin-induced activation of IL-8 in 
colonocytes 4.64E-05 7/42 
Apoptosis and survival_TNFR1 signaling pathway 5.43E-05 7/43 
Role of alpha-6/beta-4 integrins in carcinoma progression 7.35E-05 7/45 
Development_GDNF family signaling 8.50E-05 7/46 
Signal transduction_PTEN pathway 8.50E-05 7/46 
Development_Gastrin in cell growth and proliferation 8.90E-05 8/62 
Development_Regulation of epithelial-to-mesenchymal transition 
(EMT) 1.12E-04 8/64 
Cell adhesion_Plasmin signaling 1.40E-04 6/35 
Development_TGF-beta receptor signaling 1.47E-04 7/50 
Proteolysis_Putative ubiquitin pathway 1.59E-04 5/23 
Membrane-bound ESR1: interaction with G-proteins signaling 1.67E-04 7/51 
Immune response_Gastrin in inflammatory response 1.91E-04 8/69 
Development_Dopamine D2 receptor transactivation of EGFR 1.97E-04 5/24 
Development_WNT signaling pathway. Part 2 2.13E-04 7/53 
Immune response_Role of integrins in NK cells cytotoxicity 2.24E-04 6/38 
Regulation of lipid metabolism_Stimulation of Arachidonic acid 
production by ACM receptors 2.58E-04 8/72 
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PGE2 pathways in cancer 2.70E-04 7/55 
Neurophysiological process_Dopamine D2 receptor 
transactivation of PDGFR in CNS 2.93E-04 5/26 
Cell cycle_Regulation of G1/S transition (part 2) 2.93E-04 5/26 
Cytoskeleton remodeling_FAK signaling 3.38E-04 7/57 
Regulation of degradation of deltaF508 CFTR in CF 3.53E-04 5/27 
Development_Role of IL-8 in angiogenesis 3.77E-04 7/58 
Apoptosis and survival_BAD phosphorylation 3.94E-04 6/42 
Development_Mu-type opioid receptor regulation of proliferation 4.22E-04 5/28 
Development_VEGF signaling and activation 4.50E-04 6/43 
Development_Alpha-2 adrenergic receptor activation of ERK 5.70E-04 7/62 
Development_EPO-induced MAPK pathway 5.78E-04 6/45 
Immune response_IL-4 - antiapoptotic action 5.89E-04 5/30 
Transport_Macropinocytosis regulation by growth factors 6.28E-04 7/63 
Development_TGF-beta-dependent induction of EMT via RhoA, 
PI3K and ILK.  6.52E-04 6/46 
Development_Endothelin-1/EDNRA transactivation of EGFR 6.52E-04 6/46 
Regulation of degradation of wt-CFTR 6.87E-04 4/18 
Cytoskeleton remodeling_Fibronectin-binding integrins in cell 
motility 6.89E-04 5/31 
Cytoskeleton remodeling_Reverse signaling by ephrin B 6.89E-04 5/31 
Immune response_CD40 signaling 6.92E-04 7/64 
Development_EGFR signaling via small GTPases 8.01E-04 5/32 
Development_PDGF signaling via STATs and NF-kB 8.01E-04 5/32 
Development_PEDF signaling 9.18E-04 6/49 
Development_Angiotensin activation of ERK 9.27E-04 5/33 
Development_FGF2-dependent induction of EMT 1.05E-03 4/20 
G-protein signaling_G-Protein beta/gamma signaling cascades 1.07E-03 5/34 
Development_IGF-1 receptor signaling 1.14E-03 6/51 
Development_EPO-induced Jak-STAT pathway 1.22E-03 5/35 
Development_FGFR signaling pathway 1.40E-03 6/53 
Cell cycle_Influence of Ras and Rho proteins on G1/S Transition 1.40E-03 6/53 
Cytoskeleton remodeling_CDC42 in cellular processes 1.53E-03 4/22 
Development_Beta-adrenergic receptors transactivation of EGFR 1.58E-03 5/37 
Regulation of lipid metabolism_Insulin regulation of glycogen 
metabolism  1.70E-03 6/55 
Regulation of lipid metabolism_Regulation of lipid metabolism 
via LXR, NF-Y and SREBP 1.78E-03 5/38 
Development_EGFR signaling via PIP3 1.81E-03 4/23 
Transcription_Receptor-mediated HIF regulation 2.01E-03 5/39 
Cell adhesion_PLAU signaling 2.01E-03 5/39 
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Proteolysis_Role of Parkin in the Ubiquitin-Proteasomal Pathway 2.14E-03 4/24 
Regulation of CFTR activity (norm and CF) 2.23E-03 6/58 
Development_Prolactin receptor signaling 2.23E-03 6/58 
Cytoskeleton remodeling_Neurofilaments 2.50E-03 4/25 
Immune response_IL-17 signaling pathways 2.66E-03 6/60 
Translation_Insulin regulation of translation 2.80E-03 5/42 
Development_ACM2 and ACM4 activation of ERK 3.11E-03 5/43 
Signal transduction_AKT signaling 3.11E-03 5/43 
Immune response_Signaling pathway mediated by IL-6 and IL-1 3.34E-03 4/27 
Immune response_IL-4 signaling pathway 3.45E-03 5/44 
Transcription_CREB pathway 3.45E-03 5/44 
Development_Flt3 signaling 3.45E-03 5/44 
Development_Activation of Erk by ACM1, ACM3 and ACM5 3.45E-03 5/44 
Development_Ligand-independent activation of ESR1 and ESR2 3.45E-03 5/44 
Development_Thrombopoietin-regulated cell processes 3.80E-03 5/45 
Development_PIP3 signaling in cardiac myocytes 4.60E-03 5/47 
Development_TGF-beta-dependent induction of EMT via MAPK  4.60E-03 5/47 
Immune response_Histamine H1 receptor signaling in immune 
response 5.04E-03 5/48 
Muscle contraction_Relaxin signaling pathway 5.04E-03 5/48 
Development_A3 receptor signaling 5.51E-03 5/49 
Signal transduction_IP3 signaling 5.51E-03 5/49 
Cytoskeleton remodeling_Integrin outside-in signaling 5.51E-03 5/49 
Apoptosis and survival_Role of IAP-proteins in apoptosis 5.57E-03 4/31 
Immune response_Histamine signaling in dendritic cells 6.00E-03 5/50 
Immune response_IL-13 signaling via PI3K-ERK 6.00E-03 5/50 
Chemotaxis_Inhibitory action of lipoxins on IL-8- and 
Leukotriene B4-induced neutrophil migration 6.53E-03 5/51 
Mucin expression in CF via TLRs, EGFR signaling pathways 6.53E-03 5/51 
Apoptosis and survival_Caspase cascade 6.99E-03 4/33 
G-protein signaling_Proinsulin C-peptide signaling 7.09E-03 5/52 
Development_Endothelin-1/EDNRA signaling 7.69E-03 5/53 
Cell adhesion_Alpha-4 integrins in cell migration and adhesion 7.77E-03 4/34 
Development_CNTF receptor signaling 7.77E-03 4/34 
G-protein signaling_G-Protein alpha-q signaling cascades 7.77E-03 4/34 
Development_Angiopoietin - Tie2 signaling 8.62E-03 4/35 
Development_TGF-beta-dependent induction of EMT via SMADs  8.62E-03 4/35 
Development_FGF-family signaling 8.62E-03 4/35 
Neurophysiological process_EphB receptors in dendritic spine 
morphogenesis and synaptogenesis 8.62E-03 4/35 
Immune response_Fc epsilon RI pathway 8.98E-03 5/55 
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Immune response_IL-9 signaling pathway 9.52E-03 4/36 
Muscle contraction_ACM regulation of smooth muscle contraction 9.67E-03 5/56 
Immune response_TREM1 signaling pathway 9.67E-03 5/56 
Inhibitory action of Lipoxins on neutrophil migration 1.04E-02 5/57 
Development_Delta-type opioid receptor mediated 




Table B.11. Significantly enriched GeneGo pathway maps among the down-
regulated genes following miR-128 transfection into HEY cells. Significantly enriched 
(FDR <0.05) GeneGo pathway maps among the down-regulated genes after miR-128 
transfection into HEY cells are listed. Also shown are the hypergeometric distribution p-
values of enrichments from GeneGo and the ratio of number of genes actually present in 
the dataset to the number of genes in the Affymetrix array that belong to each pathway. 
Pathways are sorted based on the enrichment p-values.  
 
Maps p-value Ratio 
Cell cycle_The metaphase checkpoint 2.30E-19 18/36 
Cell cycle_Role of Nek in cell cycle regulation 8.80E-16 15/32 
Cell cycle_Role of APC in cell cycle regulation 1.88E-11 12/32 
Cell cycle_Spindle assembly and chromosome separation 2.88E-11 12/33 
Cell cycle_Chromosome condensation in prometaphase 5.33E-11 10/21 
Cell cycle_Initiation of mitosis 4.49E-10 10/25 
Cytoskeleton remodeling_Neurofilaments 2.04E-07 8/25 
Cytoskeleton remodeling_Regulation of actin cytoskeleton by Rho 
GTPases 1.79E-06 7/23 
Proteolysis_Putative ubiquitin pathway 1.79E-06 7/23 
Cytoskeleton remodeling_Cytoskeleton remodeling 3.78E-06 13/102 
Cytoskeleton remodeling_Keratin filaments 4.40E-06 8/36 
Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 9.76E-06 13/111 
Cell cycle_Role of SCF complex in cell cycle regulation 9.89E-06 7/29 
Cell cycle_Role of 14-3-3 proteins in cell cycle regulation 2.05E-05 6/22 
Development_Role of IL-8 in angiogenesis 2.47E-05 9/58 
Role of alpha-6/beta-4 integrins in carcinoma progression 2.53E-05 8/45 
Development_PIP3 signaling in cardiac myocytes 3.52E-05 8/47 
Proteolysis_Role of Parkin in the Ubiquitin-Proteasomal Pathway 3.53E-05 6/24 
DNA damage_ATM / ATR regulation of G2 / M checkpoint 5.77E-05 6/26 
Cell cycle_Influence of Ras and Rho proteins on G1/S Transition 8.61E-05 8/53 
Apoptosis and survival_BAD phosphorylation 1.26E-04 7/42 
Development_Slit-Robo signaling 1.36E-04 6/30 
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Cytoskeleton remodeling_RalA regulation pathway 1.36E-04 6/30 
Cell adhesion_Gap junctions 1.36E-04 6/30 
Signal transduction_AKT signaling 1.47E-04 7/43 
Neurophysiological process_Receptor-mediated axon growth 
repulsion 1.98E-04 7/45 
Cell cycle_Cell cycle (generic schema) 2.10E-04 5/21 
Transport_Macropinocytosis 2.29E-04 4/12 
Immune response _CCR3 signaling in eosinophils 2.38E-04 9/77 
Cell cycle_Sister chromatid cohesion 2.66E-04 5/22 
Cell adhesion_Integrin-mediated cell adhesion and migration 2.99E-04 7/48 
Development_EGFR signaling via PIP3 3.33E-04 5/23 
Cell adhesion_Chemokines and adhesion 3.93E-04 10/100 
Muscle contraction_ GPCRs in the regulation of smooth muscle 
tone 4.20E-04 9/83 
Development_Beta-adrenergic receptors transactivation of EGFR 4.53E-04 6/37 
Regulation of lipid metabolism_Regulation of lipid metabolism 
via LXR, NF-Y and SREBP 5.25E-04 6/38 
Development_Role of HDAC and calcium/calmodulin-dependent 
kinase (CaMK) in control of skeletal myogenesis 6.27E-04 7/54 
Immune response_BCR pathway 6.27E-04 7/54 
Transport_Clathrin-coated vesicle cycle 6.77E-04 8/71 
Reproduction_Progesterone-mediated oocyte maturation 6.98E-04 6/40 
Cytoskeleton remodeling_Role of PKA in cytoskeleton 
reorganization 6.98E-04 6/40 
Regulation of degradation of deltaF508 CFTR in CF 7.30E-04 5/27 
Cell cycle_Transition and termination of DNA replication 8.69E-04 5/28 
Transcription_CREB pathway 1.17E-03 6/44 
Muscle contraction_EDG5-mediated smooth muscle contraction 1.20E-03 5/30 
Apoptosis and survival_Granzyme A signaling 1.20E-03 5/30 
Cell adhesion_Histamine H1 receptor signaling in the interruption 
of cell barrier integrity 1.32E-03 6/45 
Cytoskeleton remodeling_Fibronectin-binding integrins in cell 
motility 1.40E-03 5/31 
Cytoskeleton remodeling_Reverse signaling by ephrin B 1.40E-03 5/31 
Chemotaxis_Lipoxin inhibitory action on fMLP-induced 
neutrophil chemotaxis 1.49E-03 6/46 
Signal transduction_PTEN pathway 1.49E-03 6/46 
wtCFTR and delta508 traffic / Clathrin coated vesicles formation 
(norm and CF) 1.54E-03 4/19 
Cell cycle_Start of DNA replication in early S phase 1.63E-03 5/32 
Cell adhesion_Alpha-4 integrins in cell migration and adhesion 2.15E-03 5/34 
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Chemotaxis_Inhibitory action of lipoxins on IL-8- and 
Leukotriene B4-induced neutrophil migration 2.55E-03 6/51 
Transcription_Role of heterochromatin protein 1 (HP1) family in 
transcriptional silencing 2.73E-03 4/22 
G-protein signaling_G-Protein alpha-12 signaling pathway 3.15E-03 5/37 
Cell adhesion_Role of tetraspanins in the integrin-mediated cell 
adhesion 3.15E-03 5/37 
Development_MAG-dependent inhibition of neurite outgrowth 3.15E-03 5/37 
Cell cycle_Regulation of G1/S transition (part 1) 3.55E-03 5/38 
Translation _Regulation of EIF2 activity 3.98E-03 5/39 
Muscle contraction_ACM regulation of smooth muscle contraction 4.10E-03 6/56 
Apoptosis and survival_Apoptotic Activin A signaling 4.42E-03 4/25 
Translation_Non-genomic (rapid) action of Androgen Receptor 4.45E-03 5/40 
Inhibitory action of Lipoxins on neutrophil migration 4.48E-03 6/57 
Immune response_IL-10 signaling pathway 5.11E-03 4/26 
Development_EDG5 and EDG3 in cell proliferation and 
differentiation 5.11E-03 4/26 
Cell cycle_Nucleocytoplasmic transport of CDK/Cyclins 5.91E-03 3/14 
Development_Flt3 signaling 6.73E-03 5/44 
Development_Gastrin in cell growth and proliferation 6.78E-03 6/62 
 
 
Table B.12. Significantly enriched GeneGo pathway maps among the up-regulated 
genes following miR-7 transfection into HEY cells. Significantly enriched (FDR 
<0.05) GeneGo pathway map(s) among the up-regulated genes after miR-7 transfection 
into HEY cells are listed. Also shown are the hypergeometric distribution p-value(s) of 
enrichments from GeneGo and the ratio of number of genes actually present in the dataset 
to the number of genes in the Affymetrix array that are in each pathway. In this case only 
one pathway was found to be significant. 
 
Maps p-value Ratio 




Table B.13. Significantly enriched GeneGo pathway maps among the up-regulated 
genes following miR-128 transfection into HEY cells. Significantly enriched (FDR 
<0.05) GeneGo pathway maps among the up-regulated genes after miR-128 transfection 
into HEY cells are listed. Also shown are the hypergeometric distribution p-values of 
enrichments from GeneGo and the ratio of number of genes actually present in the dataset 
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sorted based on the enrichment p-values.  
 
Maps p-value Ratio 
Immune response_Histamine H1 receptor signaling in immune 
response 2.89E-07 13/48 
Transport_Clathrin-coated vesicle cycle 1.18E-06 15/71 
Immune response_Fc epsilon RI pathway 1.59E-06 13/55 
Development_Activation of Erk by ACM1, ACM3 and ACM5 5.67E-06 11/44 
Development_Regulation of epithelial-to-mesenchymal transition 
(EMT) 9.65E-06 13/64 
Neurophysiological process_Circadian rhythm 1.13E-05 11/47 
Cytoskeleton remodeling_FAK signaling 1.45E-05 12/57 
Development_Angiotensin signaling via STATs 1.45E-05 9/32 
Development_Leptin signaling via JAK/STAT and MAPK 
cascades 1.53E-05 8/25 
Development_Cross-talk between VEGF and Angiopoietin 1 
signaling pathways 2.12E-05 8/26 
Cell adhesion_Cadherin-mediated cell adhesion 2.12E-05 8/26 
Immune response_Gastrin in inflammatory response 2.27E-05 13/69 
Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 2.32E-05 17/111 
Immune response_Neurotensin-induced activation of IL-8 in 
colonocytes 2.42E-05 10/42 
Cytoskeleton remodeling_Role of Activin A in cytoskeleton 
remodeling 2.74E-05 7/20 
Neurophysiological process_EphB receptors in dendritic spine 
morphogenesis and synaptogenesis 3.20E-05 9/35 
Development_Hedgehog and PTH signaling pathways in bone and 
cartilage development 5.17E-05 9/37 
Development_TGF-beta-dependent induction of EMT via RhoA, 
PI3K and ILK.  5.62E-05 10/46 
Immune response_Human NKG2D signaling 6.48E-05 9/38 
Immune response_IL-15 signaling via JAK-STAT cascade 7.64E-05 7/23 
Development_A3 receptor signaling 9.94E-05 10/49 
Signal transduction_IP3 signaling 9.94E-05 10/49 
Translation_Non-genomic (rapid) action of Androgen Receptor 9.97E-05 9/40 
Development_Glucocorticoid receptor signaling 1.03E-04 7/24 
Immune response_Function of MEF2 in T lymphocytes 1.19E-04 10/50 
Mucin expression in CF via TLRs, EGFR signaling pathways 1.42E-04 10/51 
Development_A2A receptor signaling 1.81E-04 9/43 
Development_A1 receptor signaling 1.98E-04 10/53 
Development_Angiopoietin - Tie2 signaling 2.17E-04 8/35 
Immune response_CD40 signaling 2.28E-04 11/64 
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Apoptosis and survival_Anti-apoptotic TNFs/NF-kB/IAP pathway 2.34E-04 7/27 
Signal transduction_Calcium signaling 2.60E-04 9/45 
Apoptosis and survival_NO synthesis and signaling 2.73E-04 10/55 
Development_GDNF family signaling 3.10E-04 9/46 
Development_Gastrin in differentiation of the gastric mucosa 3.96E-04 8/38 
Immune response_CCR5 signaling in macrophages and T 
lymphocytes 4.27E-04 10/58 
Development_Role of Activin A in cell differentiation and 
proliferation 5.72E-04 8/40 
Cytoskeleton remodeling_Reverse signaling by ephrin B 5.84E-04 7/31 
Development_EDNRB signaling 5.93E-04 9/50 
Apoptosis and survival_HTR1A signaling 5.93E-04 9/50 
Development_A2B receptor: action via G-protein alpha s 5.93E-04 9/50 
Reproduction_GnRH signaling 6.54E-04 11/72 
Transport_ACM3 in salivary glands 6.81E-04 8/41 
Neurophysiological process_Netrin-1 in regulation of axon 
guidance 6.81E-04 8/41 
Development_Gastrin in cell growth and proliferation 7.39E-04 10/62 
Signal transduction_Activation of PKC via G-Protein coupled 
receptor 7.99E-04 9/52 
Proteolysis_Role of Parkin in the Ubiquitin-Proteasomal Pathway 8.15E-04 6/24 
Immune response_IL-7 signaling in B lymphocytes 9.49E-04 8/43 
Development_Angiotensin signaling via PYK2 9.49E-04 8/43 
Apoptosis and survival_Apoptotic Activin A signaling 1.03E-03 6/25 
Development_NOTCH1-mediated pathway for NF-KB activity 
modulation 1.05E-03 7/34 
G-protein signaling_G-Protein alpha-q signaling cascades 1.05E-03 7/34 
Immune response _IFN gamma signaling pathway 1.06E-03 9/54 
Immune response_CD28 signaling 1.06E-03 9/54 
PGE2 pathways in cancer 1.21E-03 9/55 
Development_EPO-induced Jak-STAT pathway 1.26E-03 7/35 
Cytoskeleton remodeling_Cytoskeleton remodeling 1.28E-03 13/102 
Neurophysiological process_Receptor-mediated axon growth 
repulsion 1.30E-03 8/45 
Neurophysiological process_Glutamate regulation of Dopamine 
D1A receptor signaling 1.30E-03 8/45 
Cell adhesion_Histamine H1 receptor signaling in the interruption 
of cell barrier integrity 1.30E-03 8/45 
Transcription_Androgen Receptor nuclear signaling 1.30E-03 8/45 
Development_Keratinocyte differentiation 1.39E-03 9/56 
Immune response_TREM1 signaling pathway 1.39E-03 9/56 
Development_Endothelin-1/EDNRA transactivation of EGFR 1.50E-03 8/46 
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Immune response_MIF - the neuroendocrine-macrophage 
connector 1.50E-03 8/46 
Development_WNT5A signaling 1.50E-03 8/46 
Development_TGF-beta-dependent induction of EMT via MAPK  1.74E-03 8/47 
Development_Leptin signaling via PI3K-dependent pathway 1.74E-03 8/47 
Cytoskeleton remodeling_ACM3 and ACM4 in keratinocyte 
migration 1.78E-03 7/37 
Development_Prolactin receptor signaling 1.79E-03 9/58 
Development_Delta-type opioid receptor signaling via G-protein 
alpha-14 1.93E-03 6/28 
Immune response_IL-7 signaling in T lymphocytes 2.09E-03 7/38 
Cell cycle_Regulation of G1/S transition (part 1) 2.09E-03 7/38 
Development_WNT signaling pathway. Part 1. Degradation of 
beta-catenin in the absence WNT signaling 2.25E-03 5/20 
Development_Melanocyte development and pigmentation 2.29E-03 8/49 
Immune response_IL-2 activation and signaling pathway 2.29E-03 8/49 
Immune response_Bacterial infections in normal airways 2.29E-03 8/49 
Development_PACAP signaling in neural cells 2.44E-03 7/39 
Transcription_NF-kB signaling pathway 2.44E-03 7/39 
G-protein signaling_Regulation of p38 and JNK signaling 
mediated by G-proteins 2.44E-03 7/39 
Development_Thyroliberin signaling 2.56E-03 9/61 
Immune response_Histamine signaling in dendritic cells 2.61E-03 8/50 
Development_GM-CSF signaling 2.61E-03 8/50 
Delta508-CFTR traffic / ER-to-Golgi in CF 2.78E-03 4/13 
Normal wtCFTR traffic / ER-to-Golgi  2.78E-03 4/13 
Development_IGF-1 receptor signaling 2.97E-03 8/51 
Membrane-bound ESR1: interaction with G-proteins signaling 2.97E-03 8/51 
Immune response_NFAT in immune response 2.97E-03 8/51 
Some pathways of EMT in cancer cells 2.97E-03 8/51 
Development_EGFR signaling pathway 3.21E-03 9/63 
Cell adhesion_Chemokines and adhesion 3.24E-03 12/100 
Blood coagulation_GPIb-IX-V-dependent platelet activation 3.25E-03 10/75 
Immune response_PGE2 common pathways 3.36E-03 8/52 
Immune response_Antiviral actions of Interferons 3.36E-03 8/52 
Cytoskeleton remodeling_CDC42 in cellular processes 3.53E-03 5/22 
Muscle contraction_Regulation of eNOS activity in endothelial 
cells 3.58E-03 9/64 
Immune response_PIP3 signaling in B lymphocytes 3.78E-03 7/42 
Development_FGFR signaling pathway 3.79E-03 8/53 
Development_Endothelin-1/EDNRA signaling 3.79E-03 8/53 
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Development_WNT signaling pathway. Part 2 3.79E-03 8/53 
Development_PDGF signaling via STATs and NF-kB 3.95E-03 6/32 
Immune response_Role of DAP12 receptors in NK cells 4.27E-03 8/54 
Development_Role of HDAC and calcium/calmodulin-dependent 
kinase (CaMK) in control of skeletal myogenesis 4.27E-03 8/54 
Development_ACM2 and ACM4 activation of ERK 4.33E-03 7/43 
Development_VEGF signaling and activation 4.33E-03 7/43 
Apoptosis and survival_Anti-apoptotic action of Gastrin 4.33E-03 7/43 
Immune response_HTR2A-induced activation of cPLA2 4.33E-03 7/43 
Development_Angiotensin activation of ERK 4.63E-03 6/33 
Normal and pathological TGF-beta-mediated regulation of cell 
proliferation 4.63E-03 6/33 
Transcription_CREB pathway 4.94E-03 7/44 
Neurophysiological process_NMDA-dependent postsynaptic long-
term potentiation in CA1 hippocampal neurons 5.20E-03 10/80 
Signal transduction_Erk Interactions: Inhibition of Erk 5.40E-03 6/34 
Development_Role of CDK5 in neuronal development 5.40E-03 6/34 
Development_VEGF signaling via VEGFR2 - generic cascades 5.61E-03 7/45 
Development_Growth hormone signaling via STATs and PLC/IP3 6.25E-03 6/35 
IL-1 beta-dependent CFTR expression 6.31E-03 4/16 
Transcription_Transcription regulation of aminoacid metabolism 6.31E-03 5/25 
Development_G-Proteins mediated regulation MARK-ERK 
signaling 6.34E-03 7/46 
Neurophysiological process_ACM regulation of nerve impulse 6.34E-03 7/46 
Development_Hedgehog signaling 6.34E-03 7/46 
Immune response_ICOS pathway in T-helper cell 6.34E-03 7/46 
Bacterial infections in CF airways 6.64E-03 8/58 
Regulation of CFTR activity (norm and CF) 6.64E-03 8/58 
Development_PIP3 signaling in cardiac myocytes 7.15E-03 7/47 
Cell adhesion_Tight junctions 7.20E-03 6/36 
G-protein signaling_RAC1 in cellular process 7.20E-03 6/36 
Regulation of lipid metabolism_Stimulation of Arachidonic acid 
production by ACM receptors 7.86E-03 9/72 
Transcription_Transcription factor Tubby signaling pathways 7.94E-03 4/17 
Muscle contraction_Relaxin signaling pathway 8.03E-03 7/48 
G-protein signaling_G-Protein alpha-i signaling cascades 8.85E-03 5/27 
Muscle contraction_nNOS Signaling in Skeletal Muscle  8.85E-03 5/27 
Neurophysiological process_Long-term depression in cerebellum 8.99E-03 7/49 
Development_Mu-type opioid receptor signaling 9.41E-03 6/38 
Immune response_Oncostatin M signaling via JAK-Stat in mouse 
cells 9.82E-03 4/18 
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Development_TGF-beta receptor signaling 1.00E-02 7/50 
HIV-1 signaling via CCR5 in macrophages and T lymphocytes 1.07E-02 6/39 
Development_ERBB-family signaling 1.07E-02 6/39 
Transport_Macropinocytosis regulation by growth factors 1.09E-02 8/63 
Signal transduction_PKA signaling 1.12E-02 7/51 
Immune response_IL-15 signaling 1.19E-02 8/64 
wtCFTR and delta508 traffic / Clathrin coated vesicles formation 
(norm and CF) 1.20E-02 4/19 
Immune response_Delta-type opioid receptor signaling in T-cells 1.20E-02 5/29 
Immune response_CD137 signaling in immune cell 1.20E-02 5/29 
Immune response_MIF in innate immunity response 1.21E-02 6/40 










SUPPLEMENTARY INFORMATION FOR CHAPTER 4 
 
Table C.1. Differentially expressed miRNAs between HEY cells transfected with either miR-7 or negative control miRNA. List 
of differentially expressed miRNA probesets detected by microarray following miR-7 or miR-NC transfection into HEY cells (two 
independent samples per group). Probe sequence names are given with the corresponding sequence, the transcript ID provided by 
Affymetrix annotation file, the difference between averaged log2 signal values for transfection and control groups (miR7-miR-NC), 
the false discovery rate [q value (%)], the nearest human homolog found using miRBase, and the genomic location (also from 
miRBase) are given. Probesets with ‘FALSE’ calls in all groups were removed from analysis. Only probesets having a fold change 
≥1.4 in average signal value and FDR ≤5 % were called differentially expressed. These probesets correspond to seventy-one unique 
mature human miRNAs (excluding miR-7), three sequences with very poor (BLASTN E-value >1) homology to human miRNAs, two 
snoRNAs, one vault RNA, one tRNA, one mRNA (KIAA1407) fragment, and some sequences that we could not map to the human 














AACAGGUCUUG cfa-mir-1839 -0.898123 0.488495 ACA45 N/A  























TC ACA52 -0.536932 1.376021 ACA52 N/A 
csa-let-7a_st 
UGAGGUAGUAG




let-7a-3: Exon 5 of 
RP4-695020__B; let-
7a-1: Intergenic; let-
7a-2 Intergenic; let-7c: 



































(%) homolog** Genomic location 
gga-let-7k_st 
UGAGGUAGUAG
AUUGAAUAGUU gga-let-7k -0.7634225 0.488495 hsa-let-7f 
hsa-let-7f-1: 
Intergenic; hsa-let-7f-






rno-let-7f-2 -0.585445 0.488495 hsa-let-7f 
hsa-let-7f-1: 
Intergenic; hsa-let-7f-






bta-let-7f-2 -0.570095 0.488495 hsa-let-7f 
hsa-let-7f-1: 
Intergenic; hsa-let-7f-




AUUGUAUAGUU xtr-let-7f -0.558275 0.488495 hsa-let-7f 
hsa-let-7f-1: 
Intergenic; hsa-let-7f-






mml-let-7f-2 -0.544205 0.488495 hsa-let-7f 
hsa-let-7f-1: 
Intergenic; hsa-let-7f-






mdo-let-7f-2 -0.543245 0.488495 hsa-let-7f 
hsa-let-7f-1: 
Intergenic; hsa-let-7f-






mmu-let-7f-2 -0.534605 0.713954 hsa-let-7f 
hsa-let-7f-1: 
Intergenic; hsa-let-7f-
2: Intron 34/59/60 of 
HUWE1 









(%) homolog** Genomic location 
gga-let-7f_st 
UGAGGUAGUAG
AUUGUAUAGUU gga-let-7f -0.53172 0.488495 hsa-let-7f 
hsa-let-7f-1: 
Intergenic; hsa-let-7f-




AUUGUAUAGUU ssc-let-7f -0.529395 0.488495 hsa-let-7f 
hsa-let-7f-1: 
Intergenic; hsa-let-7f-




AUUGUAUAGUU dre-let-7f -0.521045 0.713954 hsa-let-7f 
hsa-let-7f-1: 
Intergenic; hsa-let-7f-






hsa-let-7f-2 -0.52087 0.713954 hsa-let-7f 
hsa-let-7f-1: 
Intergenic; hsa-let-7f-




AUUGUAUAGUU cfa-let-7f -0.5177 0.713954 hsa-let-7f 
hsa-let-7f-1: 
Intergenic; hsa-let-7f-




UUUGUACAGUU mmu-let-7g -0.637655 0.488495 hsa-let-7g Intron 2/3 of WDR82 
bta-let-7g_st 
UGAGGUAGUAG
UUUGUACAGUU bta-let-7g -0.627905 0.488495 hsa-let-7g Intron 2/3 of WDR82 
mml-let-7g_st 
UGAGGUAGUAG
UUUGUACAGUU mml-let-7g -0.60723 0.488495 hsa-let-7g Intron 2/3 of WDR82 
cfa-let-7g_st 
UGAGGUAGUAG
UUUGUACAGUU cfa-let-7g -0.598865 0.488495 hsa-let-7g Intron 2/3 of WDR82 









(%) homolog** Genomic location 
hsa-let-7g_st 
UGAGGUAGUAG

















G mml-mir-10a -0.5461905 0.713954 
hsa-miR-
10a Intron 1 of HOXB3 
cfa-miR-10_st 
UACCCUGUAGA
UCCGAAUUUGU cfa-mir-10 -0.538179 1.376021 
hsa-miR-




CCGAAUUUGU bmo-mir-10 -0.5269015 0.713954 
hsa-miR-





G ppa-mir-10a -0.515554 0.713954 
hsa-miR-




ACCGAAUUUGU mne-mir-10b -0.647604 0.713954 
hsa-miR-




ACCGAAUUUGU xtr-mir-10b -0.542885 0.713954 
hsa-miR-





G mml-mir-10b -0.5331445 0.488495 
hsa-miR-





G bta-mir-10b -0.522565 0.488495 
hsa-miR-




ACCGAAUUUGU ppa-mir-10b -0.5173075 1.376021 
hsa-miR-
10b Intron 1 of HOXD3 













CGUGGGUGUGU hsa-mir-1180 0.781506 0 
hsa-miR-




GGAGGUGG mml-mir-1224 -0.5178975 2.815705 
hsa-miR-
1224-5p 
Intron 13/16/18 of 











GUAAUAAUGC tni-mir-126 -0.5210625 0.713954 
hsa-miR-




GGCGCCA hsa-mir-1274a -0.9468385 0.488495 
hsa-miR-
1274a 












G mml-mir-137 -0.703785 0.713954 
hsa-miR-
137 






G hsa-mir-137 -0.56398 1.376021 
hsa-miR-
137 





CGUGUCUCCAG mmu-mir-139 -0.622833 0.488495 
hsa-miR-
139-5p 





CGUGUCUCCAG hsa-mir-139 -0.601006 0.713954 
hsa-miR-
139-5p 





CGUGUCUCCAG mml-mir-139 -0.562391 0.488495 
hsa-miR-
139-5p 






U bta-mir-139 -0.5498285 0.488495 
hsa-miR-
139-5p 
Intron 1/2/3/6 of 
PDE2A 













CGUGUCUCCAG rno-mir-139 -0.5198765 1.376021 
hsa-miR-
139-5p 





CCCUAUGGUAG dre-mir-140 0.568629 0.488495 
hsa-miR-
140-5p 





CCCUAUGGUAG mml-mir-140 0.5963435 0.488495 
hsa-miR-
140-5p 
























C mmu-mir-149 6.0962705 0 
hsa-miR-





C mml-mir-149 6.1961005 0 
hsa-miR-





C hsa-mir-149 6.223235 0 
hsa-miR-





U mmu-mir-155 -0.6957595 0.488495 
hsa-miR-




CGUGAUAGGGG xtr-mir-155 -0.53156 0.713954 
hsa-miR-




CAUGGUUUACA ssc-mir-15b -0.52393 1.376021 
hsa-miR-
15b 
Intron 1/2/3/4/5 of 
SMC4 













CAUGGUUUACA mmu-mir-15b -0.515075 1.376021 
hsa-miR-
15b 


















2 1.325246 0 
hsa-miR-
181a-2* 













Intron 2 of RP11-
31E23.1; hsa-miR-










Intron 2 of RP11-
31E23.1; hsa-miR-










Intron 2 of RP11-
31E23.1; hsa-miR-













Intron 2 of RP11-
31E23.1; hsa-miR-
181b-2: Intron 1 
MIR181A2HG 


















Intron 2 of RP11-
31E23.1; hsa-miR-











Intron 2 of RP11-
31E23.1; hsa-miR-










Intron 2 of RP11-
31E23.1; hsa-miR-










Intron 2 of RP11-
31E23.1; hsa-miR-










Intron 2 of RP11-
31E23.1; hsa-miR-
181b-2: Intron 1 
MIR181A2HG 

















Intron 2 of RP11-
31E23.1; hsa-miR-












Intron 2 of RP11-
31E23.1; hsa-miR-













Intron 2 of RP11-
31E23.1; hsa-miR-










Intron 2 of RP11-
31E23.1; hsa-miR-













Intron 2 of RP11-
31E23.1; hsa-miR-
181b-2: Intron 1 
MIR181A2HG 



















Intron 2 of RP11-
31E23.1; hsa-miR-









Intron 2 of RP11-
31E23.1; hsa-miR-











Intron 2 of RP11-
31E23.1; hsa-miR-












Intron 2 of RP11-
31E23.1; hsa-miR-










Intron 2 of RP11-
31E23.1; hsa-miR-
181b-2: Intron 1 
MIR181A2HG 


















Intron 2 of RP11-
31E23.1; hsa-miR-




















































GAGAUAGG ggo-mir-198 -0.6281995 0.488495 
hsa-miR-
198 Exon 11 of FSTL1 






















































Antisense to DNM2; 
hsa-miR-199a-2: 
















Antisense to DNM2; 
hsa-miR-199a-2: 
















Antisense to DNM2; 
hsa-miR-199a-2: 
Intron 1 of RP5-
1116C7.1; hsa-miR-
199b: intergenic 























Antisense to DNM2; 
hsa-miR-199a-2: 













Antisense to DNM2; 
hsa-miR-199a-2: 













Antisense to DNM2; 
hsa-miR-199a-2: 













Antisense to DNM2; 
hsa-miR-199a-2: 
Intron 1 of RP5-
1116C7.1; hsa-miR-
199b: intergenic 




















Antisense to DNM2; 
hsa-miR-199a-2: 















Antisense to DNM2; 
hsa-miR-199a-2: 











Antisense to DNM2; 
hsa-miR-199a-2: 


























GGUAAUGAUGC dre-mir-200c 1.8636275 0 
hsa-miR-
200b Intergenic 































































xtr-mir-204-2 -0.7950435 0.488495 
hsa-miR-
204 





AUCCUAUGCCU sla-mir-204 -0.7922195 1.376021 
hsa-miR-
204 





AUCCUAUGCCU tni-mir-204a -0.725559 0.488495 
hsa-miR-
204 





AUCCUAUGCCU rno-mir-204 -0.720936 0.488495 
hsa-miR-
204 





AUCCUAUGCCU fru-mir-204 -0.6663135 0.713954 
hsa-miR-
204 





AUCCUAUGCCU mdo-mir-204 -0.64758 0.488495 
hsa-miR-
204 
Intron 3/4/5/6/7 of 
TRPM3 













AUCCUAUGCCU mmu-mir-204 -0.616617 0.488495 
hsa-miR-
204 





AUCCUAUGCCU ppy-mir-204 -0.6079145 0.713954 
hsa-miR-
204 





AUCCUAUGCCU ssc-mir-204 -0.5880915 0.713954 
hsa-miR-
204 







dre-mir-204-2 -0.5807335 2.815705 
hsa-miR-
204 





AUCCUAUGCCU mml-mir-204 -0.561063 0.488495 
hsa-miR-
204 





AUCCUAUGCCU cfa-mir-204 -0.511261 1.376021 
hsa-miR-
204 















































14/15/15 of SLIT2; 
hsa-miR-218-2: Intron 
10/14 of SLIT3 



















14/15/15 of SLIT2; 
hsa-miR-218-2: Intron 
















UGGUUCCGUU hsa-mir-224 -0.9664915 0.488495 
hsa-miR-
224 
Exon 1/3 or Intron 





A rno-mir-224 -0.950823 0.488495 
hsa-miR-
224 
Exon 1/3 or Intron 





A ptr-mir-224 -0.832212 0.488495 
hsa-miR-
224 
Exon 1/3 or Intron 





A ggo-mir-224 -0.820565 0.488495 
hsa-miR-
224 
Exon 1/3 or Intron 





A ppy-mir-224 -0.7884285 0.713954 
hsa-miR-
224 
Exon 1/3 or Intron 





A ppa-mir-224 -0.7669285 0.488495 
hsa-miR-
224 
Exon 1/3 or Intron 





A ssc-mir-224 -0.7626635 0.713954 
hsa-miR-
224 
Exon 1/3 or Intron 
4/6/7 of GABRE  













UGGUUCCGUUU cfa-mir-224 -0.727016 0.488495 
hsa-miR-
224 
Exon 1/3 or Intron 





A mne-mir-224 -0.639669 0.713954 
hsa-miR-
224 
Exon 1/3 or Intron 




UGGUUCCGUU mmu-mir-224 -0.617886 0.713954 
hsa-miR-
224 
Exon 1/3 or Intron 





A mml-mir-224 -0.580054 0.713954 
hsa-miR-
224 
Exon 1/3 or Intron 




UUACUUGGCUC hsa-mir-26b 0.533673 4.102276 
hsa-miR-
26b* 








hsa-mir-29b-1 -0.949386 0.488495 
hsa-miR-
29b-1* 








1 -0.841947 0.488495 
hsa-miR-
29b-1* 






C hsa-mir-301b 0.50897 2.815705 
hsa-miR-





C mml-mir-301b 0.690126 0.312856 
hsa-miR-




AUGUUUGCAGC ggo-mir-30a -0.5554675 0.488495 
hsa-miR-




AUGUUUGCAGC ppa-mir-30a -0.5472125 0.713954 
hsa-miR-
30a* Intron 3 of C6orf155 













AUGUUUGCAGC mmu-mir-30a -0.535228 0.488495 
hsa-miR-




AUGUUUGCAGC hsa-mir-30a -0.533506 0.488495 
hsa-miR-




AUGUUUGCAGC rno-mir-30a -0.5308425 0.713954 
hsa-miR-














AUGUUUACAGC rno-mir-30e -0.549827 1.376021 
hsa-miR-
30e* 






A rno-mir-330 0.881907 0 
hsa-miR-





A mmu-mir-330 0.9112175 0 
hsa-miR-













dre-mir-338-2 0.711282 0.488495 
hsa-miR-
338-3p Intron 6/7 AATK 
rno-miR-33_st 
GUGCAUUGUAG













homology) N/A  

































CAUGUUUUGGA mmu-mir-322 -0.7171465 0.488495 
hsa-miR-




CAUGUUUUGAA mml-mir-424 -0.695418 0.488495 
hsa-miR-




CAUGUUUUGAA hsa-mir-424 -0.5167965 2.815705 
hsa-miR-




GCGCUGCUAU cfa-mir-424 -1.610662 0.488495 
hsa-miR-




GCGCUGCUAU hsa-mir-424 -1.5890045 0.488495 
hsa-miR-




CGUGUCCGCC mmu-mir-425 0.525007 1.376021 
hsa-miR-




CGUGUCCGUCC mdo-mir-425 0.5895345 0.488495 
hsa-miR-











G mmu-mir-503 -1.46896 0.488495 
hsa-miR-
503 
Intron 1 of 
MGC16121 














G rno-mir-503 -1.44376 0.488495 
hsa-miR-
503 






G hsa-mir-503 -1.260273 0.488495 
hsa-miR-
503 






G mml-mir-503 -1.2349995 0.488495 
hsa-miR-
503 





ACAGUACUG cfa-mir-503 -0.8010865 0.713954 
hsa-miR-
503 

































Intron 1/2 of ZNRF2; 
hsa-miR-550a-2: 





U rno-mir-551b 0.59941 0.713954 
hsa-miR-
551b Intron 4 C3orf50 













UUGGUUUCAG mmu-mir-551b 0.774779 0 
hsa-miR-




UUGGUUUCAG mml-mir-551b 0.8109335 0 
hsa-miR-




CUGGGACUGAG hsa-mir-584 -0.658341 0.488495 
hsa-miR-




CUGGGACUGAG mml-mir-584 -0.641268 0.488495 
hsa-miR-




UAAAAGUGCAG mml-mir-590 0.5116375 0.713954 
hsa-miR-




UAAAAGUGCAG mmu-mir-590 0.606382 0.312856 
hsa-miR-




UGGCAGUCGA mml-mir-628 0.620748 2.815705 
hsa-miR-




UGGCAGUCGA hsa-mir-628 0.9114175 0 
hsa-miR-





GA cbr-mir-231 1.0279965 0.312856 
hsa-miR-
649 (poor 




UAGGGUUGUGC cfa-mir-652 0.5623525 0.312856 
hsa-miR-




UAGGGUUGUG mml-mir-652 0.5905725 0 
hsa-miR-




UAGGGUUGUG hsa-mir-652 0.611339 0.312856 
hsa-miR-




UAGGGUUGUG rno-mir-652 0.6205725 0 
hsa-miR-
652 Intron 2 of TMEM164 













UAGGGUUGUG mmu-mir-652 0.638374 0 
hsa-miR-










A sme-mir-7a 0.9845245 0 hsa-miR-7 N/A  
dre-miR-7b_st 
UGGAAGACUUG




























U aga-mir-7 6.953598 0 hsa-miR-7 N/A  
























































dre-mir-7a-3 7.4055625 0 hsa-miR-7 N/A  



















UGAUUUUUGUU gga-mir-7b 7.5516795 0 hsa-miR-7 N/A  
mdo-miR-7_st 
UGGAAGACUAG
UGAUUUUGUUG mdo-mir-7 7.6199755 0 hsa-miR-7 N/A  
cin-miR-7_st 
UGGAAGACUAG
UGAUUUUGUUG cin-mir-7 7.675455 0 hsa-miR-7 N/A  
fru-miR-7_st 
UGGAAGACUAG
UGAUUUUGUU fru-mir-7 7.690636 0 hsa-miR-7 N/A  
sla-miR-7_st 
UGGAAGACUAG
UGAUUUUGUU sla-mir-7 7.881972 0 hsa-miR-7 N/A  
mne-miR-7_st 
UGGAAGACUAG
UGAUUUUGUU mne-mir-7 7.8886565 0 hsa-miR-7 N/A  
ptr-miR-7_st 
UGGAAGACUAG
UGAUUUUGUU ptr-mir-7 7.9328275 0 hsa-miR-7 N/A  
ppy-miR-7_st 
UGGAAGACUAG
UGAUUUUGUU ppy-mir-7 7.9417035 0 hsa-miR-7 N/A  
lla-miR-7_st 
UGGAAGACUAG
UGAUUUUGUU lla-mir-7 8.055049 0 hsa-miR-7 N/A  
ppa-miR-7_st 
UGGAAGACUAG






xtr-mir-7-3 8.108839 0 hsa-miR-7 N/A  
ssc-miR-7_st 
UGGAAGACUAG
UGAUUUUGUU ssc-mir-7 8.1703415 0 hsa-miR-7 N/A  















gga-mir-7-1 8.172161 0 hsa-miR-7 N/A  
ggo-miR-7_st 
UGGAAGACUAG
UGAUUUUGUU ggo-mir-7 8.1995385 0 hsa-miR-7 N/A  
odi-miR-7_st 
UGGAAGACUAG







hsa-mir-7-1 -1.1885415 0.488495 
hsa-miR-7-
1* 
Intron 1/3/15/16 or 






rno-mir-7a-2 -1.091384 0.488495 
hsa-miR-7-
1* 
Intron 1/3/15/16 or 






mmu-mir-7a-2 -0.5598705 1.376021 
hsa-miR-7-
1* 
Intron 1/3/15/16 or 




GGCGCAGGG rno-mir-877 0.582268 1.376021 
hsa-miR-
877 





UCCCGGCCUGC dme-mir-92b -0.598515 0.488495 
hsa-miR-




UCCCGGCCUGC dps-mir-92b -0.575535 0.488495 
hsa-miR-
















hsa-mir-92a-2 -0.5179315 0.713954 
hsa-miR-




AGCACUUCCCG hsa-mir-93 0.5775735 0.312856 
hsa-miR-
93* 
Intron 2/4/8/12/13 of 
MCM7 









(%) homolog** Genomic location 
fru-let-7h_st 
UGAGGUAGUAA
GUUGUGUUGUU fru-let-7h -0.5684115 1.376021 hsa-miR-98 




GUUGUAUUGUU bta-mir-98 -0.5280765 0.713954 hsa-miR-98 

















































GA cbr-mir-67 -8.39065 0 
Negative 
control N/A  













GA cel-mir-67 -8.751703 0 
Negative 























G mml-mir-886 -0.52657 0.713954 VTRNA2 N/A 




Table C.2. Differentially expressed genes in miR-7 transfected HEY cells compared 
to negative control miRNA transfected cells. Significantly differentially expressed 
(fold change ≥1.3, p <0.05) mRNA probeset IDs after miR-7 or miR-NC transfection into 
HEY cells are listed (three independent samples per group). For each probeset ID the 
gene title, the gene symbol, the average log2 signal value for transfected [Avg (miR-7)] 
and control [Avg (miR-NC)] group, difference between log2 signal values (miR7-miR-
NC), and the t-test p-values are shown. Probesets with Affymetrix “Absent” calls in all 
samples were removed from analysis. 
 
 




Table C.3. Differentially expressed mRNA probeset IDs in miR-7 transfected A549 
cells compared to negative control miRNA transfected cells. Result of reanalyzed data 
based on miR-7 transfection reported by (Webster et al., 2009) is presented. Only 
significantly differentially expressed genes (fold change ≤1.3, p <0.05) in A549 cells 
transfected with miR-7 compared to cells transfected with miR-NC are listed. For each 
probeset ID the gene title, the gene symbol, the GO biological process ontology, the 
average log2 signal value for transfected [Avg (miR-7)] and control [Avg (miR-NC)] 
group, ratio of log2 signal values (miR7-miR-NC), and the t-test p-values are shown. 
 




Table C.4. NF-κB binding sites within 10 kb of each of the differentially expressed 
miRNAs after miR-7 transfection in HEY cells. NF-κB binding sites were identified by 
genome-wide ChIP-seq as part of the ENCODE project. This table was downloaded from 
the UCSC genome browser (http://genome.UCSC.edu) that is a co-host (DCC) of 
ENCODE data. Only sites near (± 10 kb) of miRNAs differentially expressed following 
miR-7 transfection into HEY cells are shown. 
 




Table C.5. Differentially expressed miRNAs in HEY cells transfected with anti-
RELA siRNA compared to cells transfected with negative control siRNA. This table 
lists the miRNA probesets found to be significantly differentially expressed (fold change 
≥1.4, FDR ≤5 %) between HEY cells transfected with either two samples of anti-RELA 
 
 206
siRNA or with two samples of siNC for 48 hours. Probe sequence names are given with 
the corresponding sequence, the alignment identified by Affymetrix software, the 
difference between log2 average signal values (siRNA-siNC), the false discovery rate [q 
value (%)], the nearest human homolog we found using miRBase are given. Probesets 
with ‘FALSE’ calls in all groups were removed from analysis.  
  
Probeset 









































































































































Table C.5 (continued) 
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Probeset 




































































































































































Table C.5 (continued) 
 208
Probeset 





































































































































































Table C.5 (continued) 
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Probeset 



























































































































































































Table C.5 (continued) 
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Probeset 














































































































































































Table C.5 (continued) 
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Probeset 




























































































































































Table C.5 (continued) 
 212
Probeset 









































































































































































Table C.5 (continued) 
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Probeset 






































































































































































Table C.5 (continued) 
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Probeset 






























































































































































Table C.5 (continued) 
 215
Probeset 


















































































































































































Table C.5 (continued) 
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Probeset 










































































































































































Table C.5 (continued) 
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Probeset 













































































































































































Table C.5 (continued) 
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Probeset 





























































































































































































Table C.5 (continued) 
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Probeset 





























































































































Table C.5 (continued) 
 220
Probeset 















































































Table C.6. List of SFRS1 binding sites within the pri-miRNAs of differentially 
expressed embedded miRNAs. Pri-miRNAs of embedded miRNAs were searched for 
SFRS1 (SF2/ASF) binding sites previously identified by (Sanford et al., 2009) using 
genome-wide CLIP-seq technique. The pri-miRNA coordinates were assumed to be 
identical to the host transcriptional unit. Gene symbols of the host genes corresponding to 
 
 221
the pri-miRNAs are listed. The genomic coordinates of these pri-miRNAs are given 






















































































































































































































170031068 + chr3:169607916-169607970 
 
 
Table C.7. List of SFRS1 binding sites within the pri-miRNAs of differentially 
expressed intergenic miRNAs. Pri-miRNAs of intergenic miRNAs were searched for 
SFRS1 (SF2/ASF) binding sites previously identified by (Sanford et al., 2009) using 
genome-wide CLIP-seq technique. The pri-miRNA coordinates were assumed to be 
within ±2 kb of each pre-miRNA. The genomic coordinates (‘miR Start/End’) of these 










hsa-miR-210 chr11 - 558089 558198 557533 557577 
hsa-let-7i* chr12 + 61283733 61283816 61282744 61282800 
 
 
Table C.8. Differentially expressed transcription factors between miR-7 and 
negative control transfected HEY cells. Significantly differentially expressed (fold 
change ≥1.3, p <0.05) mRNA probeset IDs with the GO biological process “regulation of 
transcription” between HEY cells transfected with either miR-7 or miR-NC. For each 
probeset ID the gene symbol, the GO biological process annotation, difference between 
log2 signal values (miR7-miR-NC), the t-test p-value, and whether it is a miR-7 target 
based on miRanda is shown. Probesets with Affymetrix “Absent” calls in all samples 
were removed from analysis. 
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